var title_f32_27_33200="Model of the AChR";
var content_f32_27_33200=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F78580&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F78580&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Model of the acetylcholine receptor",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 435px; height: 659px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Model of the acetylcholine receptor (AChR) showing a transverse section (top panel), a top view (middle panel) and the alpha-subunit in the membrane (bottom panel). In the top panel, the extracellular and smaller intracellular vestibules that surround the transmembrane ion pore are lined with negative charges. The main immunogenic region (MIR) of the AChR is located at the top of the extracellular portion of the AChR. The transmembrane pore is formed by the M1 and M2 segments of each subunit. The narrowing of the transmembrane ion pore results from bending of the M2 segment. The narrowest part of the pore is the selectivity filter. In the middle panel, \"ACh\" indicates the alpha/delta and alpha/epsilon or alpha/gamma agonist-binding sites. The lower panel shows the arrangement of the alpha-subunit within the membrane. The subunits are homologous. Each subunit has four transmembrane segments, called M1-M4. The dots on the N-terminal extracellular segment represent the location of amino acids that contribute to the alpha-subunit agonist binding site. The binding site amino acids of the alpha-subunit are tyrosines at alpha 93, alpha 190, and alpha 198, cysteines at alpha 192 and alpha 193, and tryptophan at alpha 149. The MIR is alpha 61 to alpha 76. Note that both the N-terminal and C-terminal portions of the subunit are extracellular. The configurations of the other subunits are similar to that of the alpha-subunit.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Kaminski HJ, Suarez JI, Ruff RL. Neuromuscular junction physiology in myasthenia gravis. Neurology 1997; 48 Suppl 5:8S. Copyright &copy; 1997 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_27_33200=[""].join("\n");
var outline_f32_27_33200=null;
var title_f32_27_33201="Sclerokeratitis";
var content_f32_27_33201=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F87839&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F87839&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 535px\">",
"   <div class=\"ttl\">",
"    Sclerokeratitis due to ocular TB",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 515px; height: 179px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (Panel A) Recurrent sclerokeratitis resulting in multiple corneal peripheral scars. The patient also has active scleritis.",
"    <br/>",
"    (Panel B) Chest computed tomography (CT) revealed enlarged lymph nodes with necrosis involving pretracheal, paratracheal, and subcarinal groups, with the largest lymph node measuring 1.89 x 1.35 cm.",
"    <div class=\"footnotes\">",
"     TB: tuberculosis.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_27_33201=[""].join("\n");
var outline_f32_27_33201=null;
var title_f32_27_33202="Shoulder external rotation 90 90 with resistance";
var content_f32_27_33202=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1140px;\">",
"  <div class=\"videoplayer\" h264=\"./images/EM/86079/Sh_ext_rota_90_resist_video.mp4?title=Shoulder+external+rotation+90+90+with+resistance\" style=\"width:496px;height:288px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Shoulder external rotation 90 90 position with resistance",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Active external rotation against resistance in a &ldquo;90-90&rdquo; position is a relatively advanced rehabilitation exercise to help patients&nbsp;who are ready to begin&nbsp;resuming their usual daily activities.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Craig Parsons, MS, PT and the Physical Therapy Network.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_27_33202=[""].join("\n");
var outline_f32_27_33202=null;
var title_f32_27_33203="Nickel allergy";
var content_f32_27_33203=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F70989&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F70989&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Allergic contact dermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 402px; height: 255px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Subumbilical allergic contact dermatitis from metal fasteners in pants (nickel allergy).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William L Weston, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_27_33203=[""].join("\n");
var outline_f32_27_33203=null;
var title_f32_27_33204="Nilutamide: Drug information";
var content_f32_27_33204=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Nilutamide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?41/19/42292?source=see_link\">",
"    see \"Nilutamide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709174\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F201496\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Nilandron&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F201497\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Anandron&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F201528\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiandrogen;",
"     </li>",
"     <li>",
"      Antineoplastic Agent, Antiandrogen",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F201500\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Prostate cancer, metastatic:",
"     </b>",
"     Oral: 300 mg once daily (starting the same day or day after surgical castration) for 30 days, followed by 150 mg once daily",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F201501\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F13162644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prior to treatment initiation: Severe hepatic impairment: Use is contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     During treatment: ALT &gt;2 times ULN or jaundice: Discontinue treatment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F201476\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nilandron&reg;: 150 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F201461\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9601805\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer without regard to meals.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F201477\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of metastatic prostate cancer (in combination with surgical castration)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F5500981\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Nilutamide may be confused with nilotinib",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F201526\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Insomnia (16%), headache (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hot flashes (28% to 67%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (10% to 24%), constipation (7% to 20%), anorexia (11%), abdominal pain (10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Testicular atrophy (16%), libido decreased (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: AST increased (8% to 13%), ALT increased (8% to 9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Impaired dark adaptation (13% to 57%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Dyspnea (6% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypertension (5% to 9%), chest pain (7%), heart failure (3%), angina (2%), edema (2%), syncope (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (7% to 10%), depression (9%), hypoesthesia (5%), malaise (2%), nervousness (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Alopecia (6%), dry skin (5%), rash (5%), pruritus (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Alcohol intolerance (5%), hyperglycemia (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Vomiting (6%), diarrhea (2%), GI hemorrhage (2%), melena (2%), weight loss (2%), xerostomia (2%), dyspepsia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Nocturia (7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Anemia (7%), haptoglobin increased (2%), leukopenia (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Bone pain (6%), arthritis (2%), paresthesia (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Chromatopsia (9%), impaired light adaptation (8%), abnormal vision (6% to 7%), cataract (2%), photophobia (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Hematuria (8%), BUN increased (2%), creatinine increased (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Pneumonia (5%), cough (2%), interstitial pneumonitis (2%), rhinitis (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Flu-like syndrome  (7%), diaphoresis (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Aplastic anemia, hepatitis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F201481\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to nilutamide or any component of the formulation; severe hepatic impairment; severe respiratory insufficiency",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F201465\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatotoxicity: Hepatitis or marked increases in liver enzymes leading to drug discontinuation occurred in 1% of nilutamide patients. Rare cases of hospitalization or deaths due to severe liver injury have been reported. Discontinue treatment for jaundice or ALT &gt;2 times the upper limit of normal (ULN).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Interstitial pneumonitis:",
"     <b>",
"      [U.S. Boxed Warning]: Interstitial pneumonitis has been reported in 2% of patients exposed to nilutamide.",
"     </b>",
"     Symptoms typically include exertional dyspnea, cough, chest pain, and fever; interstitial changes (including pulmonary fibrosis) leading to hospitalization and fatalities have been reported (rarely). The suggestive signs of pneumonitis most often occurred within the first 3 months of treatment. X-rays showed interstitial or alveolo-interstitial changes; pulmonary function tests revealed a restrictive pattern with decreased DLco. Consider baseline pulmonary function testing. Discontinue if signs and/or symptoms of interstitial pneumonitis are noted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vision effects: A delay in adaptation to dark has been reported; in clinical studies, this was reported by 13% to 57% of patients. The delay ranged from seconds to a few minutes after passing from a light to a dark area. This may not abate with continued treatment although may be alleviated by wearing tinted sunglasses. Caution patients who experience adaptation delay about driving at night or through tunnels.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Females: Not indicated for use in women.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Antiandrogen withdrawal syndrome: Patients with disease progression while receiving antiandrogen therapy may experience clinical improvement with discontinuation of the antiandrogen.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F201522\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C19 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C19 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F201470\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inducers (Strong): May increase the metabolism of CYP2C19 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inhibitors (Moderate): May decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inhibitors (Strong): May decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F201493\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Ethanol: Approximately 5% of patients experience an intolerance (facial flushing, hypotension, malaise) when ethanol is combined with nilutamide. Management: Avoid ethanol.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F201472\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F201484\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Not indicated for use in women.",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13162638\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not indicated for use in women.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F201485\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F201483\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Nilandron Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (30): $713.94",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F201474\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hepatic enzymes (at baseline, regularly during the first 4 months of treatment, periodically thereafter); chest x-ray (at baseline); consider pulmonary function testing (at baseline)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F201486\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Ainedix (CO);",
"     </li>",
"     <li>",
"      Anandron (AR, AU, BR, CH, CZ, FI, FR, GR, HN, HR, HU, MX, NL, NO, PL, PT, SE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F201464\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Nonsteroidal antiandrogen which blocks testosterone effects at the androgen receptor level, preventing androgen response.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F201480\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid and complete",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic (extensive), forms active metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Terminal: 38-59 hours; Metabolites: 59-126 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (62%; &lt;2% as unchanged drug); feces (1% to 7%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bertagna C, DeGery A, Hucher M, et al, &ldquo;Efficacy of the Combination of Nilutamide Plus Orchidectomy in Patients With Metastatic Prostatic Cancer, A Meta-Analysis of Seven Randomized Double-Blind Trials (1056 Patients),&rdquo;",
"      <i>",
"       Br J Urol",
"      </i>",
"      , 1994, 73(4):396-402.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/27/33204/abstract-text/8199827/pubmed\" id=\"8199827\" target=\"_blank\">",
"        8199827",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dijkman GA, Janknegt RA, De Reijke TM, et al, &ldquo;Long-Term Efficacy and Safety of Nilutamide Plus Castration in Advanced Prostate Cancer, and the Significance of Early Prostate Specific Antigen Normalization. International Anandron Study Group,&rdquo;",
"      <i>",
"       J Urol",
"      </i>",
"      , 1997, 158(1):160-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/27/33204/abstract-text/9186345/pubmed\" id=\"9186345\" target=\"_blank\">",
"        9186345",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Du Plessis DJ, &ldquo;Castration Plus Nilutamide Vs Castration Plus Placebo in Advanced Prostate Cancer. A Review,",
"      <i>",
"       Urology",
"      </i>",
"      , 1991, 37(2 Suppl):20-4.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9701 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-E57427EB1A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_27_33204=[""].join("\n");
var outline_f32_27_33204=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709174\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201496\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201497\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201528\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201500\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201501\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13162644\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201476\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201461\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9601805\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201477\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5500981\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201526\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201481\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201465\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201522\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201470\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201493\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201472\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201484\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13162638\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201485\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201483\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201474\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201486\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201464\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201480\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9701\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9701|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?41/19/42292?source=related_link\">",
"      Nilutamide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_27_33205="Vitamin C (ascorbic acid): Patient drug information";
var content_f32_27_33205=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Vitamin C (ascorbic acid): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/45/38614?source=see_link\">",
"     see \"Vitamin C (ascorbic acid): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?8/18/8485?source=see_link\">",
"     see \"Vitamin C (ascorbic acid): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F136900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Acerola [OTC];",
"     </li>",
"     <li>",
"      Asco-Caps-1000 [OTC];",
"     </li>",
"     <li>",
"      Asco-Caps-500 [OTC];",
"     </li>",
"     <li>",
"      Asco-Tabs-1000 [OTC];",
"     </li>",
"     <li>",
"      Ascocid&reg; [OTC];",
"     </li>",
"     <li>",
"      Ascocid&reg;-500 [OTC];",
"     </li>",
"     <li>",
"      C-Gel [OTC];",
"     </li>",
"     <li>",
"      C-Gram [OTC];",
"     </li>",
"     <li>",
"      C-Time [OTC];",
"     </li>",
"     <li>",
"      Cemill 1000 [OTC];",
"     </li>",
"     <li>",
"      Cemill 500 [OTC];",
"     </li>",
"     <li>",
"      Chew-C [OTC];",
"     </li>",
"     <li>",
"      Dull-C&reg; [OTC];",
"     </li>",
"     <li>",
"      Mild-C&reg; [OTC];",
"     </li>",
"     <li>",
"      One Gram C [OTC];",
"     </li>",
"     <li>",
"      Time-C&reg; [OTC];",
"     </li>",
"     <li>",
"      Vicks&reg; Vitamin C [OTC];",
"     </li>",
"     <li>",
"      Vita-C&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F136901\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Proflavanol C&trade;;",
"     </li>",
"     <li>",
"      Revitalose C-1000&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10014589\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691572",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to help growth and good health.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691537",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat vitamin C deficiency.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691355",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower the urine's pH.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10014588\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701551",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ascorbic acid or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10014593\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697059",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are on dialysis, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696833",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take antacids within 2 hours of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10014594\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698198",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Kidney stones may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10014596\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698605",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Back pain, belly pain, or blood in the urine. May be signs of a kidney stone.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10014591\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705324",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         All products:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695899",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with a full glass of water.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695431",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mix powder with water and drink.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694286",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (solution) if you cannot swallow pills.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694604",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chewable tablet: Chew or crush well. Mix crushed tablet with food. Do not swallow it whole.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695322",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Long-acting products: Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle, vein, or into the fatty part of the skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696360",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor may teach you how to give the shot.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696118",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away needles in a needle/sharp disposal box and take the box back to your doctor when it is full.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10014592\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10014597\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699556",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store tablets at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699428",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store liquid (solution) at room temperature. Throw away any part not used after 6 weeks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699391",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a refrigerator. Do not freeze.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10014598\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11120 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.55.141.10-EC79731216-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_27_33205=[""].join("\n");
var outline_f32_27_33205=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136900\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136901\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014589\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014588\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014593\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014594\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014596\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014591\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014592\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014597\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014598\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?37/45/38614?source=related_link\">",
"      Vitamin C (ascorbic acid): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?8/18/8485?source=related_link\">",
"      Vitamin C (ascorbic acid): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_27_33206="Chronic mesenteric ischemia";
var content_f32_27_33206=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chronic mesenteric ischemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/27/33206/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/27/33206/contributors\">",
"     David A Tendler, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/27/33206/contributors\">",
"     J Thomas LaMont, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/27/33206/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/27/33206/contributors\">",
"     Paul Rutgeerts, MD, PhD, FRCP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/27/33206/contributors\">",
"     John F Eidt, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/27/33206/contributors\">",
"     Joseph L Mills, Sr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/27/33206/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/27/33206/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/27/33206/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 8, 2009.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mesenteric ischemia is caused by a reduction in intestinal blood flow, which most commonly arises from occlusion, vasospasm",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypoperfusion of the mesenteric vasculature. The clinical consequences can be catastrophic, including sepsis, bowel infarction, and death, making rapid diagnosis and treatment imperative.",
"   </p>",
"   <p>",
"    Intestinal ischemia can be divided into acute and chronic, based upon the rapidity and the degree to which blood flow is compromised.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute mesenteric ischemia refers to the sudden onset of intestinal hypoperfusion, which can be due to occlusive or nonocclusive obstruction of arterial or venous blood flow. Occlusive arterial obstruction is most commonly due to emboli or thrombosis of mesenteric arteries while occlusive venous obstruction is most commonly due to thrombosis or segmental strangulation. Nonocclusive arterial hypoperfusion is most commonly due to primary splanchnic vasoconstriction.",
"     </li>",
"     <li>",
"      Chronic mesenteric ischemia (also called intestinal angina) refers to episodic or constant intestinal hypoperfusion, which usually develops in patients with mesenteric atherosclerotic disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Chronic mesenteric ischemia involving the small intestine will be reviewed here. The anatomy of the mesenteric vasculature, acute mesenteric small intestinal ischemia, and colonic ischemia are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/21/44377?source=see_link\">",
"     \"Acute mesenteric ischemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/20/42313?source=see_link\">",
"     \"Colonic ischemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The American Gastroenterological Association (AGA) guideline for intestinal ischemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33206/abstract/1\">",
"     1",
"    </a>",
"    ], as well as other AGA guidelines, can be accessed through the AGA web site at",
"    <a class=\"external\" href=\"file://www.gastro.org/practice/medical-position-statements\">",
"     file://www.gastro.org/practice/medical-position-statements",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic mesenteric ischemia has also been referred to as \"intestinal angina,\" since it is manifested by recurrent acute episodes of abdominal pain, resulting from insufficient splanchnic blood flow during periods of heightened intestinal demand. The typical patient has a history of smoking and underlying atherosclerotic vascular disease, with approximately half of patients having known peripheral vascular disease or coronary artery disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33206/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients classically complain of dull, crampy, postprandial epigastric pain, usually within the first hour after eating. The pain can be of variable intensity and location, and may occasionally radiate to the back. The severity of the pain is increased after larger meals with high fat content [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33206/abstract/2\">",
"     2",
"    </a>",
"    ]. The pain usually subsides over the course of the next two hours. Symptoms are often progressive and may culminate in acute mesenteric ischemia (acute-on-chronic mesenteric ischemia) from thrombus formation. Such patients have a much higher morbidity and mortality following surgery than patients with chronic symptoms only. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/21/44377?source=see_link\">",
"     \"Acute mesenteric ischemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two possible explanations for the timing of symptoms have been proposed. One suggests that pain arises from a mismatch between splanchnic blood flow and intestinal metabolic demand, while the other suggests that small intestinal hypoperfusion results from blood being shunted to the stomach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33206/abstract/3\">",
"     3",
"    </a>",
"    ]. The latter explanation is probably more consistent with the typical temporal pattern.",
"   </p>",
"   <p>",
"    Weight loss, present in about 80 percent of patients, has been attributed to the development of a food aversion due to the anticipation of postprandial pain. Approximately one-third of patients have nausea, vomiting, and early satiety, which is probably a consequence of foregut ischemia from celiac artery insufficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of chronic mesenteric ischemia is supported by the demonstration of high grade stenoses in multiple mesenteric vessels, in patients with unexplained chronic abdominal pain, weight loss, and food aversion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33206/abstract/2,4\">",
"     2,4",
"    </a>",
"    ]. A high clinical index of suspicion is crucial to making the diagnosis. The constellation of progressive abdominal pain and weight loss in elderly patients frequently prompts an evaluation to rule out conditions such as malignancy, chronic cholecystitis, chronic pancreatitis, and peptic ulcer disease. The failure to identify a specific etiology in these patients should suggest chronic mesenteric ischemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33206/abstract/4\">",
"     4",
"    </a>",
"    ]. The presence of mesenteric artery stenosis alone does not establish the diagnosis since up to 18 percent of individuals over 65 in the general population have significant stenosis of the celiac or superior mesenteric artery without symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33206/abstract/5\">",
"     5",
"    </a>",
"    ]. Angiography is currently considered to be the gold standard diagnostic test. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/30/16874?source=see_link\">",
"     \"Differential diagnosis of abdominal pain in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Physical findings are usually nonspecific except for weight loss. Abdominal examination reveals a bruit in approximately 50 percent of patients.",
"   </p>",
"   <p>",
"    Routine laboratories, plain and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    contrast radiography, and endoscopic examinations are usually not diagnostic. However, calcification of mesenteric vessels may be seen on radiography, a clue to the diagnosis. CT and MR angiography are reasonable initial tests since they can identify whether a stenosis is present and determine the best route that it can be reached angiographically (ie, by groin or arm access) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33206/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H115829127\">",
"    <span class=\"h2\">",
"     Duplex ultrasonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mesenteric duplex ultrasonography has also been advocated as a reasonably accurate screening modality for the detection of high-grade celiac and superior mesenteric artery stenoses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33206/abstract/2,8\">",
"     2,8",
"    </a>",
"    ]. Sensitivity exceeding 90 percent has been reported in patients with more than a 50 percent stenosis of the superior mesenteric or celiac arteries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33206/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Postprandial duplex ultrasonography does not significantly improve upon this yield [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33206/abstract/8,11\">",
"     8,11",
"    </a>",
"    ]. A fasting peak systolic velocity &ge;275",
"    <span class=\"nowrap\">",
"     cm/s",
"    </span>",
"    predicts a 70 percent or greater angiographic stenosis with a sensitivity of 92 percent and a specificity of 96 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33206/abstract/12\">",
"     12",
"    </a>",
"    ]. Because the negative predictive value of duplex ultrasonography approaches 99 percent, it is justifiable to pursue other etiologies of abdominal pain after a negative study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33206/abstract/8\">",
"     8",
"    </a>",
"    ]. However, the number of patients who have been studied using this technique is limited, and technical considerations including the expertise of the examiner, large body habitus, intra-intestinal gas, and prior abdominal surgery should be considered in assessing the results. Angiography should be recommended if the results of noninvasive testing are equivocal or if they suggest that intervention is required. High-grade mesenteric vascular stenoses in at least two major vessels (celiac, superior mesenteric, or inferior mesenteric) with extensive collateral formation must be established in biplanar views [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33206/abstract/2,4\">",
"     2,4",
"    </a>",
"    ]. A single complete occlusion of a single artery may be the cause of intestinal angina in approximately 5 percent of patients. Angiography will further establish the feasibility of revascularization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Newer diagnostic modalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of additional approaches to diagnosis have been described including three-dimensional, breath hold, contrast-enhanced magnetic resonance angiography (MRA), which can provide highly accurate images of the arterial and venous mesenteric vasculature [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33206/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. The existing data suggest that contrast-enhanced MRA is highly sensitive for detecting stenoses at or near the origin of the SMA or celiac artery; however, the technique is much less reliable for detecting more distal lesions. In addition, cine phase-contrast MRA may be able to detect significant abnormalities in mesenteric blood flow [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33206/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. The usefulness of these techniques is currently limited by the need for significant expertise in the use of this highly specialized equipment. At present, MRA should be considered experimental as a diagnostic tool for chronic mesenteric ischemia.",
"   </p>",
"   <p>",
"    Another modality, tonometry, is currently being evaluated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33206/abstract/18-22\">",
"     18-22",
"    </a>",
"    ]. The technique uses an intraluminal catheter to measure the intestinal pH in the jejunum after a test meal. The development of intramural acidosis correlates with abdominal pain and may be a good marker of tissue ischemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33206/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An endoscopic device was described as a means to objectively measure mesenteric ischemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33206/abstract/23\">",
"     23",
"    </a>",
"    ]. With the use of a visible light spectroscopy oximeter, abnormally low mucosal oxygen saturations were measured in the proximal small bowel of patients with chronic mesenteric ischemia. These changes resolved after successful angioplasty and stent placement of the involved mesenteric arteries. Larger studies will be necessary to validate these findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapeutic options for patients suspected to have symptoms attributable to chronic mesenteric ischemia include surgical reconstruction, and percutaneous transluminal angioplasty (PTA) with or without placement of a stent.",
"   </p>",
"   <p>",
"    At many hospitals the treatment of choice depends on the availability of experienced vascular surgeons or interventional radiologists. The decision to perform open surgery versus angioplasty and stenting is based upon the patient's age, comorbidities, the number and severity of occluded vessels, and the ease of vascular access to the stenosed vessels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33206/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. In most patients angioplasty is preferred, with surgery reserved for younger patients with fewer comorbid conditions.",
"   </p>",
"   <p>",
"    Several reconstructive techniques have been described, including bypass grafting, endarterectomy, and reimplantation. The choice of procedure depends upon the judgment and experience of the surgeon since controlled trials have not demonstrated a clear superiority of any one technique [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33206/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several studies have described the long-term results of surgical reconstruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33206/abstract/27-30\">",
"     27-30",
"    </a>",
"    ]. Perioperative mortality ranged from 0 to 11 percent but up to 50 percent with patients with acute-on- chronic symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33206/abstract/31\">",
"     31",
"    </a>",
"    ]. Primary graft patency rates at five years ranged from 57 to 69 percent, and 5-year survival rates ranged from 63 to 77 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33206/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. Among the survivors, the freedom-from-recurrence rates at 5 and 10 years were approximately 80 and 60 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33206/abstract/28,30\">",
"     28,30",
"    </a>",
"    ]. In a study of 80 patients with chronic mesenteric ischemia who underwent an open surgical procedure, surgical endarterectomy appeared to achieve better long-term symptom relief compared to mesenteric bypass [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33206/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Percutaneous transluminal angioplasty (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef86512 \" href=\"mobipreview.htm?38/37/39512\">",
"     image 1",
"    </a>",
"    ) has become an alternative to surgery for the many patients with CMI who are poor surgical candidates, and for patients in whom the diagnosis remains uncertain. Despite limited published experience, most authors have reported success rates of greater than 80 percent, defined as residual stenoses of less than 50 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33206/abstract/32-36\">",
"     32-36",
"    </a>",
"    ]. Relief of abdominal pain has been achieved in 75 to 100 percent of patients and half of the patients experienced weight gain. Long term follow up indicates clinical remission in approximately 80 percent of patients at two to three years. Recurrent symptoms are usually associated with restenosis, that can often be successfully managed with repeat angioplasty [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33206/abstract/35,37\">",
"     35,37",
"    </a>",
"    ]. However, restenosis and recurrent symptoms occur in 17 to 50 percent of patients within the first year, making the limited durability of the procedure its greatest limitation.",
"   </p>",
"   <p>",
"    Although experience is limited, a number of reports have described placement of an expandable metal stent to help prevent reocclusion (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef50488 \" href=\"mobipreview.htm?34/51/35647\">",
"     image 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33206/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. One such report included 21 patients who underwent PTA and 12 patients who underwent PTA plus stenting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33206/abstract/35\">",
"     35",
"    </a>",
"    ]. The overall primary long- term (mean 38 months) clinical success rate was 83 percent among the 29 patients who experienced initial clinical success. The five year survival in this group was 76 percent. There was no statistical difference in long-term success rates between the two groups; however the mean follow up for patients who had a stent placed was only 15 months. These results compare favorably with the published surgically revascularized patients. A study of 65 patients who underwent percutaneous angioplasty and stenting of 87 mesenteric vessels demonstrated one-year primary and assisted patency rates of 65 and 97 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33206/abstract/40\">",
"     40",
"    </a>",
"    ]. Survival at 60 days was significantly diminished in patients who required bowel resection.",
"   </p>",
"   <p>",
"    An earlier retrospective study directly compared surgical revascularization with PTA and found similar efficacy and complication rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33206/abstract/41\">",
"     41",
"    </a>",
"    ]. However, one-third of patients in the PTA group had restenosis within an average of 10 months, compared with no recurrences in the surgical patients at an average follow-up period of 35 months. A later report from the same institutions compared angioplasty and stenting to the earlier surgical series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33206/abstract/42\">",
"     42",
"    </a>",
"    ]. Comparable results were observed for in-hospital complications and 30 day mortality. Length of stay was 5 days in the angioplasty patients versus 13 days for open surgery. At three years the cumulative restenosis rate and mortality rate were similar, but more patients in the angioplasty group had recurrent symptoms of intestinal angina (34 versus 13 percent).",
"   </p>",
"   <p>",
"    Another study compared",
"    <span class=\"nowrap\">",
"     PTA/stenting",
"    </span>",
"    to operative open repair in 80 consecutive patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33206/abstract/25\">",
"     25",
"    </a>",
"    ]. PTA with stenting was performed in 27 patients, PTA alone in 4 patients, and operative open repair in 49 patients. Two-year survivals, the incidence of symptomatic recurrence, and the incidence of radiographic recurrence were similar between the groups. Although radiographic primary patency was lower in the",
"    <span class=\"nowrap\">",
"     PTA/stenting",
"    </span>",
"    group (58 versus 90 percent), so was the need for a second intervention (16 versus 22 percent). A later report comparing 17 surgical reconstructions with 15 endovascular reconstructions showed significantly shorter hospital stays for patients with endovascular reconstructions (4 versus 14 days), but superior secondary and clinical two-year patency rates for surgical reconstructions (100 versus 65 percent and 100 versus 73 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33206/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There have been no large, randomized, controlled trials comparing PTA, PTA with stenting, and surgical revascularization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?10/3/10290?source=see_link\">",
"       \"Patient information: Ischemic bowel disease (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic mesenteric ischemia (also called intestinal angina) refers to episodic or constant intestinal hypoperfusion, which usually develops in patients with mesenteric atherosclerotic disease.",
"     </li>",
"     <li>",
"      Patients classically complain of dull, crampy, postprandial epigastric pain, usually within the first hour after eating. The pain can be of variable intensity and location, and may occasionally radiate to the back. The severity of the pain is increased after larger meals with high fat content. The pain usually subsides over the course of the next two hours. Symptoms are often progressive and may culminate in acute mesenteric ischemia (acute-on-chronic mesenteric ischemia) from thrombus formation. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of chronic mesenteric ischemia is supported by the demonstration of high-grade stenoses usually in multiple mesenteric vessels, in patients with unexplained chronic abdominal pain, weight loss, and food aversion. A high clinical index of suspicion is crucial to making the diagnosis. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Therapeutic options for patients suspected to have symptoms attributable to chronic mesenteric ischemia include surgical reconstruction and percutaneous transluminal angioplasty (PTA) with or without placement of a stent. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33206/abstract/1\">",
"      American Gastroenterological Association Medical Position Statement: guidelines on intestinal ischemia. Gastroenterology 2000; 118:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33206/abstract/2\">",
"      Moawad J, Gewertz BL. Chronic mesenteric ischemia. Clinical presentation and diagnosis. Surg Clin North Am 1997; 77:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33206/abstract/3\">",
"      Poole JW, Sammartano RJ, Boley SJ. Hemodynamic basis of the pain of chronic mesenteric ischemia. Am J Surg 1987; 153:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33206/abstract/4\">",
"      Reinus JF, Brandt LJ, Boley SJ. Ischemic diseases of the bowel. Gastroenterol Clin North Am 1990; 19:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33206/abstract/5\">",
"      Wilson DB, Mostafavi K, Craven TE, et al. Clinical course of mesenteric artery stenosis in elderly americans. Arch Intern Med 2006; 166:2095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33206/abstract/6\">",
"      Savastano S, Teso S, Corr&agrave; S, et al. Multislice CT angiography of the celiac and superior mesenteric arteries: comparison with arteriographic findings. Radiol Med 2002; 103:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33206/abstract/7\">",
"      Cademartiri F, Palumbo A, Maffei E, et al. Noninvasive evaluation of the celiac trunk and superior mesenteric artery with multislice CT in patients with chronic mesenteric ischaemia. Radiol Med 2008; 113:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33206/abstract/8\">",
"      Nicoloff AD, Williamson WK, Moneta GL, et al. Duplex ultrasonography in evaluation of splanchnic artery stenosis. Surg Clin North Am 1997; 77:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33206/abstract/9\">",
"      Harward TR, Smith S, Seeger JM. Detection of celiac axis and superior mesenteric artery occlusive disease with use of abdominal duplex scanning. J Vasc Surg 1993; 17:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33206/abstract/10\">",
"      Moneta GL, Lee RW, Yeager RA, et al. Mesenteric duplex scanning: a blinded prospective study. J Vasc Surg 1993; 17:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33206/abstract/11\">",
"      Gentile AT, Moneta GL, Lee RW, et al. Usefulness of fasting and postprandial duplex ultrasound examinations for predicting high-grade superior mesenteric artery stenosis. Am J Surg 1995; 169:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33206/abstract/12\">",
"      Moneta GL. Screening for mesenteric vascular insufficiency and follow-up of mesenteric artery bypass procedures. Semin Vasc Surg 2001; 14:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33206/abstract/13\">",
"      Holland GA, Dougherty L, Carpenter JP, et al. Breath-hold ultrafast three-dimensional gadolinium-enhanced MR angiography of the aorta and the renal and other visceral abdominal arteries. AJR Am J Roentgenol 1996; 166:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33206/abstract/14\">",
"      Shirkhoda A, Konez O, Shetty AN, et al. Mesenteric circulation: three-dimensional MR angiography with a gadolinium-enhanced multiecho gradient-echo technique. Radiology 1997; 202:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33206/abstract/15\">",
"      Meaney JF, Prince MR, Nostrant TT, Stanley JC. Gadolinium-enhanced MR angiography of visceral arteries in patients with suspected chronic mesenteric ischemia. J Magn Reson Imaging 1997; 7:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33206/abstract/16\">",
"      Burkart DJ, Johnson CD, Reading CC, Ehman RL. MR measurements of mesenteric venous flow: prospective evaluation in healthy volunteers and patients with suspected chronic mesenteric ischemia. Radiology 1995; 194:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33206/abstract/17\">",
"      Li KC, Hopkins KL, Dalman RL, Song CK. Simultaneous measurement of flow in the superior mesenteric vein and artery with cine phase-contrast MR imaging: value in diagnosis of chronic mesenteric ischemia. Work in progress. Radiology 1995; 194:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33206/abstract/18\">",
"      Boley SJ, Brandt LJ, Veith FJ, et al. A new provocative test for chronic mesenteric ischemia. Am J Gastroenterol 1991; 86:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33206/abstract/19\">",
"      Walley KR, Friesen BP, Humer MF, Phang PT. Small bowel tonometry is more accurate than gastric tonometry in detecting gut ischemia. J Appl Physiol 1998; 85:1770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33206/abstract/20\">",
"      Kolkman JJ, Groeneveld AB. Occlusive and non-occlusive gastrointestinal ischaemia: a clinical review with special emphasis on the diagnostic value of tonometry. Scand J Gastroenterol Suppl 1998; 225:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33206/abstract/21\">",
"      Otte JA, Geelkerken RH, Oostveen E, et al. Clinical impact of gastric exercise tonometry on diagnosis and management of chronic gastrointestinal ischemia. Clin Gastroenterol Hepatol 2005; 3:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33206/abstract/22\">",
"      Mensink PB, Geelkerken RH, Huisman AB, et al. Twenty-four hour tonometry in patients suspected of chronic gastrointestinal ischemia. Dig Dis Sci 2008; 53:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33206/abstract/23\">",
"      Friedland S, Benaron D, Coogan S, et al. Diagnosis of chronic mesenteric ischemia by visible light spectroscopy during endoscopy. Gastrointest Endosc 2007; 65:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33206/abstract/24\">",
"      Biebl M, Oldenburg WA, Paz-Fumagalli R, et al. Surgical and interventional visceral revascularization for the treatment of chronic mesenteric ischemia--when to prefer which? World J Surg 2007; 31:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33206/abstract/25\">",
"      Atkins MD, Kwolek CJ, LaMuraglia GM, et al. Surgical revascularization versus endovascular therapy for chronic mesenteric ischemia: a comparative experience. J Vasc Surg 2007; 45:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33206/abstract/26\">",
"      Shanley CJ, Ozaki CK, Zelenock GB. Bypass grafting for chronic mesenteric ischemia. Surg Clin North Am 1997; 77:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33206/abstract/27\">",
"      Park WM, Cherry KJ Jr, Chua HK, et al. Current results of open revascularization for chronic mesenteric ischemia: a standard for comparison. J Vasc Surg 2002; 35:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33206/abstract/28\">",
"      Cho JS, Carr JA, Jacobsen G, et al. Long-term outcome after mesenteric artery reconstruction: a 37-year experience. J Vasc Surg 2002; 35:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33206/abstract/29\">",
"      Jimenez JG, Huber TS, Ozaki CK, et al. Durability of antegrade synthetic aortomesenteric bypass for chronic mesenteric ischemia. J Vasc Surg 2002; 35:1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33206/abstract/30\">",
"      Mell MW, Acher CW, Hoch JR, et al. Outcomes after endarterectomy for chronic mesenteric ischemia. J Vasc Surg 2008; 48:1132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33206/abstract/31\">",
"      English WP, Pearce JD, Craven TE, et al. Chronic visceral ischemia: symptom-free survival after open surgical repair. Vasc Endovascular Surg 2004; 38:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33206/abstract/32\">",
"      Allen RC, Martin GH, Rees CR, et al. Mesenteric angioplasty in the treatment of chronic intestinal ischemia. J Vasc Surg 1996; 24:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33206/abstract/33\">",
"      Hallisey MJ, Deschaine J, Illescas FF, et al. Angioplasty for the treatment of visceral ischemia. J Vasc Interv Radiol 1995; 6:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33206/abstract/34\">",
"      Matsumoto AH, Tegtmeyer CJ, Fitzcharles EK, et al. Percutaneous transluminal angioplasty of visceral arterial stenoses: results and long-term clinical follow-up. J Vasc Interv Radiol 1995; 6:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33206/abstract/35\">",
"      Matsumoto AH, Angle JF, Spinosa DJ, et al. Percutaneous transluminal angioplasty and stenting in the treatment of chronic mesenteric ischemia: results and longterm followup. J Am Coll Surg 2002; 194:S22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33206/abstract/36\">",
"      Silva JA, White CJ, Collins TJ, et al. Endovascular therapy for chronic mesenteric ischemia. J Am Coll Cardiol 2006; 47:944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33206/abstract/37\">",
"      Sharafuddin MJ, Olson CH, Sun S, et al. Endovascular treatment of celiac and mesenteric arteries stenoses: applications and results. J Vasc Surg 2003; 38:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33206/abstract/38\">",
"      Yamakado K, Takeda K, Nomura Y, et al. Relief of mesenteric ischemia by Z-stent placement into the superior mesenteric artery compressed by the false lumen of an aortic dissection. Cardiovasc Intervent Radiol 1998; 21:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33206/abstract/39\">",
"      Waybill PN, Enea NA. Use of a Palmaz stent deployed in the superior mesenteric artery for chronic mesenteric ischemia. J Vasc Interv Radiol 1997; 8:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33206/abstract/40\">",
"      Sarac TP, Altinel O, Kashyap V, et al. Endovascular treatment of stenotic and occluded visceral arteries for chronic mesenteric ischemia. J Vasc Surg 2008; 47:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33206/abstract/41\">",
"      Rose SC, Quigley TM, Raker EJ. Revascularization for chronic mesenteric ischemia: comparison of operative arterial bypass grafting and percutaneous transluminal angioplasty. J Vasc Interv Radiol 1995; 6:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33206/abstract/42\">",
"      Kasirajan K, O'Hara PJ, Gray BH, et al. Chronic mesenteric ischemia: open surgery versus percutaneous angioplasty and stenting. J Vasc Surg 2001; 33:63.",
"     </a>",
"    </li>",
"    <li>",
"     Davies, RS, Wall, ML, Silverman, SH, et al. Surgical versus endovascular reconstruction for chronic mesenteric ischemia: A contemporary UK series. Vasc Endovascular Surg 2008; [Epub ahead of print].",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2563 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.111.122.2-0C8C6D5D65-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_27_33206=[""].join("\n");
var outline_f32_27_33206=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H115829127\">",
"      Duplex ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Newer diagnostic modalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/2563\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/2563|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?38/37/39512\" title=\"diagnostic image 1\">",
"      Superior mesenteric arterty angioplasty and stent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?34/51/35647\" title=\"diagnostic image 2\">",
"      Superior mesenteric artery stent",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/21/44377?source=related_link\">",
"      Acute mesenteric ischemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/20/42313?source=related_link\">",
"      Colonic ischemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/30/16874?source=related_link\">",
"      Differential diagnosis of abdominal pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?10/3/10290?source=related_link\">",
"      Patient information: Ischemic bowel disease (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_27_33207="Subvalvar aortic stenosis (subaortic stenosis)";
var content_f32_27_33207=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Subvalvar aortic stenosis (subaortic stenosis)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/27/33207/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/27/33207/contributors\">",
"     David W Brown, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/27/33207/contributors\">",
"     John F Keane, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/27/33207/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/27/33207/contributors\">",
"     David R Fulton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/27/33207/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/27/33207/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/27/33207/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 7, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Left ventricular outflow tract (LVOT) obstructive lesions account for approximately 6 percent of cases of congenital heart disease in children; in one series, the incidence was estimated to be 6 in 10,000 live births [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33207/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Obstruction may occur at valvar (which is by far the most common), subvalvar, and supravalvar levels.",
"   </p>",
"   <p>",
"    Subvalvar aortic stenosis (also called subaortic stenosis) will be reviewed here. Valvar and supravalvar aortic stenosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/28/38345?source=see_link\">",
"     \"Valvar aortic stenosis in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/52/40774?source=see_link\">",
"     \"Supravalvar aortic stenosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Subvalvar aortic stenosis can be induced by a fixed stenosis, or may have a dynamic component that is primarily due to the genetic disease hypertrophic cardiomyopathy (previously called idiopathic hypertrophic subaortic stenosis). Only fixed stenosis will be reviewed here; subvalvar obstruction due to hypertrophic cardiomyopathy is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/59/28600?source=see_link\">",
"     \"Types and pathophysiology of obstructive hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subvalvar aortic stenosis (AS) is the second most common form of AS. Among children with congenital AS, subvalvar AS accounts for 10 to 14 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33207/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Similar to valvar AS, subvalvar AS is more common in males, who account for 67 to 75 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33207/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other cardiac malformations occur in 50 to 65 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33207/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. One report of 35 patients found the following lesions: patent ductus arteriosus (34 percent), ventricular septal defect (VSD, 20 percent), aortic coarctation (23 percent), pulmonic stenosis (9 percent), and miscellaneous other lesions (14 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33207/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Subvalvar AS is seldom encountered in newborns and is rare in infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33207/abstract/4,6\">",
"     4,6",
"    </a>",
"    ]. In clinical practice, subvalvar AS develops and progresses over time so that most consider it an acquired rather than congenital lesion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33207/abstract/4,6-8\">",
"     4,6-8",
"    </a>",
"    ]. In some patients, it is not detected until one to six years after surgical correction of a VSD or aortic coarctation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33207/abstract/7,9\">",
"     7,9",
"    </a>",
"    ]. One hypothesis is that an underlying abnormality in LVOT architecture creates turbulence, which then contributes to progressive LVOT thickening, fibrosis, and scarring, with scarring of an otherwise normal aortic valve as well [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33207/abstract/10\">",
"     10",
"    </a>",
"    ]. At least two observations are consistent with a congenital predisposition:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among children who undergo surgery for a VSD or aortic coarctation, specific LVOT geometric abnormalities, most notably the angle between the aortic outflow and the long axis of the ventricular septum [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/27/33207/abstract/11\">",
"       11",
"      </a>",
"      ], have been identified on echocardiography that predict the subsequent development of subvalvar AS [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/27/33207/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Familial occurrence of subvalvar AS has been described in humans and Newfoundland dogs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/27/33207/abstract/12,13\">",
"       12,13",
"      </a>",
"      ], which indicates a genetic predisposition.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subvalvar AS encompasses a variety of lesions, which can occur alone or in combination. These include a thin membrane (the most common lesion), thick fibromuscular ridge, diffuse tunnel-like obstruction, abnormal mitral valve attachments, and occasionally, accessory endocardial cushion tissue.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the majority of patients, obstruction is caused by a membrane that is attached to the ventricular septum or completely encircles the LVOT (",
"      <a class=\"graphic graphic_movie graphicRef74841 \" href=\"mobipreview.htm?9/12/9418\">",
"       movie 1",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/27/33207/abstract/5,14-16\">",
"       5,14-16",
"      </a>",
"      ]. Its location ranges from immediately below the aortic valve to a point further down into the left ventricle. The aortic valve is usually tricommissural [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/27/33207/abstract/17\">",
"       17",
"      </a>",
"      ]. Some degree of muscular ventricular septal hypertrophy is present in up to 75 percent of cases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/27/33207/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Diffuse, \"tunnel-like\" narrowing of the LVOT is rare and is characterized by marked myocardial hypertrophy and, often, aortic annular hypoplasia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/27/33207/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, it has been suggested that subaortic stenosis results from an underlying abnormality in LVOT architecture, with turbulence leading to progressive LVOT fibrosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33207/abstract/4,10\">",
"     4,10",
"    </a>",
"    ]. Significant obstruction of the LVOT leads to ventricular hypertrophy and hyperdynamic function.",
"   </p>",
"   <p>",
"    Many patients have associated aortic regurgitation (AR). The mechanism is thought to be thickening of the valve leaflets due to trauma from the high velocity jets caused by the subaortic lesion. In one study of 220 patients with subaortic stenosis, a peak Doppler gradient &ge;50 mmHg at diagnosis was a significant predictor of at least moderate AR, while patients with no or trivial AR tended to have thin, mobile valve leaflets [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33207/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinically significant subvalvar AS is an isolated lesion is rare in newborns and unusual in infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33207/abstract/4\">",
"     4",
"    </a>",
"    ]. Patients with mild or moderate obstruction are typically asymptomatic. The lesion is often uncovered during evaluation of other associated cardiac defects. When uncomplicated, it is generally identified when echocardiography is performed for evaluation of a murmur, which is occurring more often and at earlier ages in recent years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;More than one-half of affected patients have a cardiac murmur during the first year of life, which becomes more typical of LV outflow obstruction as the patient gets older [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33207/abstract/5\">",
"     5",
"    </a>",
"    ]. Physical examination in fixed subvalvar AS reveals the following features (",
"    <a class=\"graphic graphic_table graphicRef51024 \" href=\"mobipreview.htm?42/11/43196\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33207/abstract/21\">",
"     21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A characteristic harsh \"shrieking\" systolic ejection type murmur heard best at the mid-left sternal border. A thrill is sometimes palpable at the same site.",
"     </li>",
"     <li>",
"      A preceding ejection click is rare unless a bicommissural aortic valve is also present.",
"     </li>",
"     <li>",
"      An early diastolic high frequency murmur of AR is heard in some patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The physical examination can also help distinguish fixed from dynamic subaortic stenosis in hypertrophic cardiomyopathy (HCM) (",
"    <a class=\"graphic graphic_table graphicRef51024 \" href=\"mobipreview.htm?42/11/43196\">",
"     table 1",
"    </a>",
"    ). In patients who are able to cooperate with a Valsalva maneuver, the intensity of the murmur typically decreases in fixed subvalvar AS and increases in HCM.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the physical examination can help to distinguish subaortic stenosis from other causes of LVOT obstruction, and echocardiography confirms the diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Echocardiography characterizes the anatomy of the subaortic lesion, and is useful to assess dimensions and function of the LV and integrity of the aortic and mitral valves. Associated congenital lesions and nonobstructive membranes can also be visualized. As echocardiography has become more commonplace, thin non-obstructive membranes and septal protrusions have been found in those without sub-aortic stenosis.",
"   </p>",
"   <p>",
"    Thin fibrous membranes are typically seen just proximal to the junction of the aortic root with the septum. On a two dimensional echocardiogram, such membranes typically appear to arise from the membranous septum, although they may arise from a thickened muscular ridge slightly further down into the ventricle (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef71372 \" href=\"mobipreview.htm?21/51/22324\">",
"     image 1",
"    </a>",
"    ). Attachments to the anterior leaflet of the mitral valve are frequently seen. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/3/1082?source=see_link\">",
"     \"Echocardiographic evaluation of the aortic valve\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The degree of obstruction to outflow in subvalvar AS is often difficult to appreciate on the two dimensional echocardiogram, and Doppler examination is indicated. Continuous wave Doppler is used to estimate the gradient and therefore the extent of obstruction across the LVOT. The measurement of the maximum instantaneous gradient by echocardiogram is often higher (as much as 37 percent) than the peak-to-peak gradient at catheterization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33207/abstract/22\">",
"     22",
"    </a>",
"    ]. Some investigators have noted a high correlation between mean gradient values estimated by Doppler and peak to peak LVOT gradients directly measured by catheter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33207/abstract/22,23\">",
"     22,23",
"    </a>",
"    ], but in our clinical experience, we have not found this to be a consistent finding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1210667092\">",
"    <span class=\"h2\">",
"     Other tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrocardiogram and chest radiography are not diagnostic but are often performed in patients with subvalvar AS. Cardiac catheterization is frequently performed for further elucidation of the anatomy, particularly in patients with multiple levels of obstruction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Electrocardiogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ECG is usually abnormal in subvalvar AS. Although the ECG remains normal in some patients with severe obstruction, the majority have LV hypertrophy with decreased anterior forces and, less often, a strain pattern. Signs of LV hypertrophy are seen in up to one-half of those with mild subaortic stenosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33207/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Chest radiograph",
"    </span>",
"    &nbsp;&mdash;&nbsp;The chest radiograph is often normal. Some patients, including those with mild stenosis, have mild cardiomegaly or LV prominence. Dilation of the ascending aorta is uncommon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33207/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Cardiac catheterization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac catheterization is frequently performed to further elucidate the mechanism and extent of subaortic obstruction, especially when multiple levels of obstruction are suspected. We do not usually perform catheterization in patients with simple membranes or ridges.",
"   </p>",
"   <p>",
"    Catheterization provides both hemodynamic and anatomic data, such as the gradient across the valve, measurement of cardiac output, and estimates of the degree of AR. Associated lesions, such as aortic coarctation, can be defined. However, fine anatomic details of nearby structures, such as the mitral valve apparatus, are better shown by echocardiography.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     COURSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with subvalvar AS often have rapidly progressive obstruction in infancy and early childhood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33207/abstract/6,8,24,25\">",
"     6,8,24,25",
"    </a>",
"    ]. However, the disorder may remain stable for years, and some adults have only mild obstruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33207/abstract/4,26,27\">",
"     4,26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One report described the course of subvalvar AS in 83 patients (age 11 months to 25 years) who were followed for a median of 6.1 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33207/abstract/24\">",
"     24",
"    </a>",
"    ]. Additional cardiac malformations were present in 47 (57 percent), and 14 (17 percent) had significant noncardiac lesions. Surgery was performed in 74 patients at a median age of 12 years. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The LV outflow gradient increased in 25 of 26 patients who had cardiac catheterization more than once before surgery",
"     </li>",
"     <li>",
"      AR that was usually mild was present before surgery in 55 percent and was absent or mild in most patients after surgery",
"     </li>",
"     <li>",
"      Infectious endocarditis occurred in 12 percent but did not occur when the gradient was decreased to &lt;80 mmHg after surgery unless there were other residual lesions",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Not surprisingly, progression of subvalvar AS appears to be slower in patients who do not present until adulthood, since they have presumably been selected out as having less severe disease. This was illustrated in a series of 134 patients (mean age 31 years) with discrete subaortic stenosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33207/abstract/27\">",
"     27",
"    </a>",
"    ]. The mean LVOT gradient increased from 39.2 to 46.8 mmHg over five years, a rate of change of 2.25 mmHg per year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33207/abstract/27\">",
"     27",
"    </a>",
"    ]. Moderate to severe aortic regurgitation was present in only 19 percent, and significant progression of aortic regurgitation was not seen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Surgical repair",
"    </span>",
"    &nbsp;&mdash;&nbsp;Definitive therapy for subvalvar AS consists of surgical correction of the obstruction, which may range from simple membrane removal to extensive ring resection, with or without myomectomy, to a Konno procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the high rate of recurrence, the timing of surgery, especially in the first decade of life is controversial. Recommendations range from early operation to longer periods of observation, varying with patient characteristics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33207/abstract/15,28-31\">",
"     15,28-31",
"    </a>",
"    ]. The appearance of significant aortic regurgitation is considered an indication for surgery because it is an acquired lesion, although the extent rarely progresses to or beyond moderate in young children. Significant aortic regurgitation appears to be more common in post-operative patients and following balloon dilation attempts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33207/abstract/20,27,31\">",
"     20,27,31",
"    </a>",
"    ]. Operating on young patients solely based upon peak systolic gradients &lt;30 mmHg is probably unnecessary, as some of these remain unchanged for many years. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Recommendations'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    This recommendation was confirmed in a large retrospective study of 313 children diagnosed with subaortic stenosis between 1975 and 1998 at a single Canadian tertiary center [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33207/abstract/32\">",
"     32",
"    </a>",
"    ]. Of these patients, diagnosed at a mean age of eight months (range birth to 17 years), surgery was performed in 159 (51 percent) with 23 (14 percent) requiring reoperation. Patients who underwent surgical resection were more likely to have a mean LV outflow gradient by echocardiogram Doppler greater than 30 mmHg, which was associated with accelerated gradient progression and progressive aortic regurgitation. Of the 238 patients with echographic data available who had a mean LV Doppler outflow gradient less than 30 mmHg, freedom from intervention was 49 percent at 15 years follow-up.",
"   </p>",
"   <p>",
"    This study must be interpreted carefully, due to its retrospective design, the lack of standardized quantitative assessment of aortic regurgitation by echocardiogram, the lack of adequate echo data in 75 patients (24 percent of the study cohort), and the fact that this was a single institution with adoption of the mean LV outflow gradient of &gt;30 mmHg as an indication for operation. However, despite these limitations, these results nevertheless confirm that a sizeable subset of patients with subaortic stenosis will have stable gradients for years. In this study, the mean Doppler LV outflow gradient greater than 30 mmHg was a powerful distinguishing tool for both the risk of progression of subaortic obstruction and worsening aortic regurgitation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33207/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Earlier investigators also noted that patients vary in their rates of progression, with some remaining stable for long periods [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33207/abstract/4,26,27\">",
"     4,26,27",
"    </a>",
"    ], with slower progression in patients presenting as adults, presumably due to selection for less severe disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33207/abstract/27\">",
"     27",
"    </a>",
"    ]. Progression of aortic regurgitation was also noted to be more common in patients with mean Doppler LV outflow gradients &gt;30 mmHg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33207/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Method of correction",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to valvar AS, subvalvar AS does not respond to balloon dilation. Thus, the appropriate intervention for patients with significant obstruction is surgical resection of the subvalvar membrane or fibrous crescent, with myomectomy for those with significant muscular or tunnel-like obstruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33207/abstract/15,33,34\">",
"     15,33,34",
"    </a>",
"    ]. For patients with diffusely narrow LV outflow tracts, the Konno procedure and its modifications, which involve incision of the ventricular septum and patch augmentation of the LVOT, may be necessary.",
"   </p>",
"   <p>",
"    The outcome after surgery has improved, with very low operative mortality rates.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One report evaluated 168 patients with fixed subaortic stenosis with an average age of 7.8 years at the time of initial diagnosis between 1959 and 1987 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/27/33207/abstract/34\">",
"       34",
"      </a>",
"      ]. Early and late mortality among 132 patients who had surgery was 8 and 2 percent, respectively. A similar rate of early mortality (6.6 percent) was described in another series of patients who underwent surgery between 1965 and 1979 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/27/33207/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The outcomes were much better in a later study of 75 patients (mean age 8.6 years) undergoing surgery between 1982 and 1995. There were no perioperative deaths and no late cardiac deaths at more than six years of follow-up [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/27/33207/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Recurrence rates of obstruction of 27 and 33 percent have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33207/abstract/15,35-37\">",
"     15,35-37",
"    </a>",
"    ]. Younger age at initial surgery is a risk factor for recurrence. Reoperation rates ranging from 7.2 to 27 percent have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33207/abstract/15,34-42\">",
"     15,34-42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The rate of reoperation was significantly lower in one report when surgery was performed when the peak LVOT gradient was &le;40 mmHg (0.9 versus 6.5 percent per year in patients with a higher gradient) as was the need for concomitant repair of the aortic valve (20 versus 49 percent), although this may reflect differences in the substrate rather than timing of the surgery alone (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef71372 \" href=\"mobipreview.htm?21/51/22324\">",
"     image 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33207/abstract/15\">",
"     15",
"    </a>",
"    ]. However, the median age was only six years, follow-up was only six years, and peak gradients were calculated rather than measured in some patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33207/abstract/15\">",
"     15",
"    </a>",
"    ]. Indeed, many centers would not recommend surgery for peak gradients &lt;40 mm alone, as many remain stable for many years.",
"   </p>",
"   <p>",
"    Another report identified closer lesion proximity to the aortic valve (&lt; 6 mm), peak LV outflow Doppler gradient &ge;60 mmHg, and intraoperative peeling of the membrane from the aortic or mitral valves as factors significantly associated with need for re-operation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33207/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to recurrent obstruction, reported postoperative complications that occurred primarily in earlier surgical case series included mitral valve damage, AR, VSD creation, or bundle branch or complete heart block. In past case series, complications, such as high residual gradients and death, were also more frequently seen in the rare tunnel-like obstruction than in simple membrane resection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33207/abstract/34\">",
"     34",
"    </a>",
"    ]. However, in a more recent case series of 46 patients with complex and tunnel-like subaortic stenosis, there were no deaths, and only two patients developed recurrent obstruction over a median three-year follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33207/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following is our approach to the timing of surgery in patients with subaortic stenosis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We defer surgery in the first decade of life if the obstruction is moderate or less (maximum instantaneous Doppler gradient &le;50 mmHg) and regurgitation is no more than trivial. This peak Doppler gradient is similar to the threshold mean Doppler gradient for surgical intervention of &gt;30 mmHg advocated by another large referral center [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/27/33207/abstract/32\">",
"       32",
"      </a>",
"      ]. Others recommend surgical intervention in any patient who has an LVOT gradient &ge;50 mmHg and in infants or young children (up to school age) with a well-defined gradient &ge;30 mmHg [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/27/33207/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Children with an LVOT gradient less than 30 mmHg and no significant left ventricular hypertrophy must be followed closely for progression, especially in the first several years of life. We usually see toddlers at least twice each year and more often if there is evidence of progression. Older children are followed at less frequent intervals. We perform echocardiography for any change in symptoms or the examination.",
"     </li>",
"     <li>",
"      An older child with a gradient less than 30 mmHg may be followed medically until there is significant progression of the obstruction documented by echocardiography or catheterization, or definite progression of aortic regurgitation to at least a mild degree. The inexactness of predictions of gradient by Doppler must always be considered in the decision-making process. We often perform catheterization in children with borderline values or with multiple levels of obstruction.",
"     </li>",
"     <li>",
"      Unoperated adults with stable gradients below 50 mmHg and without significant LV hypertrophy must also be followed closely, since some of these patients will eventually require surgery.",
"     </li>",
"     <li>",
"      \"Prevention\" of aortic regurgitation alone is not a criterion for surgery, although, as noted above, the appearance and worsening of regurgitation is frequently used as a criterion for surgery.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Endocarditis prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the 2007 American Heart Association guidelines, antibiotic prophylaxis to prevent bacterial endocarditis is no longer recommended in patients with subvalvar AS except in those with a prior history of endocarditis or with a repair that required prosthetic material or device. In the latter, antibiotic prophylaxis is recommended for the first six months after repair unless a residual defect is present in which case prophylactic antibiotics are continued beyond the six-month period. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/36/585?source=see_link\">",
"     \"Antimicrobial prophylaxis for bacterial endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1210666930\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subvalvar aortic stenosis (AS) is the second most common form of AS.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Subvalvar AS is rare in newborns and infants. It develops and progresses over time so that most experts in the field consider it an acquired rather than a congenital lesion. It has been proposed that subvalvar AS is due to progressive left ventricular outflow tract (LVOT) thickening and scarring due to turbulence caused by an underlying abnormality in LVOT architecture. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Physiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A variety of lesions can cause subvalvar AS including a thin membrane (most common), thick fibromuscular ridge, diffuse tunnel-like obstruction, abnormal mitral valve attachments, and occasionally, accessory endocardial cushion tissue. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Anatomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with mild or moderate obstruction are typically asymptomatic. The lesion is often uncovered during evaluation of other associated cardiac defects. When uncomplicated, it is generally identified when echocardiography is performed for evaluation of a murmur. More than one-half of affected patients have a harsh systolic ejection murmur heard best at the mid-left sternal border. Many patients also have associated aortic regurgitation. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of subvalvar AS is made by echocardiography. Electrocardiogram and chest radiography are not diagnostic but are often performed in patients with subvalvar AS. Cardiac catheterization is frequently performed to provide more information regarding the anatomy and the hemodynamic effects of the lesion, particularly in patients with multiple levels of obstruction. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical course of subvalvar AS varies from stable asymptomatic disease to rapidly progressive obstructive severe disease. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Course'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The definite treatment for subvalvar AS is surgical correction of the obstruction. Recommendations for the need and timing of surgery vary because of a high rate of recurrence. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In our practice, we use the following management approach:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We defer surgery in the first decade of life if the obstruction is moderate or less (maximum instantaneous Doppler gradient &le;50 mmHg or mean LVOT gradient &lt;30 mmHg) and regurgitation is no more than trivial.",
"     </li>",
"     <li>",
"      Patients with more severe obstruction are surgically corrected.",
"     </li>",
"     <li>",
"      Children with a LVOT gradient less than 30 mmHg and no significant left ventricular hypertrophy are followed closely for progression of obstruction.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33207/abstract/1\">",
"      Hoffman JI, Christianson R. Congenital heart disease in a cohort of 19,502 births with long-term follow-up. Am J Cardiol 1978; 42:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33207/abstract/2\">",
"      Kitchiner D, Jackson M, Malaiya N, et al. Incidence and prognosis of obstruction of the left ventricular outflow tract in Liverpool (1960-91): a study of 313 patients. Br Heart J 1994; 71:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33207/abstract/3\">",
"      Liu CW, Hwang B, Lee BC, et al. Aortic stenosis in children: 19-year experience. Zhonghua Yi Xue Za Zhi (Taipei) 1997; 59:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33207/abstract/4\">",
"      Leichter DA, Sullivan I, Gersony WM. \"Acquired\" discrete subvalvular aortic stenosis: natural history and hemodynamics. J Am Coll Cardiol 1989; 14:1539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33207/abstract/5\">",
"      Newfeld EA, Muster AJ, Paul MH, et al. Discrete subvalvular aortic stenosis in childhood. Study of 51 patients. Am J Cardiol 1976; 38:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33207/abstract/6\">",
"      Choi JY, Sullivan ID. Fixed subaortic stenosis: anatomical spectrum and nature of progression. Br Heart J 1991; 65:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33207/abstract/7\">",
"      Cicini MP, Giannico S, Marino B, et al. \"Acquired\" subvalvular aortic stenosis after repair of a ventricular septal defect. Chest 1992; 101:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33207/abstract/8\">",
"      Freedom RM, Pelech A, Brand A, et al. The progressive nature of subaortic stenosis in congenital heart disease. Int J Cardiol 1985; 8:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33207/abstract/9\">",
"      Kleinert S, Geva T. Echocardiographic morphometry and geometry of the left ventricular outflow tract in fixed subaortic stenosis. J Am Coll Cardiol 1993; 22:1501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33207/abstract/10\">",
"      Gewillig M, Daenen W, Dumoulin M, Van der Hauwaert L. Rheologic genesis of discrete subvalvular aortic stenosis: a Doppler echocardiographic study. J Am Coll Cardiol 1992; 19:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33207/abstract/11\">",
"      Barkhordarian R, Wen-Hong D, Li W, et al. Geometry of the left ventricular outflow tract in fixed subaortic stenosis and intact ventricular septum: an echocardiographic study in children and adults. J Thorac Cardiovasc Surg 2007; 133:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33207/abstract/12\">",
"      Urbach J, Glaser J, Balkin J, et al. Familial membranous subaortic stenosis. Cardiology 1985; 72:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33207/abstract/13\">",
"      Pyle RL, Patterson DF, Chacko S. The genetics and pathology of discrete subaortic stenosis in the Newfoundland dog. Am Heart J 1976; 92:324.",
"     </a>",
"    </li>",
"    <li>",
"     Latson LA. Aortic stenosis: valvar, supravalvar, and fibromuscular subvalvar. In: The Science and Practice of Pediatric Cardiology, Garson A, Bricker JT, Fisher DJ, Neish SR (Eds), Williams and Wilkins, Baltimore 1998. p.1257.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33207/abstract/15\">",
"      Brauner R, Laks H, Drinkwater DC Jr, et al. Benefits of early surgical repair in fixed subaortic stenosis. J Am Coll Cardiol 1997; 30:1835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33207/abstract/16\">",
"      Katz NM, Buckley MJ, Liberthson RR. Discrete membranous subaortic stenosis. Report of 31 patients, review of the literature, and delineation of management. Circulation 1977; 56:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33207/abstract/17\">",
"      Maizza AF, Ho SY, Anderson RH. Obstruction of the left ventricular outflow tract: anatomical observations and surgical implications. J Heart Valve Dis 1993; 2:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33207/abstract/18\">",
"      Brown JW, Stevens LS, Holly S, et al. Surgical spectrum of aortic stenosis in children: a thirty-year experience with 257 children. Ann Thorac Surg 1988; 45:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33207/abstract/19\">",
"      Maron BJ, Redwood DR, Roberts WC, et al. Tunnel subaortic stenosis: left ventricular outflow tract obstruction produced by fibromuscular tubular narrowing. Circulation 1976; 54:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33207/abstract/20\">",
"      McMahon CJ, Gauvreau K, Edwards JC, Geva T. Risk factors for aortic valve dysfunction in children with discrete subvalvar aortic stenosis. Am J Cardiol 2004; 94:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33207/abstract/21\">",
"      Bonow RO, Carabello B, de Leon AC Jr, et al. Guidelines for the management of patients with valvular heart disease: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Valvular Heart Disease). Circulation 1998; 98:1949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33207/abstract/22\">",
"      Currie PJ, Hagler DJ, Seward JB, et al. Instantaneous pressure gradient: a simultaneous Doppler and dual catheter correlative study. J Am Coll Cardiol 1986; 7:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33207/abstract/23\">",
"      Bengur AR, Snider AR, Serwer GA, et al. Usefulness of the Doppler mean gradient in evaluation of children with aortic valve stenosis and comparison to gradient at catheterization. Am J Cardiol 1989; 64:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33207/abstract/24\">",
"      Wright GB, Keane JF, Nadas AS, et al. Fixed subaortic stenosis in the young: medical and surgical course in 83 patients. Am J Cardiol 1983; 52:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33207/abstract/25\">",
"      Chaikhouni A, Crawford FA Jr, Sade RM, et al. Discrete subaortic stenosis. Clin Cardiol 1984; 7:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33207/abstract/26\">",
"      de Vries AG, Hess J, Witsenburg M, et al. Management of fixed subaortic stenosis: a retrospective study of 57 cases. J Am Coll Cardiol 1992; 19:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33207/abstract/27\">",
"      Oliver JM, Gonz&aacute;lez A, Gallego P, et al. Discrete subaortic stenosis in adults: increased prevalence and slow rate of progression of the obstruction and aortic regurgitation. J Am Coll Cardiol 2001; 38:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33207/abstract/28\">",
"      Coleman DM, Smallhorn JF, McCrindle BW, et al. Postoperative follow-up of fibromuscular subaortic stenosis. J Am Coll Cardiol 1994; 24:1558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33207/abstract/29\">",
"      Freedom RM. The long and the short of it: some thoughts about the fixed forms of left ventricular outflow tract obstruction. J Am Coll Cardiol 1997; 30:1843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33207/abstract/30\">",
"      Douville EC, Sade RM, Crawford FA Jr, Wiles HB. Subvalvar aortic stenosis: timing of operation. Ann Thorac Surg 1990; 50:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33207/abstract/31\">",
"      Gersony WM. Natural history of discrete subvalvar aortic stenosis: management implications. J Am Coll Cardiol 2001; 38:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33207/abstract/32\">",
"      Karamlou T, Gurofsky R, Bojcevski A, et al. Prevalence and associated risk factors for intervention in 313 children with subaortic stenosis. Ann Thorac Surg 2007; 84:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33207/abstract/33\">",
"      Binet JP, Losay J, Demontoux S, et al. Subvalvular aortic stenosis: long-term surgical results. Thorac Cardiovasc Surg 1983; 31:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33207/abstract/34\">",
"      Vogt J, Dische R, Rupprath G, et al. Fixed subaortic stenosis: an acquired secondary obstruction? A twenty-seven year experience with 168 patients. Thorac Cardiovasc Surg 1989; 37:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33207/abstract/35\">",
"      Hirata Y, Chen JM, Quaegebeur JM, Mosca RS. The role of enucleation with or without septal myectomy for discrete subaortic stenosis. J Thorac Cardiovasc Surg 2009; 137:1168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33207/abstract/36\">",
"      Serraf A, Zoghby J, Lacour-Gayet F, et al. Surgical treatment of subaortic stenosis: a seventeen-year experience. J Thorac Cardiovasc Surg 1999; 117:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33207/abstract/37\">",
"      Dodge-Khatami A, Schmid M, Rousson V, et al. Risk factors for reoperation after relief of congenital subaortic stenosis. Eur J Cardiothorac Surg 2008; 33:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33207/abstract/38\">",
"      Geva A, McMahon CJ, Gauvreau K, et al. Risk factors for reoperation after repair of discrete subaortic stenosis in children. J Am Coll Cardiol 2007; 50:1498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33207/abstract/39\">",
"      Stewart JR, Merrill WH, Hammon JW Jr, et al. Reappraisal of localized resection for subvalvar aortic stenosis. Ann Thorac Surg 1990; 50:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33207/abstract/40\">",
"      Giuffre RM, Ryerson LM, Vanderkooi OG, et al. Surgical outcome following treatment of isolated subaortic obstruction. Adv Ther 2004; 21:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33207/abstract/41\">",
"      Erentug V, Bozbuga N, Polat A, et al. Coronary bypass procedures in patients with renal artery stenosis. J Card Surg 2005; 20:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33207/abstract/42\">",
"      Darcin OT, Yagdi T, Atay Y, et al. Discrete subaortic stenosis: surgical outcomes and follow-up results. Tex Heart Inst J 2003; 30:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33207/abstract/43\">",
"      Jahangiri M, Nicholson IA, del Nido PJ, et al. Surgical management of complex and tunnel-like subaortic stenosis. Eur J Cardiothorac Surg 2000; 17:637.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5776 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-61.234.146.186-C2273CD5CA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_27_33207=[""].join("\n");
var outline_f32_27_33207=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1210666930\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Echocardiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1210667092\">",
"      Other tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Electrocardiogram",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Chest radiograph",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Cardiac catheterization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      COURSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Surgical repair",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Method of correction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Recommendations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Endocarditis prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1210666930\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5776\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5776|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?21/51/22324\" title=\"diagnostic image 1\">",
"      Fixed subaortic stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5776|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?9/12/9418\" title=\"movie 1\">",
"      Subvalvar aortic stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5776|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?42/11/43196\" title=\"table 1\">",
"      Causes LV outflow obstruction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/36/585?source=related_link\">",
"      Antimicrobial prophylaxis for bacterial endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/3/1082?source=related_link\">",
"      Echocardiographic evaluation of the aortic valve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/52/40774?source=related_link\">",
"      Supravalvar aortic stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/59/28600?source=related_link\">",
"      Types and pathophysiology of obstructive hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/28/38345?source=related_link\">",
"      Valvar aortic stenosis in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_27_33208="Tamoxifen: Drug information";
var content_f32_27_33208=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Tamoxifen: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?5/28/5574?source=see_link\">",
"    see \"Tamoxifen: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/6/43111?source=see_link\">",
"    see \"Tamoxifen: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709103\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F15512098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Soltamox&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F224658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Tamox&reg;;",
"     </li>",
"     <li>",
"      Mylan-Tamoxifen;",
"     </li>",
"     <li>",
"      Nolvadex&reg;-D;",
"     </li>",
"     <li>",
"      PMS-Tamoxifen;",
"     </li>",
"     <li>",
"      Teva-Tamoxifen",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F224705\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Estrogen Receptor Antagonist;",
"     </li>",
"     <li>",
"      Selective Estrogen Receptor Modulator (SERM)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F224662\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     For the treatment of breast cancer, patients receiving both tamoxifen and chemotherapy, should receive treatment sequentially, with tamoxifen following completion of chemotherapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Breast cancer treatment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Adjuvant therapy (females):",
"     </i>",
"     20 mg once daily for 5 years",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Metastatic (males and females):",
"     </i>",
"     20-40 mg/day (doses &gt;20 mg should be given in 2 divided doses).",
"     <b>",
"      Note:",
"     </b>",
"     Although the FDA-approved labeling recommends dosing up to 40 mg/day, clinical benefit has not been demonstrated with doses above 20 mg/day (Bratherton, 1984).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Premenopausal women: Duration of treatment is 5 years (NCCN Breast Cancer guidelines v.1.2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Postmenopausal women: Duration of tamoxifen treatment is 2-3 years followed by an aromatase inhibitor (AI) to complete 5 years; if contraindications or intolerant to AI, may take tamoxifen for the full 5 years",
"     <b>",
"      or",
"     </b>",
"     extended therapy: 4.5-6 years of tamoxifen followed by 5 years of an AI (NCCN Breast Cancer guidelines v.1.2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      DCIS (females), to reduce the risk for invasive breast cancer:",
"     </i>",
"     20 mg once daily for 5 years",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Breast cancer risk reduction (pre- and postmenopausal high-risk females):",
"     </b>",
"     20 mg once daily for 5 years",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Induction of ovulation (unlabeled use):",
"     </b>",
"     20 mg once daily (range: 20-80 mg once daily) for 5 days (Steiner, 2005)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Paget&rsquo;s disease of the breast (risk reduction; with DCIS or without associated cancer):",
"     </b>",
"     20 mg once daily for 5 years (NCCN Breast Cancer Guidelines, v.1.2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment for DVT, pulmonary embolism, cerebrovascular accident, or prolonged immobilization:",
"     </b>",
"     Discontinue tamoxifen (NCCN Breast Cancer Risk Reduction Guidelines, v.2.2010)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F224680\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/6/43111?source=see_link\">",
"      see \"Tamoxifen: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Females: Precocious puberty and McCune-Albright syndrome (unlabeled use): Oral: A dose of 20 mg/day has been reported in patients 2-10 years of age; safety and efficacy have not been established for treatment of longer than 1 year duration (Eugster, 2003)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F224663\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F224631\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Soltamox&trade;: 10 mg/5 mL (150 mL) [sugar free; contains ethanol, propylene glycol; licorice flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 10 mg, 20 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F224614\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874993\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication when used in females for breast cancer prevention or treatment of ductal carcinoma",
"     <i>",
"      in situ",
"     </i>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Nolvadex&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088661.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088661.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F3878251\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer tablets or oral solution orally with or without food. Use supplied dosing cup for oral solution.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F224634\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of metastatic (female and male) breast cancer; adjuvant treatment of breast cancer after primary treatment with surgery and radiation; reduce risk of invasive breast cancer in women with ductal carcinoma",
"     <i>",
"      in situ",
"     </i>",
"     (DCIS) after surgery and radiation; reduce the incidence of breast cancer in women at high risk",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F224701\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of mastalgia, gynecomastia, ovarian cancer, endometrial cancer, uterine sarcoma, and desmoid tumors; risk reduction in women with Paget&rsquo;s disease of the breast (with DCIS or without associated cancer); induction of ovulation; treatment of precocious puberty in females, secondary to McCune-Albright syndrome",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F224713\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Tamoxifen may be confused with pentoxifylline, Tambocor&trade;, tamsulosin, temazepam",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F224703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Vasodilation (41%), flushing (33%), hypertension (11%), peripheral edema (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Mood changes (12% to 18%), pain (3% to 16%), depression (2% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Skin changes (6% to 19%), rash (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hot flashes (3% to 80%), fluid retention (32%), altered menses (13% to 25%), amenorrhea (16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (5% to 26%), weight loss (23%), vomiting (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Vaginal discharge (13% to 55%), vaginal bleeding (2% to 23%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (18%), arthritis (14%), arthralgia (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Pharyngitis (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Lymphedema (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Chest pain (5%), venous thrombotic events (5%), edema (4%), cardiovascular ischemia (3%), angina (2%), deep venous thrombus (&le;2%), MI (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Insomnia (9%), dizziness (8%), headache (8%), anxiety (6%), fatigue (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Alopecia (&le;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Oligomenorrhea (9%), breast pain (6%), menstrual disorder (6%), breast neoplasm (5%), hypercholesterolemia (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain (9%),  weight gain  (9%), constipation (4% to 8%), diarrhea (7%), dyspepsia (6%), throat irritation (oral solution 5%), abdominal cramps (1%), anorexia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection (10%), leukorrhea (9%), vaginal hemorrhage (6%), vaginitis (5%), vulvovaginitis (5%), ovarian cyst (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Thrombocytopenia (&le;10%), anemia (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: AST increased (5%), serum bilirubin increased (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain (10%), bone pain (6% to 10%), osteoporosis (7%), fracture (7%), arthrosis (5%),  joint disorder (5%), myalgia (5%), paresthesia (5%), musculoskeletal pain (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Cataract (7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Serum creatinine increased (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Cough (4% to 9%), dyspnea (8%), bronchitis (5%), sinusitis (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Infection/sepsis (&le;9%), diaphoresis (6%), flu-like syndrome (6%), cyst (5%), neoplasm (5%), allergic reaction (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1 or frequency not defined (limited to important or life-threatening): Angioedema, bullous pemphigoid, cholestasis, corneal changes, endometrial cancer, endometrial hyperplasia, endometrial polyps, endometriosis, erythema multiforme, fatty liver, hepatic necrosis, hepatitis, hypercalcemia, hyperlipidemia, hypersensitivity reactions, hypertriglyceridemia, impotence (males), interstitial pneumonitis, loss of libido (males), pancreatitis, phlebitis, pruritus vulvae, pulmonary embolism, retinal vein thrombosis, retinopathy, second primary tumors, Stevens-Johnson syndrome, stroke; tumor pain and local disease flare (including increase in lesion size and erythema) during treatment of metastatic breast cancer (generally resolves with continuation); uterine fibroids, vaginal dryness, visual color perception changes",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F224637\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to tamoxifen or any component of the formulation; concurrent warfarin therapy or history of deep vein thrombosis or pulmonary embolism (when tamoxifen is used for cancer risk reduction in women at high risk for breast cancer and in women with DCIS)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F224618\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression: Thrombocytopenia and/or leukopenia may occur; neutropenia and pancytopenia have been reported rarely. Although the relationship to tamoxifen therapy is uncertain, rare hemorrhagic episodes have occurred in patients with significant thrombocytopenia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gynecologic effects/malignancies:",
"     <b>",
"      [U.S. Boxed Warning]: Tamoxifen use for breast cancer risk reduction in women at high-risk for breast cancer and in women with DCIS is associated with an increased incidence of uterine or endometrial cancers.",
"     </b>",
"     Endometrial hyperplasia, polyps, endometriosis, uterine fibroids, and ovarian cysts have occurred. Amenorrhea and menstrual irregularities have been reported with tamoxifen use. Monitor and promptly evaluate any report of abnormal vaginal bleeding.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatotoxicity: Liver abnormalities such as cholestasis, fatty liver, hepatitis, and hepatic necrosis have occurred. Hepatocellular carcinomas have been reported in some studies; relationship to treatment is unclear.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular effects: Decreased visual acuity, retinal vein thrombosis, retinopathy, corneal changes, color perception changes and increased incidence of cataracts (and the need for cataract surgery) have been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thromboembolic events:",
"     <b>",
"      [U.S. Boxed Warning]: Serious and life-threatening events, including stroke and pulmonary emboli have occurred at an incidence greater than placebo during use for breast cancer risk reduction in women at high-risk for breast cancer and in women with DCIS;",
"     </b>",
"     these events are rare, but require consideration in risk:benefit evaluation. In patients already diagnosed with breast cancer, the benefits of tamoxifen use are greater than the risks. An increased incidence of thromboembolic events has been associated with use; risk is increased with concomitant chemotherapy; use with caution in individuals with a history of thromboembolic events.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone mineral density: Tamoxifen use may be associated with changes in bone mineral density (BMD) and the effects may be dependent upon menstrual status. In postmenopausal women, tamoxifen use is associated with a protective effect on bone mineral density (BMD), preventing loss of BMD which lasts over the 5-year treatment period. In premenopausal women, a decline (from baseline) in BMD mineral density has been observed in women who continued to menstruate; may be associated with an increased risk of fractures.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperlipidemia: Use with caution in patients with hyperlipidemias; infrequent postmarketing cases of hyperlipidemias have been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Metastatic breast cancer: Local disease flare and increased bone and tumor pain may occur; may be associated with (good) tumor response; onset is shortly after therapy initiation and usually resolves rapidly. In patients with bone metastasis, hypercalcemia has occurred usually within a few weeks of therapy initiation. Institute appropriate hypercalcemia management; discontinue if severe.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; High potential for interactions: Tamoxifen is associated with a high potential for drug interactions, including CYP- and Pgp-mediated interactions. Decreased efficacy and an increased risk of breast cancer recurrence has been reported with concurrent moderate or strong CYP2D6 inhibitors (Aubert, 2009; Dezentje, 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Selective serotonin reuptake inhibitors (SSRI): Concomitant use with select SSRIs may result in decreased tamoxifen efficacy. Strong CYP2D6 inhibitors (eg, fluoxetine, paroxetine) and moderate CYP2D6 inhibitors (eg, sertraline) are reported to interfere with transformation to the active metabolite endoxifen. Weak CYP2D6 inhibitors (eg, venlafaxine, citalopram) have minimal effect on the conversion to endoxifen (Jin, 2005; NCCN Breast Cancer Risk Reduction Guidelines v.2.2010); escitalopram is also a weak CYP2D6 inhibitor. In a retrospective analysis of breast cancer patients taking tamoxifen and SSRIs, concomitant use of paroxetine and tamoxifen was associated with an increased risk of death due to breast cancer (Kelly, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CYP2D6 poor metabolizers: Lower plasma concentrations of endoxifen (active metabolite) have been observed in patients associated with reduced CYP2D6 activity (Jin, 2005) and may be associated with reduced efficacy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F224698\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2A6 (minor), CYP2B6 (minor), CYP2C9 (major), CYP2D6 (major), CYP2E1 (minor), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2B6 (weak), CYP2C8 (moderate), CYP2C9 (weak), CYP3A4 (weak), P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F224623\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglutethimide: May increase the metabolism of Tamoxifen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anastrozole: Tamoxifen may decrease the serum concentration of Anastrozole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bexarotene (Systemic): May decrease the serum concentration of Tamoxifen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a p-glycoprotein inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Substrates: CYP2C8 Inhibitors (Moderate) may decrease the metabolism of CYP2C8 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inducers (Strong): May increase the metabolism of CYP2C9 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Moderate): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Strong): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites. Management: Consider alternatives with less of an inhibitory effect on CYP2D6 activity when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, strong CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: P-glycoprotein/ABCB1 Inhibitors may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate.  Management: Dabigatran dose reductions may be needed.  Specific recommendations vary considerably according to US vs Canadian labeling, specific P-gp inhibitor, renal function, and indication for dabigatran treatment.  Refer to full monograph or dabigatran labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Everolimus.  Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Letrozole: Tamoxifen may decrease the serum concentration of Letrozole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP2C9 Substrates. Management: Use CYP2C9 substrates at the lowest recommended dose, and monitor closely for adverse effects, during and in the 2 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mipomersen: Tamoxifen may enhance the hepatotoxic effect of Mipomersen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ospemifene: Selective Estrogen Receptor Modulators may enhance the adverse/toxic effect of Ospemifene. Ospemifene may also enhance adverse/toxic effects of other Selective Estrogen Receptor Modulators. Selective Estrogen Receptor Modulators may diminish the therapeutic effect of Ospemifene. Ospemifene may also diminish the therapeutic effects of other Selective Estrogen Receptor Modulators.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prucalopride: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Prucalopride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Tamoxifen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Silodosin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Silodosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topotecan: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Tamoxifen may increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F224652\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Food: Grapefruit juice may decrease the metabolism of tamoxifen. Management: Avoid grapefruit juice.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herb/Nutraceutical: Black cohosh and dong quai have estrogenic properties. St John's wort may decrease levels/effects of tamoxifen. Management: Avoid black cohosh and dong quai in estrogen-dependent tumors. Avoid St John's wort.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F224626\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F224641\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies have demonstrated fetal adverse effects and fetal loss. There have been reports of vaginal bleeding, birth defects and fetal loss in pregnant women. Tamoxifen use during pregnancy may have a potential long term risk to the fetus of a DES-like syndrome. For sexually-active women of childbearing age, initiate during menstruation (negative &beta;-hCG immediately prior to initiation in women with irregular cycles). Tamoxifen may induce ovulation. Barrier or nonhormonal contraceptives are recommended. Pregnancy should be avoided during treatment and for 2 months after treatment has been discontinued.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F224667\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F224642\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if tamoxifen is excreted in breast milk, however, it has been shown to inhibit lactation. Due to the potential for adverse reactions, women taking tamoxifen should not breast-feed.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F7904065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tablets and oral solution may be taken with or without food. Avoid grapefruit and grapefruit juice.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F224640\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Soltamox Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg/5 mL (150 mL): $180.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Tamoxifen Citrate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (60): $113.65",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (30): $113.65",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F224628\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with platelets, serum calcium, LFTs; triglycerides and cholesterol (in patients with pre-existing hyperlipidemias); INR and PT (in patients on vitamin K antagonists); abnormal vaginal bleeding; breast and gynecologic exams (baseline and routine), mammogram (baseline and routine); signs/symptoms of DVT (leg swelling, tenderness) or PE (shortness of breath); ophthalmic exam (if vision problem or cataracts); bone mineral density (premenopausal women)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F224643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Bilem (TH);",
"     </li>",
"     <li>",
"      Citofen (HR);",
"     </li>",
"     <li>",
"      Diemon (AR);",
"     </li>",
"     <li>",
"      Fenahex (PH);",
"     </li>",
"     <li>",
"      Genox (AU, NZ);",
"     </li>",
"     <li>",
"      Ginarsan (PE);",
"     </li>",
"     <li>",
"      Ginarsan Forte (PE);",
"     </li>",
"     <li>",
"      Gynatam (PH);",
"     </li>",
"     <li>",
"      Gyraxen (PH);",
"     </li>",
"     <li>",
"      Kessar (CN, FR, GR, IT, ZA);",
"     </li>",
"     <li>",
"      Mamofen (IN);",
"     </li>",
"     <li>",
"      Medtax (PH);",
"     </li>",
"     <li>",
"      Moxafen (AE, BH, CY, EG, IL, IQ, IR, JO, KP, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Neophedan (ZA);",
"     </li>",
"     <li>",
"      Nolvadex (AE, AT, AU, BB, BE, BF, BG, BH, BJ, BM, BR, BS, BZ, CI, CN, CR, CY, DE, DO, EC, EG, ES, ET, FI, FR, GH, GM, GN, GR, GT, GY, HK, HN, HR, IE, IL, IN, IQ, IR, IT, JM, JO, KE, KP, KW, LB, LR, LU, LY, MA, ML, MR, MU, MW, MX, NE, NG, NI, NL, NO, NZ, OM, PA, PK, PL, PR, PT, QA, SA, SC, SD, SE, SG, SL, SN, SR, SV, SY, TN, TR, TT, TW, TZ, UG, VE, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Nolvadex-D (AU, CO, EE, HK, IE, MY, NZ, PY, SG, TH, UY);",
"     </li>",
"     <li>",
"      Novofen (HK, SG, TH, TW);",
"     </li>",
"     <li>",
"      Novofen Forte (BZ, GY, SR);",
"     </li>",
"     <li>",
"      Novofen-D (BB, BM, BS, BZ, GY, JM, NL, PR, SR, TT);",
"     </li>",
"     <li>",
"      Retaxim (HR);",
"     </li>",
"     <li>",
"      Soltamox (GB);",
"     </li>",
"     <li>",
"      Tadex (FI, TW);",
"     </li>",
"     <li>",
"      Tamec (CH);",
"     </li>",
"     <li>",
"      Tamifen (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Tamizam (BE, LU);",
"     </li>",
"     <li>",
"      Tamofen (CL, DK, FI, HK, ID, IL, NO, TW);",
"     </li>",
"     <li>",
"      Tamoplex (KP, PE, PH);",
"     </li>",
"     <li>",
"      Tamorex (KP);",
"     </li>",
"     <li>",
"      Tamosin (AU);",
"     </li>",
"     <li>",
"      Tamoxi (IL);",
"     </li>",
"     <li>",
"      Tamoxifen-Eurogenerics (LU);",
"     </li>",
"     <li>",
"      Tamoxifen-Hexal (LU);",
"     </li>",
"     <li>",
"      Tamoxifen-ratioparm (LU);",
"     </li>",
"     <li>",
"      Tamoxifen-Teva (HU);",
"     </li>",
"     <li>",
"      Tamoxifen-Zeneca (LU);",
"     </li>",
"     <li>",
"      Taxus (EC, PE);",
"     </li>",
"     <li>",
"      Tecnofen (MX);",
"     </li>",
"     <li>",
"      Xifen (PH);",
"     </li>",
"     <li>",
"      Zitazonium (CZ, HK, HU, PH, RU)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F224617\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Competitively binds to estrogen receptors on tumors and other tissue targets, producing a nuclear complex that decreases DNA synthesis and inhibits estrogen effects; nonsteroidal agent with potent antiestrogenic properties which compete with estrogen for binding sites in breast and other tissues; cells accumulate in the G",
"     <sub>",
"      0",
"     </sub>",
"     and G",
"     <sub>",
"      1",
"     </sub>",
"     phases; therefore, tamoxifen is cytostatic rather than cytocidal.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F224636\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: High concentrations found in uterus, endometrial and breast tissue",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 99%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic; via CYP2D6 to 4-hydroxytamoxifen and via CYP3A4/5 to N-desmethyl-tamoxifen. Each is then further metabolized into endoxifen (4-hydroxy-tamoxifen via CYP3A4/5 and N-desmethyl-tamoxifen via CYP2D6); both 4-hydroxy-tamoxifen and endoxifen are 30- to 100-fold more potent than tamoxifen",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Tamoxifen: ~5-7 days; N-desmethyl tamoxifen: ~14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: ~5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (26% to 51%); urine (9% to 13%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Aubert RE, Stanek EJ, Yao J, et al, &ldquo;Risk of Breast Cancer Recurrence in Women Initiating Tamoxifen With CYP2D6 Inhibitors,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(18S):CRA508 [abstract CRA508 from 2009 ASCO Annual Meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boostanfar R, Jain JK, Mishell DR Jr, et al, &ldquo;A Prospective Randomized Trial Comparing Clomiphene Citrate With Tamoxifen Citrate for Ovulation Induction,&rdquo;",
"      <i>",
"       Fertil Steril",
"      </i>",
"      , 2001, 75(5):1024-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/27/33208/abstract-text/11334921/pubmed\" id=\"11334921\" target=\"_blank\">",
"        11334921",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bratherton DG, Brown CH, Bucha a  R, et al, &ldquo;A Comparison of Two Doses of Tamoxifen (Nolvadex) in Postmenopausal Women With Advanced Breast Cancer: 10 mg bd Versus 20 mg bd,&rdquo;",
"      <i>",
"       Br J Cancer",
"      </i>",
"      , 1984, 50(2):199-205.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/27/33208/abstract-text/6380554/pubmed\" id=\"6380554\" target=\"_blank\">",
"        6380554",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Burstein HJ, Prestrud AA, Seidenfeld J, et al, &ldquo;American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women with Hormone Receptor-Positive Breast Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2010, 28(23):3784-96.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/27/33208/abstract-text/20625130/pubmed\" id=\"20625130\" target=\"_blank\">",
"        20625130",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cohen I, Altaras MM, Lew S, et al, &ldquo;Ovarian Endometrioid Carcinoma and Endometriosis Developing in a Postmenopausal Breast Cancer Patient During Tamoxifen Therapy: A Case Report and Review of the Literature,&rdquo;",
"      <i>",
"       Gynecol Oncol",
"      </i>",
"      , 1994, 55(3 Pt 1):443-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/27/33208/abstract-text/7835785/pubmed\" id=\"7835785\" target=\"_blank\">",
"        7835785",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dezentje V, Van Blijderveen NJ, Gelderblom H, et al, &ldquo;Concomitant CYP2D6 Inhibitor Use and Tamoxifen Adherence in Early-Stage Breast Cancer: A Pharmacoepidemiologic Study,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(18S):CRA509 [abstract CRA509 from 2009 ASCO Annual Meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Early Breast Cancer Trialists' Collaborative Group (EBCTCG), &ldquo;Effects of Chemotherapy and Hormonal Therapy for Early Breast Cancer on Recurrence and 15-Year Survival: An Overview of the Randomised Trials,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2005, 365(9472):1687-717.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/27/33208/abstract-text/15894097/pubmed\" id=\"15894097\" target=\"_blank\">",
"        15894097",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Eastell R, Adams JE, Coleman RE, et al, &ldquo;Effect of Anastrozole on Bone Mineral Density: 5-Year Results From the Anastrozole, Tamoxifen, Alone or in Combination Trial 18233230,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2008, 26(7):1051-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/27/33208/abstract-text/18309940/pubmed\" id=\"18309940\" target=\"_blank\">",
"        18309940",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Eugster EA, Rubin SD, Reiter EO, et al, &ldquo;Tamoxifen Treatment for Precocious Puberty in McCune-Albright Syndrome: A Multicenter Trial,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2003, 143(1):60-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/27/33208/abstract-text/12915825/pubmed\" id=\"12915825\" target=\"_blank\">",
"        12915825",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goetz MP, Kamal A, and Ames MM, &ldquo;Tamoxifen Pharmacogenomics: The Role of CYP2D6 as a Predictor of Drug Response,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 2008, 83(1):160-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/27/33208/abstract-text/17882159/pubmed\" id=\"17882159\" target=\"_blank\">",
"        17882159",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hochner-Celnikier D, Anteby E, and Yagel S, &ldquo;Ovarian Cysts in Tamoxifen-Treated Premenopausal Women With Breast Cancer - A Management Dilemma,&rdquo;",
"      <i>",
"       Am J Obstet Gynecol",
"      </i>",
"      , 1995, 172(4 Pt 1):1323-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/27/33208/abstract-text/7726283/pubmed\" id=\"7726283\" target=\"_blank\">",
"        7726283",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jin Y, Desta Z, Stearns V, et al, &ldquo;CYP2D6 Genotype, Antidepressant Use, and Tamoxifen Metabolism During Adjuvant Breast Cancer Treatment,&rdquo;",
"      <i>",
"       J Natl Cancer Inst",
"      </i>",
"      , 2005, 97(1):30-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/27/33208/abstract-text/15632378/pubmed\" id=\"15632378\" target=\"_blank\">",
"        15632378",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jordan VC, \"Tamoxifen: A Most Unlikely Pioneering Medicine,\"",
"      <i>",
"       Nat Rev Drug Discov",
"      </i>",
"      , 2003, 2(3):205-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/27/33208/abstract-text/12612646/pubmed\" id=\"12612646\" target=\"_blank\">",
"        12612646",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jubelirer SJ, &ldquo;The Management of Menopausal Symptoms in Women With Breast Cancer,&rdquo;",
"      <i>",
"       W V Med J",
"      </i>",
"      , 1995, 91(2):54-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/27/33208/abstract-text/7610643/pubmed\" id=\"7610643\" target=\"_blank\">",
"        7610643",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kelly CM, Juurlink DN, Gomes T, et al, &ldquo;Selective Serotonin Reuptake Inhibitors and Breast Cancer Mortality in Women Receiving Tamoxifen: A Population Based Cohort Study,&rdquo;",
"      <i>",
"       BMJ",
"      </i>",
"      , 2010, 340:c693.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/27/33208/abstract-text/20142325/pubmed\" id=\"20142325\" target=\"_blank\">",
"        20142325",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Khatcheressian JL, Wolff AC, Smith TJ, et al, &ldquo;American Society of Clinical Oncology 2006 Update of the Breast Cancer Follow-Up and Management Guidelines in the Adjuvant Setting,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2006, 24(31):5091-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/27/33208/abstract-text/17033037/pubmed\" id=\"17033037\" target=\"_blank\">",
"        17033037",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      LiVolsi VA, Salhany KE, and Dowdy YG, &ldquo;Endocervical Adenocarcinoma in Tamoxifen-Treated Patient,&rdquo;",
"      <i>",
"       Am J Obstet Gynecol",
"      </i>",
"      , 1995, 172(3):1065.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/27/33208/abstract-text/7892857/pubmed\" id=\"7892857\" target=\"_blank\">",
"        7892857",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Breast Cancer,&rdquo; Version 1.2011. Available at  file://www.nccn.org/professionals/physician_gls/PDF/breast.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Breast Cancer Risk Reduction, Version 2.2010.&rdquo; Available at file://www.nccn.org/professionals/physician_gls/PDF/breast_risk.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Ovarian Cancer,&rdquo; Version 2.2011. Available at file://www.nccn.org/professionals/physician_gls/PDF/ovarian.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Uterine Neoplasms,&rdquo; Version 1.2011. Available at file://www.nccn.org/professionals/physician_gls/PDF/uterine.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pandya KJ, Raubertas RF, Flynn PJ,  et al, &ldquo;Oral Clonidine in Postmenopausal Patients With Breast Cancer Experiencing Tamoxifen-Induced Hot Flashes: A University of Rochester Cancer Center Community Clinical Oncology Program Study,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2000, 132:788-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/27/33208/abstract-text/10819701/pubmed\" id=\"10819701\" target=\"_blank\">",
"        10819701",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rutqvist LE, Johansson H, Signomklao T, et al, &ldquo;Adjuvant Tamoxifen Therapy for Early Stage Breast Cancer and Second Primary Malignancies. Stockholm Breast Cancer Study Group,&rdquo;",
"      <i>",
"       J Natl Cancer Inst",
"      </i>",
"      , 1995, 87(9):645-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/27/33208/abstract-text/7752269/pubmed\" id=\"7752269\" target=\"_blank\">",
"        7752269",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sideras K, Ingle JN, Ames MM, et al, &ldquo;Coprescription of Tamoxifen and Medications That Inhibit CYP2D6,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2010, 28(16):2768-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/27/33208/abstract-text/20439629/pubmed\" id=\"20439629\" target=\"_blank\">",
"        20439629",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Steiner AZ, Terplan M, and Paulson RJ, &ldquo;Comparison of Tamoxifen and Clomifene Citrate for Ovulation Induction: A Meta-Analysis,&rdquo;",
"      <i>",
"       Hum Reprod",
"      </i>",
"      , 2005, 20(6):1511-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/27/33208/abstract-text/15845599/pubmed\" id=\"15845599\" target=\"_blank\">",
"        15845599",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, &ldquo;Consensus on Infertility Treatment Related to Polycystic Ovary Syndrome,&rdquo;",
"      <i>",
"       Fertil Steril",
"      </i>",
"      , 2008, 89(3):505-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/27/33208/abstract-text/18243179/pubmed\" id=\"18243179\" target=\"_blank\">",
"        18243179",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vehmanen L, Elomaa I, Blomqvist C, et al, &ldquo;Tamoxifen Treatment After Adjuvant Chemotherapy Has Opposite Effects on Bone Mineral Density in Premenopausal Patients Depending on Menstrual Status,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2006, 24(4):675-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/27/33208/abstract-text/16446340/pubmed\" id=\"16446340\" target=\"_blank\">",
"        16446340",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Visvanathan K, Chlebowski RT, Hurley P, et al, &ldquo;American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Pharmacologic Interventions Including Tamoxifen, Raloxifene, and Aromatase Inhibition for Breast Cancer Risk Reduction,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(19):3235-58.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/27/33208/abstract-text/19470930/pubmed\" id=\"19470930\" target=\"_blank\">",
"        19470930",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Winer EP, Hudis C, Burstein HJ, et al, &ldquo;American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors as Adjuvant Therapy for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Status Report 2004,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(3):619-29.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/27/33208/abstract-text/15545664/pubmed\" id=\"15545664\" target=\"_blank\">",
"        15545664",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9972 Version 45.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.166.191.243-0970125B04-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_27_33208=[""].join("\n");
var outline_f32_27_33208=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709103\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15512098\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224658\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224705\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224662\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224680\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224663\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224631\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224614\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874993\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3878251\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224634\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224701\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224713\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224703\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224637\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224618\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224698\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224623\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224652\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224626\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224641\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224667\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224642\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7904065\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224640\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224628\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224643\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224617\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224636\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9972\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9972|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?5/28/5574?source=related_link\">",
"      Tamoxifen: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/6/43111?source=related_link\">",
"      Tamoxifen: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_27_33209="Lansoprazole, amoxicillin, and clarithromycin: Drug information";
var content_f32_27_33209=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Lansoprazole, amoxicillin, and clarithromycin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?32/49/33556?source=see_link\">",
"    see \"Lansoprazole, amoxicillin, and clarithromycin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F16572472\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Bone Fracture Risk with Proton Pump Inhibitors: Health Canada Issues Alert",
"     </span>",
"     <span class=\"collapsible-date\">",
"      April 2013",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Health Canada has informed healthcare professionals that proton pump inhibitors (PPIs) may increase the risk of bone fractures. The risk of fracture was observed to be higher in patients receiving multiple daily doses for &ge;1 year; age, gender, and concomitant health conditions may also be a factor. Patients with risk factors for osteoporosis should be closely monitored and should receive a PPI at the lowest effective dose and for the shortest duration of therapy appropriate for the condition.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       For more information, refer to file://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2013/26523a-eng.php.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F186897\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Prevpac&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F186898\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Hp-PAC&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F186912\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Macrolide Combination;",
"     </li>",
"     <li>",
"      Antibiotic, Penicillin;",
"     </li>",
"     <li>",
"      Gastrointestinal Agent, Miscellaneous;",
"     </li>",
"     <li>",
"      Proton Pump Inhibitor;",
"     </li>",
"     <li>",
"      Substituted Benzimidazole",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F186901\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <i>",
"      H. pylori",
"     </i>",
"     eradication: Oral: Lansoprazole 30 mg, amoxicillin 1 g, and clarithromycin 500 mg taken together twice daily for 10 or 14 days",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F186902\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F608953\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Use is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15668413\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Bioavailability of lansoprazole increased in hepatic impairment. Consider dose reduction in severe hepatic impairment",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F186886\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Combination package [each administration card contains]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Prevpac&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Capsule: Amoxicillin 500 mg (4 capsules/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Capsule, delayed release (Prevacid&reg;): Lansoprazole 30 mg (2 capsules/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Tablet (Biaxin&reg;): Clarithromycin 500 mg (2 tablets/day)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F186876\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F186888\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Eradication of",
"     <i>",
"      H. pylori",
"     </i>",
"     to reduce the risk of recurrent duodenal ulcer",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F186917\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Prevpac&reg; may be confused with Prevacid&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F186910\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Frequencies noted refer to experience with combination therapy. Also see individual agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     3% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (7%), taste perversion (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;3% (Limited to important or life-threatening): Abdominal pain, candidiasis (oral and vaginal), confusion, dark stools, dermatologic reactions, dizziness, dry mouth, glossitis, myalgia, nausea, rectal itching, stomatitis, thirst, tongue discoloration, vaginitis, vomiting",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F186891\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to lansoprazole, amoxicillin, any penicillin, clarithromycin, any macrolide, or any component of the formulation; concurrent use with pimozide, cisapride, or ergot derivatives (eg, ergotamine, dihydroergotamine), astemizole, terfenadine, colchicine (if patient has concomitant renal or hepatic impairment), lovastatin, simvastatin; history of cholestatic jaundice or hepatic dysfunction with prior clarithromycin use; history of QT prolongation or ventricular arrhythmia, including torsade de pointes",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F186879\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Altered cardiac conduction: Macrolides have been associated with rare QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation and ventricular arrhythmias, including torsade de pointes; use with caution in patients at risk of prolonged cardiac repolarization; avoid use in patients with uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia, and patients receiving Class IA (eg, quinidine, procainamide) or Class III (eg, amiodarone, dofetilide, sotalol) antiarrhythmic agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactoid/hypersensitivity reactions: Serious and occasionally severe or fatal hypersensitivity (anaphylactoid) reactions have been reported in patients on penicillin therapy, especially with a history of beta-lactam hypersensitivity, history of sensitivity to multiple allergens, or previous IgE-mediated reactions (eg, anaphylaxis, angioedema, urticaria). Use with caution in asthmatic patients. Severe acute reactions have (rarely) been reported with clarithromycin, including anaphylaxis, Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug rash with eosinophilia and systemic symptoms (DRESS), and Henoch-Sch&ouml;nlein purpura; discontinue therapy immediately and urgently initiate treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Atrophic gastritis: Long-term omeprazole therapy has caused atrophic gastritis (by biopsy); this may also occur with lansoprazole.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull;",
"     <i>",
"      Clostridium difficile",
"     </i>",
"     -associated diarrhea (CDAD): Use of proton pump inhibitors (PPIs) may increase risk of CDAD, especially in hospitalized patients; consider CDAD diagnosis in patients with persistent diarrhea that does not improve. Use the lowest dose and shortest duration of PPI therapy appropriate for the condition being treated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fractures: Increased incidence of osteoporosis-related bone fractures of the hip, spine, or wrist may occur with proton pump inhibitor therapy. Patients on high-dose or long-term therapy should be monitored. Use the lowest effective dose for the shortest duration of time, use vitamin D and calcium supplementation, and follow appropriate guidelines to reduce risk of fractures in patients at risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypomagnesemia: Reported rarely, usually with prolonged PPI use of &gt;3 months (most cases &gt;1 year of therapy). May be symptomatic or asymptomatic; severe cases may cause tetany, seizures, and cardiac arrhythmias. Consider obtaining serum magnesium concentrations prior to beginning long-term therapy, especially if taking concomitant digoxin, diuretics, or other drugs known to cause hypomagnesemia; and periodically thereafter. Hypomagnesemia may be corrected by magnesium supplementation, although discontinuation of lansoprazole may be necessary; magnesium levels typically return to normal within 1 week of stopping.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Superinfection: Prolonged use of amoxicillin or clarithromycin may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Coronary artery disease (CAD): Use clarithromycin with caution in patients with CAD; postmarketing safety trial suggests increased risk of cardiovascular mortality with short-term clarithromycin use (vs placebo) in patients with stable CAD. However, more smokers were randomized to the clarithromycin arm (Jespersen, 2006).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastric malignancy: Relief of symptoms does not preclude the presence of a gastric malignancy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal infection (eg,",
"     <i>",
"      Salmonella, Campylobacter",
"     </i>",
"     ): Use of proton pump inhibitors may increase risk of these infections.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Infectious mononucleosis: A high percentage of patients with infectious mononucleosis have developed rash during amoxicillin therapy; ampicillin-class antibiotics not recommended in these patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use lansoprazole with caution in patients with severe hepatic impairment; dosage reductions recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myasthenia gravis: Use clarithromycin with caution in patients with myasthenia gravis; exacerbation of symptoms and new onset of symptoms has occurred.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use amoxicillin with caution in patients with renal impairment; dosage adjustment recommended. Use clarithromycin with caution in severe renal impairment; dosage adjustment required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Clopidogrel: Proton pump inhibitors (PPIs) may diminish the therapeutic effect of clopidogrel thought to be due to reduced formation of the active metabolite of clopidogrel. The manufacturer of clopidogrel recommends either avoidance of both omeprazole (even when scheduled 12 hours apart) and esomeprazole or use of a PPI with comparatively less effect on the active metabolite of clopidogrel (eg, pantoprazole). Although lansoprazole exhibits the most potent CYP2C19 inhibition",
"     <i>",
"      in vitro",
"     </i>",
"     (Li, 2004; Ogilvie, 2011), an",
"     <i>",
"      in vivo",
"     </i>",
"     study of extensive CYP2C19 metabolizers showed less reduction of the active metabolite of clopidogrel by lansoprazole/dexlansoprazole compared to esomeprazole/omeprazole (Frelinger, 2012). In contrast to these warnings, others have recommended the continued use of PPIs, regardless of the degree of inhibition, in patients with a history of GI bleeding or multiple risk factors for GI bleeding who are also receiving clopidogrel since no evidence has established clinically meaningful differences in outcome; however, a clinically-significant interaction cannot be excluded in those who are poor metabolizers of clopidogrel (Abraham, 2010; Levine, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; High potential for other interactions: Concomitant use of lansoprazole with some drugs may require cautious use, may not be recommended, or may require dosage adjustments. Clarithromycin is a major inhibitor of CYP3A4: Use caution with any agents with substantial metabolism through the CYP3A4 pathway.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use of clarithromycin may increase risk of torsade de pointes, particularly with concurrent renal/hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use:",
"     <i>",
"      Helicobacter pylori",
"     </i>",
"     eradication: Short-term combination therapy (&le;7 days) has been associated with a higher incidence of treatment failure. The American College of Gastroenterology recommends 10-14 days of therapy (triple or quadruple) for eradication of",
"     <i>",
"      H. pylori",
"     </i>",
"     (Chey, 2007).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F186907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F186882\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ado-Trastuzumab Emtansine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Ado-Trastuzumab Emtansine. Specifically, strong CYP3A4 inhibitors may increase concentrations of the cytotoxic DM1 component.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfentanil: Macrolide Antibiotics may decrease the metabolism of Alfentanil.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alfuzosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: May enhance the potential for allergic or hypersensitivity reactions to Amoxicillin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Almotriptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Almotriptan.  Management: Limit initial almotriptan adult dose to 6.25 mg and maximum adult dose to 12.5 mg/24-hrs when used with a strong CYP3A4 inhibitor. Avoid concurrent use in patients with impaired hepatic or renal function.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alosetron: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alosetron.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Proton Pump Inhibitors may increase the serum concentration of Amphetamines. Specifically, data indicate that Proton Pump Inhibitors may increase the rate at which Amphetamines are absorbed.  Total exposure to Amphetamines is not significantly changed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): Macrolide Antibiotics may decrease the metabolism of Antifungal Agents (Azole Derivatives, Systemic). Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Macrolide Antibiotics.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antineoplastic Agents (Vinca Alkaloids): Macrolide Antibiotics may increase the serum concentration of Antineoplastic Agents (Vinca Alkaloids). Macrolides may also increase the distribution of Vinca Alkaloids into certain cells and/or tissues.  Management: Consider an alternative to using a macrolide antibiotic when possible in order to avoid the potential for increased vinca alkaloid toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Apixaban.  Management: Apixaban U.S. prescribing information states dose reduction criteria that may be applied under some circumstances. The apixaban Canadian product monograph suggests that any combined use is contraindicated. See full interaction monograph for details.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.  Management: See full interaction monograph for details.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: Proton Pump Inhibitors may decrease the serum concentration of Atazanavir.  Management: Avoid concurrent PPI in HIV treatment-experienced patients.  For treatment-naive patients, atazanavir/ritonavir dose should be given approximately 12 hours after the PPI, and the PPI should not exceed the equivalent of 20 mg omeprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Avanafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Avanafil.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Axitinib.  Management: Avoid concurrent use of axitinib with any strong CYP3A inhibitor whenever possible.  If a strong CYP3A inhibitor must be used with axitinib, a 50% axitinib dose reduction is recommended.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bedaquiline: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bedaquiline.  Management: Limit the duration of concomitant administration of bedaquiline with CYP3A4 inhibitors to no more than 14 days, unless the benefit of continued administration is judged to outweigh the possible risks. Monitor for toxic effects of bedaquiline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines (metabolized by oxidation): Macrolide Antibiotics may decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Proton Pump Inhibitors may diminish the therapeutic effect of Bisphosphonate Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of Clarithromycin. Clarithromycin may increase the serum concentration of Boceprevir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bortezomib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bortezomib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: Proton Pump Inhibitors may decrease the serum concentration of Bosutinib.  Management: Consider alternatives to proton pump inhibitors, such as antacids or H2 receptor antagonists.  Administer alternative agents more than 2 hours before or after bosutinib.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brentuximab Vedotin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brinzolamide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brinzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Systemic, Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Systemic, Oral Inhalation).  Management: Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor.  This interaction is likely less severe with orally inhaled budesonide.  Monitor patients closely for signs/symptoms of corticosteroid excess.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BusPIRone: Macrolide Antibiotics may decrease the metabolism of BusPIRone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cabozantinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cabozantinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: Macrolide Antibiotics may decrease the metabolism of Calcium Channel Blockers.  Management: Consider using a noninteracting macrolide. Monitor for increased therapeutic effects of calcium channel blockers if an interacting macrolide antibiotic is initiated, or decreased effects if a macrolide is discontinued.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Clevidipine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: Macrolide Antibiotics may decrease the metabolism of CarBAMazepine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Macrolide Antibiotics may increase the serum concentration of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefditoren: Proton Pump Inhibitors may decrease the serum concentration of Cefditoren.  Management: If possible, avoid use of cefditoren with proton pump inhibitors (PPIs). Consider alternative methods to minimize/control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of PPIs can not be avoided.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cilostazol: Macrolide Antibiotics may decrease the metabolism of Cilostazol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cisapride: Macrolide Antibiotics may decrease the metabolism of Cisapride.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clopidogrel: Lansoprazole may decrease serum concentrations of the active metabolite(s) of Clopidogrel.  Management: Due to the possible risk for impaired clopidogrel effectiveness, clinicians should carefully consider the need for proton pump inhibitor therapy in patients receiving clopidogrel.  Other acid-lowering therapies do not appear to share this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clopidogrel: Macrolide Antibiotics may diminish the therapeutic effect of Clopidogrel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Macrolide Antibiotics may decrease the metabolism of CloZAPine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: Clarithromycin may increase the serum concentration of Cobicistat. Cobicistat may increase the serum concentration of Clarithromycin.  Management: In patients with an estimated creatinine clearance of 50 to 60 mL/min, the clarithromycin dose needs to be reduced by 50% when used together with the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP3A4 inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Conivaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Corticosteroids (Orally Inhaled).  Management: Monitor for signs and symptoms of adrenal suppression if inhaled budesonide or mometasone are coadministered with a strong CYP3A4 inhibitor.  Avoid combining inhaled fluticasone with any strong CYP3A4 inhibitor.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Beclomethasone (Oral Inhalation); Triamcinolone (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Macrolide Antibiotics may decrease the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Crizotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Macrolide Antibiotics may decrease the metabolism of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase serum concentrations of the active metabolite(s) of Clarithromycin. Clarithromycin may increase the serum concentration of CYP3A4 Inducers (Strong). CYP3A4 Inducers (Strong) may decrease the serum concentration of Clarithromycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inhibitors (Strong) may decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Proton Pump Inhibitors may decrease serum concentrations of the active metabolite(s) of Dabigatran Etexilate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: Proton Pump Inhibitors may decrease the serum concentration of Dasatinib.  Management: Antacids (taken 2 hours before or after dasatinib administration) can be used in place of the proton pump inhibitor if some acid-reducing therapy is needed.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Delavirdine: Proton Pump Inhibitors may decrease the serum concentration of Delavirdine.  Management: Chronic therapy with proton pump inhibitors (PPIs) should be avoided in patients treated with delavirdine.  The clinical significance of short-term PPI therapy with delavirdine is uncertain, but such therapy should be undertaken with caution.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexmethylphenidate: Proton Pump Inhibitors may increase the absorption of Dexmethylphenidate. Specifically, proton pump inhibitors may interfere with the normal release of drug from the extended-release capsules (Focalin XR brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dienogest: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dienogest.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dihydroergotamine: Clarithromycin may increase the serum concentration of Dihydroergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disopyramide: Macrolide Antibiotics may enhance the QTc-prolonging effect of Disopyramide. Macrolide Antibiotics may decrease the metabolism of Disopyramide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dronedarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dutasteride: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dutasteride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eletriptan: Macrolide Antibiotics may decrease the metabolism of Eletriptan.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Enzalutamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Eplerenone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: Macrolide Antibiotics may decrease the metabolism of Eplerenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: Macrolide Antibiotics may enhance the adverse/toxic effect of Ergot Derivatives. Specifically leading to the development of ergotism.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Cabergoline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergotamine: Clarithromycin may increase the serum concentration of Ergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Erlotinib: Proton Pump Inhibitors may decrease the serum concentration of Erlotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: May decrease the serum concentration of Macrolide Antibiotics. Clarithromycin AUC is reduced and levels of the active metabolite (14-hydroxy-clarithromycin) are modestly increased. Management: For the treatment of",
"     <i>",
"      Mycobacterium avium",
"     </i>",
"     complex, consider changing to alternative agent, such as azithromycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Everolimus.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.  Management: Monitor patients extra closely for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Fesoterodine.  Management: Avoid fesoterodine doses greater than 4 mg daily in adult patients who are also receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May increase the serum concentration of Proton Pump Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluticasone (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluticasone (Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Oral Inhalation).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fusidic Acid: May diminish the therapeutic effect of Penicillins.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gefitinib: Proton Pump Inhibitors may decrease the serum concentration of Gefitinib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GlipiZIDE: Clarithromycin may increase the serum concentration of GlipiZIDE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GlyBURIDE: Clarithromycin may increase the serum concentration of GlyBURIDE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GuanFACINE: CYP3A4 Inhibitors (Strong) may increase the serum concentration of GuanFACINE.  Management: Reduce the guanfacine dose by 50% when adding a strong CYP3A4 inhibitor.  Limit the guanfacine dose to 2 mg/day when starting guanfacine in a patient who is taking a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Halofantrine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Halofantrine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: Moderate Risk QTc-Prolonging Agents may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HMG-CoA Reductase Inhibitors: Macrolide Antibiotics may decrease the metabolism of HMG-CoA Reductase Inhibitors.  Management: Avoid lovastatin or simvastatin with erythro-, clarithro-, or telithromycin. Limit pitavastatin to a 1 mg/day maximum adult dose with erythromycin.  Atorvastatin dose adjustments may be required. Increase monitoring for toxicity with any such combination.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Fluvastatin; Pravastatin; Rosuvastatin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iloperidone: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolites P88 and P95 may be increased. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Iloperidone.  Management: Reduce iloperidone dose by half when administered with a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imatinib: Lansoprazole may enhance the dermatologic adverse effect of Imatinib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indinavir: Proton Pump Inhibitors may decrease the serum concentration of Indinavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Salts: Proton Pump Inhibitors may decrease the absorption of Iron Salts.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ferric Gluconate; Ferumoxytol; Iron Dextran Complex; Iron Sucrose.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: Proton Pump Inhibitors may decrease the serum concentration of Itraconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivabradine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivacaftor.  Management: Decrease ivacaftor dose to 150 mg twice a week in patients also receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ixabepilone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ixabepilone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): Proton Pump Inhibitors may decrease the serum concentration of Ketoconazole (Systemic). Ketoconazole (Systemic) may increase the serum concentration of Proton Pump Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lapatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lapatinib.  Management: If an overlap in therapy cannot be avoided, consider reducing lapatinib dose to 500 mg/day during, and within 1 week of completing, treatment with the strong CYP3A4 inhibitor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lomitapide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lovastatin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lovastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lumefantrine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lumefantrine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lurasidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maraviroc: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Maraviroc.  Management: Reduce the adult dose of maraviroc to 150 mg twice daily when used with a strong CYP3A4 inhibitor.  Do not use maraviroc with strong CYP3A4 inhibitors in patients with Clcr less than 30 mL/min.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mesalamine: Proton Pump Inhibitors may diminish the therapeutic effect of Mesalamine. Proton pump inhibitor-mediated increases in gastrointestinal pH may cause the premature release of mesalamine from specific sustained-release mesalamine products.  Management: Consider avoiding concurrent administration of high-dose proton pump inhibitors (PPIs) with sustained-release mesalamine products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Penicillins may increase the serum concentration of Methotrexate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Proton Pump Inhibitors may increase the serum concentration of Methotrexate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: Proton Pump Inhibitors may increase the absorption of Methylphenidate. Specifically, proton pump inhibitors may interfere with the normal release of drug from the extended-release capsules (Ritalin LA brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MethylPREDNISolone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.  Management: Consider methylprednisolone dose titration and/or adjustments in patients receiving strong CYP3A4 inhibitors (eg, azole antifungals, protease inhibitors) and monitor for  increased steroid related adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Mifepristone.  Management: Limit mifepristone adult dose, when used for treatment of hyperglycemia in Cushing's syndrome, to a maximum of 300 mg/day when combined with a strong CYP3A4 inhibitor. Monitor for increased mifepristone toxicity regardless of dose or indication.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Moderate Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): Proton Pump Inhibitors may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, the absorption of iron may be decreased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Proton Pump Inhibitors may decrease the serum concentration of Mycophenolate. Specifically, concentrations of the active mycophenolic acid may be reduced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Penicillins may decrease serum concentrations of the active metabolite(s) of Mycophenolate. This effect appears to be the result of impaired enterohepatic recirculation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nelfinavir: Proton Pump Inhibitors may decrease serum concentrations of the active metabolite(s) of Nelfinavir. Proton Pump Inhibitors may decrease the serum concentration of Nelfinavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nilotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: Proton Pump Inhibitors may decrease the serum concentration of Nilotinib.  Management: Avoid this combination when possible since separation of doses is not likely to be an adequate method of minimizing the interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nisoldipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nisoldipine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ospemifene: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ospemifene.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paricalcitol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Paricalcitol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pazopanib.  Management: Avoid concurrent use of pazopanib with strong inhibitors of CYP3A4 whenever possible.  If it is not possible to avoid such a combination, reduce pazopanib adult dose to 400 mg.  Further dose reductions may also be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: CYP3A4 Inhibitors (Strong) may decrease the metabolism of Pimecrolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: Macrolide Antibiotics may enhance the QTc-prolonging effect of Pimozide. Macrolide Antibiotics may decrease the metabolism of Pimozide. This mechanism may not apply to azithromycin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: Proton Pump Inhibitors may decrease the serum concentration of Ponatinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ponatinib.  Management: Per ponatinib U.S. prescribing information, the starting dose of ponatinib should be reduced to 30 mg daily during treatment with any strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Posaconazole: Proton Pump Inhibitors may decrease the serum concentration of Posaconazole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prasugrel: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Prasugrel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Penicillins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May diminish the therapeutic effect of Clarithromycin. Specifically, certain protease inhibitors may decrease formation of the active 14-hydroxy-clarithromycin metabolite, which may negatively impact clarithromycin effectiveness vs. H. influenzae and other non-MAC infections. Clarithromycin may increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Clarithromycin. Clarithromycin dose adjustment in renally impaired patients may be needed. Management: Avoid clarithromycin doses greater than 1000 mg/day when used with a protease inhibitor. Further dose reductions may be needed in patients with impaired renal function. Consider alternative antimicrobial for any non-MAC infection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prucalopride: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Prucalopride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Macrolide Antibiotics may decrease the metabolism of QuiNIDine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNINE: Macrolide Antibiotics may increase the serum concentration of QuiNINE.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Raltegravir: Proton Pump Inhibitors may increase the serum concentration of Raltegravir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ranolazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Red Yeast Rice: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Red Yeast Rice. Specifically, concentrations of lovastatin and related compounds found in Red Yeast Rice may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regorafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Regorafenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Repaglinide: Macrolide Antibiotics may increase the serum concentration of Repaglinide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: Macrolide Antibiotics may decrease the metabolism of Rifamycin Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Rifapentine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rilpivirine: Proton Pump Inhibitors may decrease the serum concentration of Rilpivirine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Risedronate: Proton Pump Inhibitors may diminish the therapeutic effect of Risedronate. Proton Pump Inhibitors may increase the serum concentration of Risedronate. This applies specifically to use of delayed-release risedronate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Clarithromycin may increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RomiDEPsin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of RomiDEPsin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ruxolitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ruxolitinib.  Management: Reduce ruxolitinib initial adult dose to 10 mg twice daily in patients receiving strong CYP3A4 inhibitors whose platelet count is 100*10^9/L or greater.  Avoid in patients with lower platelet count.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salmeterol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Salmeterol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saquinavir: Proton Pump Inhibitors may increase the serum concentration of Saquinavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Saxagliptin.  Management: Saxagliptin U.S. product labeling recommends limiting saxagliptin adult dose to 2.5 mg/day when used with a strong CYP3A4 inhibitor. Monitor for increased saxagliptin levels/effects. A similar recommendation is not made in the Canadian product labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: Macrolide Antibiotics may decrease the metabolism of Selective Serotonin Reuptake Inhibitors.",
"     <b>",
"      Exceptions:",
"     </b>",
"     FluvoxaMINE; PARoxetine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sildenafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Sildenafil.  Management: When used for treatment of pulmonary arterial hypertension, use of sildenafil with strong CYP3A4 inhibitors should be avoided.  When used for erectile dysfunction, starting dose should be reduced to 25 mg.  Max dose with ritonavir is 25 mg per 48 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Silodosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Silodosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Simvastatin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sirolimus: Macrolide Antibiotics may decrease the metabolism of Sirolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of SORAfenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Proton Pump Inhibitors may increase the serum concentration of Tacrolimus (Systemic).  Management: Tacrolimus dose adjustment may be required. Rabeprazole, pantoprazole, or selected H2-receptor antagonists (i.e., ranitidine or famotidine) may be less likely to interact. Genetic testing may predict patients at highest risk.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Macrolide Antibiotics may increase the serum concentration of Tacrolimus (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): Macrolide Antibiotics may increase the serum concentration of Tacrolimus (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tadalafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tadalafil.  Management: Recommendations regarding use of tadalafil in patients also receiving strong CYP3A4 inhibitors may vary based on indication and/or international labeling. Consult appropriate product labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamsulosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tamsulosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Clarithromycin may increase the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Clarithromycin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Temsirolimus: Macrolide Antibiotics may enhance the adverse/toxic effect of Temsirolimus. Levels of sirolimus, the active metabolite, may be increased, likely due to inhibition of CYP-mediated metabolism.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Terfenadine: Macrolide Antibiotics may enhance the QTc-prolonging effect of Terfenadine. Macrolide Antibiotics may increase the serum concentration of Terfenadine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: May diminish the therapeutic effect of Penicillins.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Macrolide Antibiotics may decrease the metabolism of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ticagrelor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May decrease the serum concentration of Proton Pump Inhibitors. These data are derived from studies with Ritonavir-boosted Tipranavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tofacitinib.  Management: Reduce the adult dose of tofacitinib to 5 mg daily in patients receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolterodine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolterodine.  Management: The maximum recommended dose of long-acting tolterodine is 2 mg/day when used together with a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolvaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topotecan: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: CYP3A4 Inhibitors (Strong) may enhance the adverse/toxic effect of Toremifene. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Toremifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vardenafil: Clarithromycin may increase the serum concentration of Vardenafil.  Management: Recommendations regarding the concomitant use of vardenafil with clarithromycin vary between international labelings and between commercially available vardenafil brand name products (Levitra, Staxyn). Consult appropriate product labelings.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vemurafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vemurafenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vilazodone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vilazodone.  Management: Limit maximum adult vilazodone dose to 20 mg/day in patients receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vismodegib: Proton Pump Inhibitors may decrease the serum concentration of Vismodegib.  Management: Carefully consider the need for any medication that increases the pH of the upper GI tract (PPIs, H2RAs, antacids), as these could significantly reduce vismodegib systemic exposure. Vismodegib dose increases are unlikely to compensate for this effect.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Macrolide Antibiotics may increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Lansoprazole may increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Penicillins may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: Proton Pump Inhibitors may increase the serum concentration of Voriconazole. Voriconazole may increase the serum concentration of Proton Pump Inhibitors.  Management: In patients receiving omeprazole 40 mg/day or greater, reduce omeprazole dose by half when initiating voriconazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zidovudine: Clarithromycin may enhance the myelosuppressive effect of Zidovudine. Clarithromycin may decrease the serum concentration of Zidovudine.  Management: Monitor response to zidovudine closely when used with clarithromycin, and consider staggering zidovudine and clarithromycin doses when possible in order to minimize the potential for interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zopiclone: Macrolide Antibiotics may increase the serum concentration of Zopiclone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zuclopenthixol.  Management: Consider zuclopenthixol dosage reduction with concomitant use of a strong CYP3A4 inhibitor (eg, ketoconazole) in poor CYP2D6 metabolizers or with strong CYP2D6 inhibitors (eg, paroxetine). Monitor for increased zuclopenthixol levels/toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F186883\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F186893\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal reproduction studies using clarithromycin. See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F186904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F186894\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     According to the manufacturer, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother. See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F7885591\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential, BUN, creatinine, liver function test periodically with prolonged use",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F186895\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Lanzopral Heli-Pak (PE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F186890\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Abraham NS, Hlatky MA, Antman EM, et al, &ldquo;ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use: A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122(24):2619-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/27/33209/abstract-text/21060077/pubmed\" id=\"21060077\" target=\"_blank\">",
"        21060077",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chey WD, Wong BC, and Practice Parameters Committee of the American College of Gastroenterology, &ldquo;American College of Gastroenterology, Guideline on the Management of",
"      <i>",
"       Helicobacter pylori",
"      </i>",
"      Infection,&rdquo;",
"      <i>",
"       Am J Gastroenterol",
"      </i>",
"      , 2007, 102(8):1808-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/27/33209/abstract-text/17608775/pubmed\" id=\"17608775\" target=\"_blank\">",
"        17608775",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Frelinger AL 3rd, Lee RD, Mulford DJ, et al, \"A Randomized, 2-Period, Crossover Design Study to Assess the Effects of Dexlansoprazole, Lansoprazole, Esomeprazole, and Omeprazole on the Steady-State Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Volunteers,\"",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2012, 59(14):1304-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/27/33209/abstract-text/22464259/pubmed\" id=\"22464259\" target=\"_blank\">",
"        22464259",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jespersen CM, Als-Nielsen B, Damgaard M, et al, \"Randomised Placebo Controlled Multicentre Trial to Assess Short Term Clarithromycin for Patients With Stable Coronary Heart Disease: CLARICOR Trial,\"",
"      <i>",
"       BMJ",
"      </i>",
"      , 2006, 332(7532):22-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/27/33209/abstract-text/16339220/pubmed\" id=\"16339220\" target=\"_blank\">",
"        16339220",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levine GN, Bates ER, Blankenship JC, et al, &ldquo;2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(23):e574-651.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/27/33209/abstract-text/22064601/pubmed\" id=\"22064601\" target=\"_blank\">",
"        22064601",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Li XQ, Andersson TB, Ahlstr&ouml;m M, et al, \"Comparison of Inhibitory Effects of the Proton Pump-Inhibiting Drugs Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole, and Rabeprazole on Human Cytochrome P450 Activities,\"",
"      <i>",
"       Drug Metab Dispos",
"      </i>",
"      , 2004, 32(8):821-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/27/33209/abstract-text/15258107/pubmed\" id=\"15258107\" target=\"_blank\">",
"        15258107",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ogilvie BW, Yerino P, Kazmi F, et al, \"The Proton Pump Inhibitor, Omeprazole, But Not Lansoprazole or Pantoprazole, Is a Metabolism-Dependent Inhibitor of CYP2C19: Implications for Coadministration With Clopidogrel,\"",
"      <i>",
"       Drug Metab Dispos",
"      </i>",
"      , 2011, 39(11):2020-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/27/33209/abstract-text/21795468/pubmed\" id=\"21795468\" target=\"_blank\">",
"        21795468",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Paoluzi P, Iacopini F, Crispino P, et al, &ldquo;2-Week Triple Therapy for",
"      <i>",
"       Helicobacter pylori",
"      </i>",
"      Infection is Better Than 1-Week in Clinical Practice: a Large Prospective Single-Center Randomized Study,&rdquo;",
"      <i>",
"       Helicobacter",
"      </i>",
"      , 2006, 11(6):562-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/27/33209/abstract-text/17083378/pubmed\" id=\"17083378\" target=\"_blank\">",
"        17083378",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10089 Version 47.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.81.197.98-C50D28AF5E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_27_33209=[""].join("\n");
var outline_f32_27_33209=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16572472\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186897\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186898\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186912\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186901\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186902\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F608953\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15668413\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186886\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186876\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186888\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186917\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186910\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186891\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186879\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186907\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186882\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186883\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186893\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186904\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186894\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7885591\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186895\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186890\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10089\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10089|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?32/49/33556?source=related_link\">",
"      Lansoprazole, amoxicillin, and clarithromycin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_27_33210="Reactive arthritis (formerly Reiter syndrome)";
var content_f32_27_33210=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Reactive arthritis (formerly Reiter syndrome)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/27/33210/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/27/33210/contributors\">",
"     David T Yu, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/27/33210/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/27/33210/contributors\">",
"     Joachim Sieper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/27/33210/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/27/33210/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/27/33210/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reactive arthritis is conventionally defined as an arthritis that arises following an infection, although the pathogens cannot be cultured from the affected joints. It is generally regarded as a form of spondyloarthritis.",
"   </p>",
"   <p>",
"    The definition, clinical features, approach to diagnosis and differential diagnosis, and management of reactive arthritis will be reviewed here. Mechanisms that may play a role in reactive arthritis and in other spondyloarthritides are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/14/6377?source=see_link\">",
"     \"Mechanisms for the induction of rheumatic symptoms by gastrointestinal disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/51/12090?source=see_link\">",
"     \"Pathogenesis of spondyloarthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27140925\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term &ldquo;reactive arthritis&rdquo; was introduced in 1969 as &ldquo;an arthritis which developed soon after or during an infection elsewhere in the body, but in which the microorganisms cannot be recovered from the joint&rdquo; [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33210/abstract/1\">",
"     1",
"    </a>",
"    ]. The original definition did not specify the pathogens that were accepted as causes of reactive arthritis, and, in 1999, a panel of experts determined a specific list of gastrointestinal and urogenital pathogens that could be considered causative [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33210/abstract/2\">",
"     2",
"    </a>",
"    ]. These included Chlamydia trachomatis, Yersinia, Salmonella, Shigella, and Campylobacter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33210/abstract/2\">",
"     2",
"    </a>",
"    ]. Escherichia coli, Clostridium difficile, and Chlamydia pneumoniae have since been added to the list [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33210/abstract/3-6\">",
"     3-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional causative pathogens, alternative terms, and diagnostic and therapeutic strategies for reactive arthritis have subsequently been proposed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33210/abstract/7\">",
"     7",
"    </a>",
"    ]. However, none of the newer diagnostic or therapeutic approaches or alternate names has been adequately validated. Another problem is that many of the studies generating these approaches involved patients seen in rheumatology clinics or followed outbreaks of disease after exposure to a common pathogen; such patients are not likely to be representative of the affected patients in the general community. Thus, the definition of reactive arthritis is still evolving.",
"   </p>",
"   <p>",
"    Two major clinical features that characterize reactive arthritis were identified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33210/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An interval ranging from several days to weeks between the antecedent infection and arthritis",
"     </li>",
"     <li>",
"      A typically mono- or oligoarticular pattern of the arthritis, often involving the lower extremities",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    By convention, reactive arthritis of more than six months duration was regarded as being chronic instead of acute.",
"   </p>",
"   <p>",
"    The term &ldquo;reactive arthritis&rdquo; has sometimes been used historically to refer to the clinical triad of postinfectious arthritis, urethritis, and conjunctivitis, which was formerly called Reiter syndrome. However, these patients represent only a subset of patients with reactive arthritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33210/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients suspected of having reactive arthritis whose features satisfy the Assessment of SpondyloArthritis International Society (ASAS) criteria for axial or peripheral spondyloarthritis are also considered as having a spondyloarthritis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/57/9114?source=see_link&amp;anchor=H26#H26\">",
"     \"Clinical manifestations, diagnosis, and management of undifferentiated spondyloarthritis and related spondyloarthritides\", section on 'ASAS Classification criteria'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reactive arthritis is an uncommon disease that typically occurs in young adults, affecting both men and women. Much of the data on the prevalence and annual incidence of reactive arthritis in populations come from the Scandinavian countries. The prevalence is estimated to be 30 to 40 per 100,000 adults, and the annual incidence is from 0.6 to 27 per 100,000 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33210/abstract/3,4,6,10\">",
"     3,4,6,10",
"    </a>",
"    ]. In a US population-based study in Oregon and Minnesota, the incidence of reactive arthritis following documented enteric bacterial infections ranged from 0.6 to 3.1 cases per 100,000, depending upon the organism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33210/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among patients with any of the spondyloarthritis variants seen by rheumatologists, those with reactive arthritis are a very small minority. This was illustrated by a study of 1379 Spanish spondyloarthritis patients, of whom only 16 (1.2 percent) were diagnosed with reactive arthritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33210/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most cases of reactive arthritis appear sporadically, but outbreaks may follow single source infections. In such outbreaks, the proportion of infected subjects who developed subsequent reactive arthritis has ranged from 0 to 21 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33210/abstract/6,10\">",
"     6,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The causative pathogens, incidence, and prevalence of reactive arthritis depend upon the geographic region. In general, among the pathogens, Chlamydia is probably the most endemic. However, only a small minority of patients infected with Chlamydia develop arthritis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with reactive arthritis typically present with an asymmetric oligoarthritis, usually one to four weeks following the inciting infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33210/abstract/2,6,7,13\">",
"     2,6,7,13",
"    </a>",
"    ].The extent of the interval between infection and the onset of arthritis considered consistent with a reactive arthritis by expert consensus is a minimum of several days and a maximum of several weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33210/abstract/2\">",
"     2",
"    </a>",
"    ]. In at least half of patients, all symptoms resolve in less than six months; in most patients, symptoms resolve within one year. The several types of clinical manifestations of reactive arthritis include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Symptoms of preceding enteric or genitourinary infection (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Preceding infection'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Musculoskeletal signs and symptoms (see",
"      <a class=\"local\" href=\"#H6\">",
"       'Musculoskeletal signs and symptoms'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Extraarticular signs and symptoms (see",
"      <a class=\"local\" href=\"#H9\">",
"       'Extraarticular signs and symptoms'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other than those symptoms due to the infection that has triggered the arthritis, the articular and extraarticular manifestations are similar regardless of the particular enteric or genitourinary organism or species of organism causing the disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33210/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Preceding infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The characteristic symptoms of the enteric or genitourinary infections that can cause reactive arthritis are diarrhea or urethritis. Patients with arthritis induced by enteric bacteria can also develop aseptic urethritis. In some patients with infectious urethritis, especially Chlamydia, the infection may be asymptomatic and is identified only upon studies performed because of suspicion of reactive arthritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33210/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/17/32025?source=see_link\">",
"     \"Approach to the adult with acute diarrhea in developed countries\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/46/26345?source=see_link\">",
"     \"Epidemiology and causes of acute diarrhea in developed countries\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/43/19126?source=see_link\">",
"     \"Infectious causes of dysuria in adult men\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/30/10729?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Chlamydia trachomatis infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The enteric bacteria commonly associated with reactive arthritis include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Salmonella of various serovars",
"     </li>",
"     <li>",
"      Shigella, especially Shigella flexneri, but also Shigella dysenteriae and sonnei",
"     </li>",
"     <li>",
"      Yersinia, including Yersinia enterocolitica 0:3 and 0:9 and Yersinia pseudotuberculosis",
"     </li>",
"     <li>",
"      Campylobacter, especially Campylobacter jejuni",
"     </li>",
"     <li>",
"      Clostridium difficile",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The genital pathogen commonly accepted to be the cause of reactive arthritis is Chlamydia trachomatis.",
"   </p>",
"   <p>",
"    Other bacteria also reported to cause reactive arthritis include Chlamydia pneumoniae, Escherichia coli, Ureaplasma urealyticum, and Mycoplasma genitalium. Intravesical Bacillus Calmette-Guerin (BCG) treatment for bladder cancer has also been identified as a rare cause of reactive arthritis. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Differential diagnosis'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/23/31096?source=see_link&amp;anchor=H12#H12\">",
"     \"Complications of intravesical BCG immunotherapy\", section on 'Arthritis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Reactive arthritis has also been reported in patients with human immunodeficiency virus (HIV) infection, in which it is generally thought to be related to other infections to which patients have been exposed, rather than to HIV itself [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33210/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. An association between reactive arthritis and HLA-B27 has been noted in Caucasian HIV-infected patients but not in patients from sub-Saharan Africa, where the prevalence of HLA-B27 is much lower [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33210/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Musculoskeletal signs and symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The musculoskeletal features of reactive arthritis include two major manifestations: arthritis and enthesitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33210/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The typical picture of arthritis, seen in rheumatology clinics, is an acute onset asymmetric oligoarthritis, often affecting the lower extremities (",
"    <a class=\"graphic graphic_picture graphicRef67863 \" href=\"mobipreview.htm?2/57/2962\">",
"     picture 1",
"    </a>",
"    ). However, about 50 percent of patients have arthritis in the upper extremities, and some have polyarthritis in the small joints [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33210/abstract/19\">",
"     19",
"    </a>",
"    ]. Less often, axial arthritis may occur, with areas involved including the spine at any level and also the sacroiliac joints. By convention, the minority of patients with arthritis that does not resolve within six months is defined as having chronic reactive arthritis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Enthesitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The enthesis is the site of insertion of ligaments, tendons, joint capsule, or fascia to bone; enthesitis (or enthesopathy), the term for inflammation around the enthesis, can occur in patients with reactive arthritis and other forms of spondyloarthritis. Swelling at the heels is among the most characteristic symptom of enthesitis. Common sites of heel involvement are at the insertions of the Achilles tendon and of the plantar fascia on the calcaneus. Pain, swelling, and local tenderness are suggestive clinical features. Estimates of the frequency of enthesitis in patients with reactive arthritis have ranged from 20 to 90 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33210/abstract/11,19-22\">",
"     11,19-22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one study in the US of patients with documented enteric infections and a symptom of reactive arthritis, enthesitis was more common than arthritis or inflammatory back pain, occurring in 89 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33210/abstract/11,19\">",
"     11,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Enthesitis is discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/57/9114?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical manifestations, diagnosis, and management of undifferentiated spondyloarthritis and related spondyloarthritides\", section on 'Enthesitis (enthesopathy)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H915480\">",
"    <span class=\"h3\">",
"     Dactylitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients also develop dactylitis, which typically presents as sausage digits (",
"    <a class=\"graphic graphic_picture graphicRef50959 \" href=\"mobipreview.htm?1/31/1521\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33210/abstract/23\">",
"     23",
"    </a>",
"    ]. The frequency of dactylitis in reactive arthritis has not been reported. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/57/9114?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical manifestations, diagnosis, and management of undifferentiated spondyloarthritis and related spondyloarthritides\", section on 'Dactylitis (sausage digits)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Extraarticular signs and symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extraarticular involvement in reactive arthritis is associated with a variety of manifestations, which may be present during the acute or chronic phase of illness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33210/abstract/4,13\">",
"     4,13",
"    </a>",
"    ]. The relative frequency of each of these manifestations has not been well-analyzed. In one European cohort of 186 patients enrolled in a clinical trial, the frequencies of eye and skin involvement were approximately 20 and 15 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33210/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Extraarticular manifestations include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Conjunctivitis and, less frequently, anterior uveitis (",
"      <a class=\"graphic graphic_picture graphicRef77483 \" href=\"mobipreview.htm?40/16/41219\">",
"       picture 3",
"      </a>",
"      ). Episcleritis and corneal ulcers are also occasionally seen.",
"     </li>",
"     <li>",
"      Genitourinary tract symptoms, such as dysuria, pelvic pain, urethritis, cervicitis, prostatitis, salpingo-oophoritis, or cystitis",
"     </li>",
"     <li>",
"      Oral lesions, including mucosal ulcers (",
"      <a class=\"graphic graphic_picture graphicRef53868 \" href=\"mobipreview.htm?9/55/10100\">",
"       picture 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef83797 \" href=\"mobipreview.htm?23/32/24066\">",
"       picture 5",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Constitutional symptoms, such as fever, malaise, headache, and weight loss, which may occur during the acute phase of illness and then generally resolve",
"     </li>",
"     <li>",
"      Rashes such as keratoderma blennorrhagica (hyperkeratotic skin lesions on soles and palms) (",
"      <a class=\"graphic graphic_picture graphicRef50133 \" href=\"mobipreview.htm?11/52/12099\">",
"       picture 6",
"      </a>",
"      ) and erythema nodosum (",
"      <a class=\"graphic graphic_picture graphicRef80056 \" href=\"mobipreview.htm?8/46/8943\">",
"       picture 7",
"      </a>",
"      ) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/43/30393?source=see_link&amp;anchor=H23#H23\">",
"       \"Neutrophilic dermatoses\", section on 'Reactive arthritis'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Nail changes that resemble those seen in psoriasis, although pitting of the nails, which is often present in psoriasis, is typically absent in reactive arthritis (",
"      <a class=\"graphic graphic_picture graphicRef83793 \" href=\"mobipreview.htm?13/16/13573\">",
"       picture 8",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef83796 \" href=\"mobipreview.htm?5/50/5923\">",
"       picture 9",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Genital lesions such as circinate balanitis (",
"      <a class=\"graphic graphic_picture graphicRef62093 \" href=\"mobipreview.htm?5/9/5267\">",
"       picture 10",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Cardiac manifestations, which are uncommon but include pericarditis during the acute illness and valve disease, such as aortic insufficiency, with greater chronicity of illness",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    None of these manifestations is specific for reactive arthritis. Balanitis, for example, may result from any of numerous causes other than reactive arthritis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/33/14872?source=see_link&amp;anchor=H6#H6\">",
"     \"Balanitis and balanoposthitis in adults\", section on 'Etiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86465727\">",
"    <span class=\"h1\">",
"     LABORATORY AND IMAGING FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several types of findings may be present, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Serologic or other evidence of antecedent or concomitant infection",
"     </li>",
"     <li>",
"      Elevated acute phase reactants",
"     </li>",
"     <li>",
"      Positive testing for HLA-B27",
"     </li>",
"     <li>",
"      Inflammatory synovitis",
"     </li>",
"     <li>",
"      Imaging abnormalities consistent with enthesitis or arthritis",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19942326\">",
"    <span class=\"h2\">",
"     Laboratory findings",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86465809\">",
"    <span class=\"h3\">",
"     Antecedent or concommitant infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory tests, such as stool cultures to test for Salmonella, Shigella, Campylobacter, and Yersinia, can sometimes confirm a preceding or concomitant infection with one of the pathogens that classically induce reactive arthritis. However, by the time patients develop arthritis, the pathogens may no longer be retrievable. Urine and genital swab testing can sometimes detect Chlamydial infection using nucleic acid amplification techniques. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/13/8408?source=see_link&amp;anchor=H1790526#H1790526\">",
"     \"Screening for Chlamydia trachomatis\", section on 'Nucleic acid amplification tests'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H372392492\">",
"     'Chronic Chlamydia-related arthritis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Serological testing is used primarily in epidemiologic studies to test for preceding infections but is generally not useful in clinical practice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33210/abstract/7,24,25\">",
"     7,24,25",
"    </a>",
"    ]. Infections by Yersinia, Salmonella, Campylobacter, and Chlamydia cause strong antibody responses, and the triggering enteric infections can still be identified by serology in more than 50 percent of Yersinia or Salmonella infected patients, if such testing is performed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33210/abstract/26\">",
"     26",
"    </a>",
"    ]. In communities in which these infections are endemic and often clinically silent, serological testing is not specific for recent episodes of infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86466138\">",
"    <span class=\"h3\">",
"     Acute inflammatory changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute phase reactants such as the erythrocyte sedimentation rate or C-reactive protein may be elevated, depending upon the degree of systemic involvement and upon the acuity and activity of disease. In many patients, however, these studies may be normal; elevations in acute phase reactants were found in less than half of patients diagnosed with reactive arthritis in one study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33210/abstract/11\">",
"     11",
"    </a>",
"    ]. Some patients exhibit peripheral blood leukocytosis with increased numbers of granulocytes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86465746\">",
"    <span class=\"h3\">",
"     Genetic predisposition",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of HLA-B27, which is increased in patients with the various forms of spondylarthritis, including reactive arthritis, is generally estimated at 30 to 50 percent in patients with reactive arthritis, although values range widely [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33210/abstract/6,13\">",
"     6,13",
"    </a>",
"    ]. In hospital-based studies with more severely affected patients, frequencies as high as 60 to 80 percent have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33210/abstract/27\">",
"     27",
"    </a>",
"    ]; however, estimates in population-based studies and analyses of disease outbreaks are generally much lower and occasionally have shown no increase in HLA-B27 prevalence compared with the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33210/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/14/6377?source=see_link&amp;anchor=H7#H7\">",
"     \"Mechanisms for the induction of rheumatic symptoms by gastrointestinal disease\", section on 'Role of HLA-B27'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86466217\">",
"    <span class=\"h3\">",
"     Inflammatory synovitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The findings in synovial fluid are nonspecific and are characteristic of inflammatory arthritis, with elevated leukocyte counts, predominantly neutrophils. White blood cell (WBC) counts are typically between 2000 and 64,000 WBC per mm",
"    <sup>",
"     3",
"    </sup>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33210/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/56/20360?source=see_link\">",
"     \"Synovial fluid analysis and the diagnosis of septic arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/14/28904?source=see_link\">",
"     \"Evaluation of the adult with monoarticular pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86466394\">",
"    <span class=\"h2\">",
"     Imaging abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no specific findings on plain radiographs that can establish a diagnosis of reactive arthritis. Changes are usually limited to those associated with joint swelling if inflammatory arthritis is present. Patients with concurrent or past heel pain may show calcaneal spurs, but such findings are nonspecific and can be seen in other forms of arthritis and in asymptomatic individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33210/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with chronic joint disease, imaging studies such as ultrasonography, scintigraphy (radionuclide bone scanning), or magnetic resonance imaging (MRI) can also identify changes consistent with enthesitis or sacroiliitis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/9/151?source=see_link&amp;anchor=H13#H13\">",
"     \"Clinical manifestations of ankylosing spondylitis in adults\", section on 'Musculoskeletal imaging features'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19942542\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of reactive arthritis is a clinical diagnosis. There is no single definitive diagnostic test, nor are there validated diagnostic criteria. The diagnosis can generally be made in patients with all three of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Characteristic musculoskeletal findings &mdash; Such findings may include oligoarthritis of peripheral joints, most often with asymmetric involvement of the lower extremity, enthesitis, dactylitis, or inflammatory back pain. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Musculoskeletal signs and symptoms'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H86466217\">",
"       'Inflammatory synovitis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H86466394\">",
"       'Imaging abnormalities'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Evidence of preceding extraarticular infection &mdash; The preceding infection may be documented by microbiologic studies, such as bacterial culture or nucleic acid amplification, or by a characteristic clinical history. Patients with enteric bacterial infection typically have a history of a diarrheal illness, and patients with a genitourinary tract infection often describe symptoms of urethritis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/13/8408?source=see_link&amp;anchor=H1790526#H1790526\">",
"       \"Screening for Chlamydia trachomatis\", section on 'Nucleic acid amplification tests'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Inability to identify the causative pathogen does not exclude the diagnosis of reactive arthritis. Even in well-controlled studies, pathogens can be identified in only about 50 percent of the patients. In those cases, the diagnosis of infections would depend entirely upon the history. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Preceding infection'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H86465809\">",
"       'Antecedent or concommitant infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lack of evidence for another more likely cause of oligoarthritis, monoarthritis, or enthesitis &mdash; Similar musculoskeletal findings may occur in patients with other disorders, such as septic arthritis; other forms of spondyloarthritis; crystal-induced arthritis; other forms of inflammatory polyarthritis, such as rheumatoid arthritis or systemic lupus; poststreptococcal arthritis; or Lyme arthritis. These alternative diagnoses can usually be excluded based upon the history, physical examination, and laboratory examination. (See",
"      <a class=\"local\" href=\"#H19942416\">",
"       'Diagnostic evaluation'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H20\">",
"       'Differential diagnosis'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Algorithms derived from observational data provide support for these criteria, although longitudinal data are not available and although the probabilities described below are estimates, given the lack of a definitive diagnostic test for reactive arthritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33210/abstract/26\">",
"     26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with new onset of arthritis in a pattern characteristic of reactive arthritis (eg, an asymmetrical mono- or oligoarthritis predominantly of the lower extremities), in whom alternative diagnoses (eg, gout, osteoarthritis, and traumatic arthritis) have been excluded, the probability of reactive arthritis has been estimated to be about 40 percent.",
"     </li>",
"     <li>",
"      In a patient with a typical arthritis presentation, in whom other diagnoses have been excluded,",
"      <strong>",
"       plus",
"      </strong>",
"      symptomatic enteritis with a positive stool culture for bacteria associated with reactive arthritis, the probability of reactive arthritis is high.",
"     </li>",
"     <li>",
"      In a patient with a typical arthritis presentation, in whom other diagnoses have been excluded,",
"      <strong>",
"       plus",
"      </strong>",
"      a history of proven symptomatic preceding infection by Chlamydia trachomatis, the probability of reactive arthritis is very high (increased to about 90 percent). If the patient does not have a symptomatic Chlamydia trachomatis infection but Chlamydia trachomatis can be detected in the urine, the probability is roughly 60 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The diagnostic values of inflammatory spinal pain and extraarticular features, including conjunctivitis, balanitis, and keratoderma blennorrhagica, have not been systematically evaluated in longitudinal studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19942416\">",
"    <span class=\"h2\">",
"     Diagnostic evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnostic evaluation in a patient suspected of reactive arthritis depends upon the presenting symptoms and likely infectious etiology. In most patients, we do the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A thorough history and physical examination. The history is directed, in particular, at distinguishing musculoskeletal manifestations characteristic of reactive arthritis from those suggesting an alternative diagnosis and at determining whether there are symptoms to indicate a preceding or concomitant infection, especially diarrhea or urethritis. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Musculoskeletal signs and symptoms'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Preceding infection'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Extraarticular signs and symptoms'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'Differential diagnosis'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      The physical examination should include a detailed examination of the joints, including the heels, digits, and spine, as well as the rest of the joint examination. The general examination should aim at excluding other systemic or localized arthritic disorders. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Musculoskeletal signs and symptoms'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'Differential diagnosis'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Plain radiographs of affected joints and entheses to exclude other causes of joint pain, including other forms of arthritis and stress fractures",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We perform the following studies, depending upon the history and findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with a joint effusion, we perform arthrocentesis and examination of the synovial fluid, including total and differential white blood cell counts, crystal search, and examination for bacteria by Gram stain and culture to exclude septic arthritis. (See",
"      <a class=\"local\" href=\"#H86466217\">",
"       'Inflammatory synovitis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/52/23368?source=see_link\">",
"       \"Joint aspiration or injection in adults: Technique and indications\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/56/20360?source=see_link\">",
"       \"Synovial fluid analysis and the diagnosis of septic arthritis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients with recent diarrhea, we obtain stool cultures to test for Salmonella, Shigella, Campylobacter, and Yersinia. Serologic testing for enteric pathogens is generally not indicated because the limited specificity of such testing [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/27/33210/abstract/26\">",
"       26",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/17/32025?source=see_link\">",
"       \"Approach to the adult with acute diarrhea in developed countries\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/44/24265?source=see_link&amp;anchor=H20#H20\">",
"       \"Differential diagnosis of microbial foodborne disease\", section on 'Inflammatory diarrhea as the major presenting symptom'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/63/41974?source=see_link&amp;anchor=H11#H11\">",
"       \"Clinical manifestations and diagnosis of Yersinia infections\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients suspected of infection with Chlamydia trachomatis and in patients with neither gastrointestinal nor genitourinary symptoms, we obtain a urine sample for testing for Chlamydia using nucleic acid amplification techniques. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/18/18728?source=see_link\">",
"       \"Genital Chlamydia trachomatis infections in men\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/46/42728?source=see_link\">",
"       \"Genital Chlamydia trachomatis infections in women\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/13/8408?source=see_link&amp;anchor=H1790526#H1790526\">",
"       \"Screening for Chlamydia trachomatis\", section on 'Nucleic acid amplification tests'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional testing which may further increase or decrease support for the diagnosis, but which alone is not diagnostic or exclusionary, includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Routine laboratory testing &mdash; We obtain a complete blood count and differential, acute phase reactants, renal and liver chemistries, and urinalysis to obtain supportive evidence of acute inflammation and to exclude other systemic disorders. (See",
"      <a class=\"local\" href=\"#H86466138\">",
"       'Acute inflammatory changes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Testing for HLA-B27 &mdash; We obtain HLA-B27 testing in patients with an intermediate likelihood of reactive arthritis. The prevalence of HLA-B27 in patients with reactive arthritis is generally estimated at 30 to 50 percent. Thus, a positive test would increase the likelihood of reactive arthritis being the correct diagnosis, rather than a different form of arthritis, other than another type of spondyloarthritis. A negative test would not lower the likelihood of reactive arthritis, as frequencies of HLA-B27 in the general population are usually much lower. In patients with an intermediate likelihood of another form of spondyloarthritis (eg, ankylosing spondylitis), a positive test would increase, and a negative test would decrease, suspicion of that diagnosis. (See",
"      <a class=\"local\" href=\"#H86465746\">",
"       'Genetic predisposition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Serologic testing for rheumatoid arthritis (RA) &mdash; Rheumatoid factor and anticyclic citrullinated peptide antibody testing are obtained in patients with polyarthritis suspected of possible RA. At least one of these antibodies is present in over 70 to 80 percent of patients with RA, but both are usually absent in patients with reactive arthritis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/55/6010?source=see_link\">",
"       \"Diagnosis and differential diagnosis of rheumatoid arthritis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute inflammatory monoarthritis or oligoarthritis may occur in a variety of disorders. Particularly important",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    common causes of arthritis to differentiate from reactive arthritis include bacterial infection (eg, septic arthritis and Lyme disease, which are identified by joint fluid examination and culture and by serologic testing of patients potentially exposed while in an endemic area, respectively) and crystal-induced inflammation, which is diagnosed by the history and identification of crystals (typically monosodium urate or calcium pyrophosphate) upon examination of the joint fluid. The general approaches to the evaluation of acute monoarthritis and polyarthritis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/14/28904?source=see_link\">",
"     \"Evaluation of the adult with monoarticular pain\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/56/20360?source=see_link\">",
"     \"Synovial fluid analysis and the diagnosis of septic arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/49/4890?source=see_link\">",
"     \"Clinical manifestations and diagnosis of gout\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/38/7785?source=see_link\">",
"     \"Clinical manifestations and diagnosis of calcium pyrophosphate crystal deposition disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/15/34039?source=see_link\">",
"     \"Evaluation of the adult with polyarticular pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The differential diagnosis of reactive arthritis can be guided, in part, by the pattern of symptoms and findings that are associated with the arthritis and that may suggest a related infectious or other systemic disorder. The following conditions should also be considered in the differential diagnosis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diarrhea and arthritis &mdash; Various systemic conditions affecting the gastrointestinal (GI) tract and some infectious disorders may cause diarrhea in association with chronic or self-limited arthritis, features that may suggest reactive arthritis. Enteroviral infection-associated arthritis may represent a substantial number of cases of nonspecific, self-limited inflammatory joint disease; although arthritis is an uncommon manifestation of enterovirus infection, viral gastroenteritis is relatively common. Additional symptoms suggestive of a viral etiology include the presence of myalgias, an evanescent rash, and constitutional symptoms such as fever. Both large and small joints may be involved. Sore throat, pleuritic pain, and myocarditis are other features suggestive of enteroviral infection. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/51/23354?source=see_link&amp;anchor=H10#H10\">",
"       \"Specific viruses that cause arthritis\", section on 'Enterovirus infections: Coxsackie virus and Echovirus'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Inflammatory bowel diseases (eg, Crohn&rsquo;s disease and ulcerative colitis), Beh&ccedil;et&rsquo;s disease, celiac (sprue) disease, Whipple&rsquo;s disease, parasitic infections, and intestinal bypass surgery may cause diarrhea and arthritis. These conditions can usually be differentiated from reactive arthritis by the history, including the chronicity of the gastrointestinal symptoms and other features suggesting the alternative diagnosis; by physical examination; and, as indicated clinically, by serology, biopsy, or culture. These conditions are discussed in greater detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/44/25289?source=see_link\">",
"       \"Arthritis associated with gastrointestinal disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Genitourinary",
"      <span class=\"nowrap\">",
"       symptoms/disorders",
"      </span>",
"      and arthritis &mdash; Disseminated gonococcal infection (DGI) is the primary cause to consider when urethral, uterine, cervical, or tuboovarian inflammation occurs in a patient with arthritis. The presence of a rash and tenosynovitis are suggestive. However, purulent arthritis due to gonococcal infection can occur in the absence of these findings. Culture of synovial fluid, the urethra, and other potentially infected mucosal sites is helpful in the diagnosis or exclusion of DGI or gonococcal arthritis. Nucleic acid amplification testing may be substituted for culture of genitourinary sites when it is available. The clinical manifestations and diagnosis of gonococcal infection and DGI are discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/35/26166?source=see_link\">",
"       \"Diagnosis of gonococcal infections\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/56/3976?source=see_link\">",
"       \"Disseminated gonococcal infection\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Arthritis and arthralgias are a rare complication of intravesical Bacillus Calmette-Guerin (BCG) treatment for bladder cancer. Affected patients commonly experience polyarthritis or oligoarthritis, predominantly of the lower extremities, within two weeks after instilling BCG. Approximately 20 percent of reported patients complain of axial pain compatible with spondyloarthritis, and over one-half of patients are HLA-B27 positive. Associated genitourinary symptoms include cystitis, fever, and hematuria. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/23/31096?source=see_link&amp;anchor=H12#H12\">",
"       \"Complications of intravesical BCG immunotherapy\", section on 'Arthritis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Arthritis/spondyloarthritis/enthesitis",
"      </span>",
"      without preceding infectious symptoms &mdash; Other members of the spondyloarthritis family, especially undifferentiated spondyloarthritis with peripheral joint involvement, may present with arthritis and, sometimes, with enthesitis, which are indistinguishable from the musculoskeletal manifestations of reactive arthritis. Such conditions are distinguished from reactive arthritis by the lack of history and laboratory findings to suggest recent infection with the organisms associated with reactive arthritis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/57/9114?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and management of undifferentiated spondyloarthritis and related spondyloarthritides\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Poststreptococcal arthritis &mdash; Arthritis is a common manifestation in patients with acute rheumatic fever (ARF) following streptococcal pharyngitis. These patients typically lack features common to the spondyloarthritides (eg, enthesitis), and this condition is generally not considered to be a form of reactive arthritis. Other clinical and laboratory manifestations of rheumatic fever and evidence of recent streptococcal infection distinguish these patients from those with reactive arthritis. A &ldquo;poststreptococcal reactive arthritis&rdquo; has been described, but most consider such patients to have ARF. These issues are discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/20/23879?source=see_link&amp;anchor=H13#H13\">",
"       \"Clinical manifestations and diagnosis of acute rheumatic fever\", section on 'Poststreptococcal reactive arthritis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several major aspects to management. In some patients, particularly those with genitourinary infection, treatment of the infection that triggered the arthritis is indicated; arthritis and associated periarticular conditions should be treated in patients with symptomatic joint disease. Additional interventions may also be required for the treatment of extraarticular manifestations. (See",
"    <a class=\"local\" href=\"#H372392471\">",
"     'Treatment of the infection'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H206516\">",
"     'Treatment of arthritis'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H286986590\">",
"     'Treatment of other clinical features'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H372392471\">",
"    <span class=\"h2\">",
"     Treatment of the infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotics are not used to treat the arthritis specifically but may be indicated for treatment of the underlying infection if there is evidence of ongoing genitourinary infection or carriage of potentially pathogenic organisms. A role for antibiotic therapy in the treatment of chronic arthritis has not been established. (See",
"    <a class=\"local\" href=\"#H372392492\">",
"     'Chronic Chlamydia-related arthritis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H372392478\">",
"    <span class=\"h3\">",
"     Enteric infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, antibiotics are not indicated for uncomplicated enteric infections, but some patients with active enteric infections may require treatment, depending upon their comorbidities and upon the specific organism. For example, therapy may be indicated in patients with severe gastrointestinal disease, in older adults, or in immunocompromised hosts. Treatment of enteric infections is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/17/32025?source=see_link\">",
"     \"Approach to the adult with acute diarrhea in developed countries\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/29/29145?source=see_link\">",
"     \"Travelers' diarrhea\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with chronic reactive arthritis induced by enteric bacteria, the available evidence does not support the use of long-term antibiotics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33210/abstract/19,20,30-33\">",
"     19,20,30-33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H372392485\">",
"    <span class=\"h3\">",
"     Genitourinary tract infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast with most patients with enteritis, patients with acute Chlamydia trachomatis infection of the genitourinary tract and their sexual partners should receive antimicrobial treatment. Treatment regimens are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/44/34505?source=see_link\">",
"     \"Treatment of Chlamydia trachomatis infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with a history of Chlamydia-induced arthritis should be evaluated for recurrent genitourinary infection if arthritis or genitourinary symptoms recur and should be retreated with antibiotics if testing for Chlamydia infection is positive. Antibiotic treatment of the infection might prevent relapses of arthritis in patients with recurrent genitourinary tract symptoms alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33210/abstract/34\">",
"     34",
"    </a>",
"    ]. Prompt treatment of acute Chlamydia infections prior to the development of reactive arthritis, in both patients and partners, may lower the probability of developing reactive arthritis, although this has not been proven. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/18/18728?source=see_link\">",
"     \"Genital Chlamydia trachomatis infections in men\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/46/42728?source=see_link\">",
"     \"Genital Chlamydia trachomatis infections in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The approach to the evaluation and treatment of persistent or recurrent genitourinary tract symptoms despite initial antibiotic therapy is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/44/34505?source=see_link&amp;anchor=H342755#H342755\">",
"     \"Treatment of Chlamydia trachomatis infection\", section on 'Persistent or recurrent symptoms'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H372392492\">",
"    <span class=\"h4\">",
"     Chronic Chlamydia-related arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;We do not advise the routine use of long-term antibiotics to treat established reactive arthritis. However, one study has suggested that combination antibiotics might be useful in the subset of patients with PCR-proven Chlamydia-induced arthritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33210/abstract/35\">",
"     35",
"    </a>",
"    ], although results are mixed in randomized trials of long-term therapy with single antibiotics and although most do not show benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33210/abstract/20,30-33,36\">",
"     20,30-33,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Evidence supporting the use of combination antibiotics for patients with chronic Chlamydia-related arthritis was suggested in a trial involving 42 patients with reactive arthritis of at least six months&rsquo; duration, who tested positive for C. trachomatis or C. pneumoniae by a special polymerase chain reaction (PCR) in blood or affected synovial tissue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33210/abstract/35\">",
"     35",
"    </a>",
"    ]. Patients were randomly assigned to receive six months of treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    plus either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    or to receive placebo. The composite endpoint for improvement in musculoskeletal signs and symptoms was reached more often by the patients receiving combination antibiotics (17 of 27 [63 percent] versus 3 of 15 [20 percent], p = 0.01). Adverse events were mild and comparable between groups. However, there were limitations to the study: the numbers in each group were too small to compare the different antibiotic regimens, and the study was limited to patients with evidence of persistent Chlamydial infection by a special PCR using peripheral blood or synovial samples instead of routine urine samples. Serologic tests did not correlate with these PCR results, and the PCR assays that were used in the study are not yet available for routine clinical use and are not of proven clinical utility. Further studies with larger numbers of patients are required to confirm these findings. There is no evidence of benefit for such treatment in patients with any other form of reactive arthritis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H206516\">",
"    <span class=\"h2\">",
"     Treatment of arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of arthritis with antiinflammatory and immunosuppressive agents can be divided into two stages: the treatment of acute reactive arthritis and the treatment of refractory (chronic) reactive arthritis, usually defined as disease of greater than six months&rsquo; duration. (See",
"    <a class=\"local\" href=\"#H205667\">",
"     'Acute reactive arthritis'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H205684\">",
"     'Chronic reactive arthritis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The initial treatment goal is symptomatic relief of the arthritis, because the disease is self-limited in a substantial majority of patients, and joint injury with significant continued symptoms is infrequent. (See",
"    <a class=\"local\" href=\"#H30217817\">",
"     'Prognosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The approach to therapy is based upon both clinical experience in reactive arthritis and upon evidence of benefit for these therapies in other inflammatory arthritides, particularly other forms of spondyloarthritis, given the paucity of randomized trials and longitudinal observational studies in patients with reactive arthritis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/57/9114?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and management of undifferentiated spondyloarthritis and related spondyloarthritides\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/23/35194?source=see_link\">",
"     \"Assessment and treatment of ankylosing spondylitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/18/40234?source=see_link\">",
"     \"Treatment of psoriatic arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In clinical practice, disease activity and the response to therapy are assessed by the swollen or tender joint counts, by the intensity of joint pain, by the presence and severity of enthesitis, and by global assessments by the clinician and patient. There are no validated indices for assessment of disease activity in reactive arthritis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H205667\">",
"    <span class=\"h3\">",
"     Acute reactive arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with acute reactive arthritis, we initiate treatment with nonsteroidal antiinflammatory drugs (NSAIDs), which are usually the principal form of therapy, and may administer intraarticular",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    systemic glucocorticoids in patients with disease resistant to NSAIDs. (See",
"    <a class=\"local\" href=\"#H205784\">",
"     'Initial therapy'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H205791\">",
"     'Intraarticular glucocorticoids'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H27140953\">",
"     'Systemic glucocorticoids'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H205784\">",
"    <span class=\"h4\">",
"     Initial therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest treatment with antiinflammatory doses of NSAIDs (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    500 mg two to three times daily,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/29/38352?source=see_link\">",
"     diclofenac",
"    </a>",
"    50 mg three times daily, or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    50 mg three to four times daily) for symptomatic therapy for most patients, unless contraindicated (eg, due to allergy, cardiovascular, or renal status). Maximum antiinflammatory doses and continuous use may be necessary to control pain and inflammation. An adequate trial of a given NSAID is usually at least two weeks in duration. Individual responses vary, and more than one NSAID may need to be tried before identifying an effective agent. There is no evidence that NSAIDs shorten or otherwise affect the course of the disease.",
"   </p>",
"   <p>",
"    NSAIDs are used initially because treatment of the infection does not alleviate the signs or symptoms of arthritis, because the disease is most frequently self-limited, and because most patients will not require disease-modifying antirheumatic drugs (DMARDs) to control inflammation or to prevent erosive joint changes. The use of NSAIDs is based upon their ability to provide significant symptomatic relief in other forms of spondyloarthritis and upon clinical experience with their use in reactive arthritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33210/abstract/6,13,37-39\">",
"     6,13,37-39",
"    </a>",
"    ]; there have been few formal trials of NSAIDs in reactive arthritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33210/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/23/35194?source=see_link&amp;anchor=H25#H25\">",
"     \"Assessment and treatment of ankylosing spondylitis in adults\", section on 'Nonsteroidal antiinflammatory drugs'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients receiving NSAIDs should be cautioned regarding the risk of gastrointestinal (GI), renal, hepatic, and cardiovascular adverse effects, including the risk of NSAID gastropathy and GI bleeding. Complete blood counts, renal function, and hepatic aminotransferases should be measured after two months on a given agent and then every three to six months thereafter in patients continuing to require antiinflammatory dosing regimens of NSAIDs, depending upon the comorbidities present. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/36/5703?source=see_link\">",
"     \"NSAIDs: Therapeutic use and variability of response in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/49/17177?source=see_link\">",
"     \"Nonselective NSAIDs: Overview of adverse effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/48/13066?source=see_link\">",
"     \"Overview of selective COX-2 inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H173124366\">",
"    <span class=\"h4\">",
"     Inadequate response to NSAIDs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraarticular glucocorticoids can be administered in patients with persistent symptoms despite treatment with NSAIDs, and oral glucocorticoids may be of benefit in patients who do not respond to these therapies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H205791\">",
"    <span class=\"h5\">",
"     Intraarticular glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients who do not respond adequately to NSAIDs, we suggest injection of major affected joints with intraarticular glucocorticoids. In our experience, intraarticular injection with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    acetonide (40 mg for a large joint, such as the knee, and lower doses for smaller joints), or an alternative agent in equivalent doses, is generally effective in reducing joint inflammation and in providing symptomatic relief similar to that seen in other forms of spondyloarthritis or in rheumatoid arthritis. These may result in symptomatic relief sufficient to avoid the need for oral glucocorticoids or DMARD therapy and the side effects associated with use of these agents. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/6/41065?source=see_link&amp;anchor=H7#H7\">",
"     \"Use of glucocorticoids in the treatment of rheumatoid arthritis\", section on 'Intraarticular therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is no evidence in our experience, nor are there any reports, of a greater frequency of adverse events or of disease worsening associated with the use of intraarticular or systemic glucocorticoids, despite the infectious etiology of reactive arthritis and the detection of the causative microbes in the joints of some patients with reactive arthritis. This issue has not been systematically evaluated. Pain and swelling of the plantar fascia can also be relieved by local glucocorticoid injections. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/14/30951?source=see_link\">",
"     \"Intraarticular and soft tissue injections: What agent(s) to inject and how frequently?\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/6/41065?source=see_link\">",
"     \"Use of glucocorticoids in the treatment of rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/52/23368?source=see_link\">",
"     \"Joint aspiration or injection in adults: Technique and indications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/57/28564?source=see_link\">",
"     \"Joint aspiration or injection in adults: Complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27140953\">",
"    <span class=\"h5\">",
"     Systemic glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients who do not respond adequately to NSAIDs and intraarticular glucocorticoid injections or in those with a large number of involved joints, we suggest low to moderate doses of oral glucocorticoids (eg, a starting dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    20 mg daily), which should be reduced gradually to the lowest dose required to control symptoms. In our experience, use of these agents for a limited period and in a tolerable dose range may preclude need for use of DMARD therapy. There are no randomized trials of systemic glucocorticoids in reactive arthritis. The use of glucocorticoids for inflammatory joint disease, the adverse effects of these agents, and strategies for the prevention of glucocorticoid-induced osteoporosis are described in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/6/41065?source=see_link\">",
"     \"Use of glucocorticoids in the treatment of rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/36/17994?source=see_link\">",
"     \"Prevention and treatment of glucocorticoid-induced osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H206028\">",
"    <span class=\"h4\">",
"     Resistant to NSAIDs and glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment with a DMARD is indicated in patients who do not respond adequately to initial therapies. The duration prior to beginning DMARDs depends upon the degree of disease activity and upon the relative risks and benefits of NSAIDs and glucocorticoids in a given patient, given the comorbidities that are present and the dose of glucocorticoids required to control symptoms. We generally use DMARDs in patients who have not responded adequately to at least two different NSAIDs over a total of four weeks and who require ongoing therapy with more than 7.5 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    or equivalent for more than three to six months. (See",
"    <a class=\"local\" href=\"#H205684\">",
"     'Chronic reactive arthritis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H205684\">",
"    <span class=\"h3\">",
"     Chronic reactive arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients who develop refractory reactive arthritis, usually defined as disease lasting greater than six months, or who are resistant to initial therapy for acute arthritis with NSAIDs and glucocorticoids, we initiate therapy with a nonbiologic (traditional) DMARD, usually",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    or, alternatively,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    . In patients with disease that is refractory to a nonbiologic DMARD, we administer therapy with a tumor necrosis factor (TNF) inhibitor. The use of these medications for reactive arthritis is based upon limited data and upon clinical experience. (See",
"    <a class=\"local\" href=\"#H206028\">",
"     'Resistant to NSAIDs and glucocorticoids'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H206213\">",
"     'Nonbiologic DMARD use'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H206245\">",
"     'Resistant to nonbiologic DMARDs'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H206213\">",
"    <span class=\"h4\">",
"     Nonbiologic DMARD use",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20433847\">",
"    <span class=\"h5\">",
"     Sulfasalazine",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    (SSZ) in patients with refractory reactive arthritis or with reactive arthritis resistant to initial therapy for acute arthritis. We initiate treatment with 500 mg once daily and increase the daily dose stepwise (in increments of 500 mg each week) to 1000 mg twice daily. The dose can be increased to a maximum of 3000",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    (taken in two or three divided doses) if required. (See",
"    <a class=\"local\" href=\"#H206028\">",
"     'Resistant to NSAIDs and glucocorticoids'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H205684\">",
"     'Chronic reactive arthritis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The use of SSZ in patients with reactive arthritis is based primarily upon one randomized trial in patients with reactive arthritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33210/abstract/42\">",
"     42",
"    </a>",
"    ] and is further supported by a meta-analysis and randomized trials comparing it with placebo in patients with ankylosing spondylitis and with psoriatic arthritis and by randomized trials comparing it with placebo and other nonbiologic DMARDs in rheumatoid arthritis. We prefer SSZ over",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    because of its better documented efficacy in patients with peripheral spondyloarthritis, including psoriatic arthritis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/23/35194?source=see_link&amp;anchor=H36#H36\">",
"     \"Assessment and treatment of ankylosing spondylitis in adults\", section on 'Sulfasalazine'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/18/40234?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment of psoriatic arthritis\", section on 'Sulfasalazine'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/27/2490?source=see_link\">",
"     \"Sulfasalazine in the treatment of rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Benefit from SSZ was suggested by a 36-week randomized trial involving 134 patients with chronic reactive arthritis who had not responded adequately to NSAIDs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33210/abstract/42\">",
"     42",
"    </a>",
"    ]. Response in the trial was defined by a composite measure that included patient self-assessment, clinician assessment, and improvement in joint pain or tenderness and in joint swelling. Results for the primary outcome measure showed a trend toward benefit with SSZ that was not statistically significant but that might be clinically meaningful if real. SSZ was well-tolerated, with minor gastrointestinal side effects in some patients.",
"   </p>",
"   <p>",
"    In general, the most common adverse effect causing discontinuation of therapy with SSZ is gastrointestinal upset, but central nervous system symptoms, rash, and other infrequent side effects may also occur. The use and monitoring of SSZ, as well as its adverse effects, are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/27/2490?source=see_link&amp;anchor=H4#H4\">",
"     \"Sulfasalazine in the treatment of rheumatoid arthritis\", section on 'Adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20433855\">",
"    <span class=\"h5\">",
"     Methotrexate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     Methotrexate",
"    </a>",
"    (MTX) may be used as an alternative nonbiologic DMARD for patients who may be allergic to or intolerant of SSZ or who do not respond to SSZ treatment. However, MTX has not been formally studied in patients with reactive arthritis, and there is a lack of evidence to support the use of MTX for axial disease in ankylosing spondylitis, even though clinical experience suggests it may be of benefit for treating peripheral arthritis in such patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/23/35194?source=see_link&amp;anchor=H6377225#H6377225\">",
"     \"Assessment and treatment of ankylosing spondylitis in adults\", section on 'Other DMARDs'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of MTX is based upon clinical experience with its use for peripheral spondyloarthritis, including psoriatic arthritis, and upon evidence in meta-analyses and in randomized trials for its efficacy in rheumatoid arthritis. In reactive arthritis, we use MTX in the same fashion and doses (15 to 25 mg given on one day weekly) as are employed in psoriatic arthritis and in rheumatoid arthritis. The use and adverse effects of MTX are described in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/18/40234?source=see_link&amp;anchor=H9#H9\">",
"     \"Treatment of psoriatic arthritis\", section on 'Methotrexate'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/26/32169?source=see_link\">",
"     \"Use of methotrexate in the treatment of rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11223?source=see_link\">",
"     \"Major side effects of low-dose methotrexate\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20433862\">",
"    <span class=\"h5\">",
"     Duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The nonbiologic DMARDs are continued for at least four months (SSZ) or three months (MTX) at the maximally tolerated therapeutic dose (up to 3",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    SSZ or up to 25",
"    <span class=\"nowrap\">",
"     mg/week",
"    </span>",
"    MTX) to determine if there is a response to therapy and are then discontinued three to six months after the patients have entered into remission, with resolution of clinical signs and symptoms of disease activity. Some patients who do not respond to the initial DMARD therapy may respond to the alternative agent, in our experience; however, whether to use a second nonbiologic DMARD or to proceed directly to the use a biologic agent in such patients has not been formally evaluated. If disease recurs, we resume therapy with the previously effective agent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H206245\">",
"    <span class=\"h4\">",
"     Resistant to nonbiologic DMARDs",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who have reactive arthritis that is refractory to NSAIDs and glucocorticoids and who do not respond to or have a contraindication to the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , we use an anti-tumor necrosis factor (TNF) agent (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    50",
"    <span class=\"nowrap\">",
"     mg/week",
"    </span>",
"    administered by subcutaneous injection or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    3 to 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    administered intravenously on weeks zero, two, and six and then every eight weeks). In patients who do not respond to an initial trial of one agent after three months of therapy, another TNF inhibitor can be tried instead. An effort can be made to discontinue therapy in patients who have been in remission induced by a TNF inhibitor for at least three months, but treatment should be resumed with the medication if disease then recurs.",
"   </p>",
"   <p>",
"    The use of TNF inhibitors in patients with reactive arthritis is directly supported only by case reports and by small case series. Their use, rather than the use of other nonbiologic or biologic DMARDs, is also supported by clinical experience and by their effectiveness in the treatment of other spondyloarthropathies, including axial and peripheral spondyloarthritis and the various forms of psoriatic arthritis. The dosing and agents, the evidence supporting their use in patients with other types of spondyloarthritis, and the adverse effects of TNF inhibitors are described in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/23/35194?source=see_link&amp;anchor=H26#H26\">",
"     \"Assessment and treatment of ankylosing spondylitis in adults\", section on 'Tumor necrosis factor alpha antagonists'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/18/40234?source=see_link&amp;anchor=H18#H18\">",
"     \"Treatment of psoriatic arthritis\", section on 'TNF inhibitors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/55/40825?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors: An overview of adverse effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Evidence directly supporting the use of TNF inhibitors in reactive arthritis is illustrated by the following examples [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33210/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A group of patients with reactive arthritis (seven patients) or undifferentiated spondyloarthritis (nine patients) were treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      for six months; a treatment response (a composite of pain score and tender and swollen joint counts) was achieved by 9 of the 10 patients who completed the study, including patients from both groups [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/27/33210/abstract/43\">",
"       43",
"      </a>",
"      ]. None of the patients experienced a worsening of arthritis or an exacerbation of any suspected underlying infections.",
"     </li>",
"     <li>",
"      An observational study in France reported the efficacy and safety of anti-TNF therapies in 10 patients with reactive arthritis of recent onset (within 12 months) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/27/33210/abstract/44\">",
"       44",
"      </a>",
"      ]. Five, four, and one patient(s) each received",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39303?source=see_link\">",
"       adalimumab",
"      </a>",
"      , respectively. Nine of 10 patients met response criteria, with reduction in tender and swollen joint counts, pain score, and serum C-reactive protein levels. All eight patients taking glucocorticoids successfully discontinued them after a median of four months. Six patients discontinued the anti-TNF therapy after a median of 7.5 months; three relapsed after stopping but responded to retreatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are no studies of patients with reactive arthritis refractory to the above therapies, although other approaches to the treatment of chronic inflammatory arthritis have been evaluated in spondyloarthritis, including psoriatic arthritis, and in rheumatoid arthritis. In the very uncommon patients who are resistant to treatment with the agents noted above, including at least two TNF inhibitors, the diagnosis should be reevaluated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/23/35194?source=see_link&amp;anchor=H6377225#H6377225\">",
"     \"Assessment and treatment of ankylosing spondylitis in adults\", section on 'Other DMARDs'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/18/40234?source=see_link&amp;anchor=H23#H23\">",
"     \"Treatment of psoriatic arthritis\", section on 'Experimental therapies'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/6/42090?source=see_link&amp;anchor=H8152313#H8152313\">",
"     \"Treatment of rheumatoid arthritis resistant to initial DMARD therapy in adults\", section on 'Resistant to two TNF inhibitors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/6/42090?source=see_link&amp;anchor=H266402509#H266402509\">",
"     \"Treatment of rheumatoid arthritis resistant to initial DMARD therapy in adults\", section on 'Resistant to standard therapies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H286986590\">",
"    <span class=\"h2\">",
"     Treatment of other clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some extraarticular manifestations, including ocular involvement and mucous membrane and skin manifestations, require additional interventions. The management approaches are based upon the treatments used for these or for similar manifestations in patients with other disorders and upon clinical experience [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33210/abstract/45-47\">",
"     45-47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    None of these interventions has been systematically evaluated in randomized trials or has been the subject of observational studies in patients with reactive arthritis, and most treatment studies of antiarthritic or antibiotic therapy for reactive arthritis and reviews of this disease do not discuss the effects of such therapies on these manifestations or the recommended approaches for their treatment. Extraarticular manifestations that may require treatment include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ocular manifestations &mdash; Patients with eye pain, visual disturbance, or abnormal eye findings should be referred for ophthalmologic evaluation, as a slit-lamp examination may be required to determine if uveitis is present. The diagnosis and treatment of conjunctivitis and anterior uveitis are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/17/20760?source=see_link\">",
"       \"Conjunctivitis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/16/23817?source=see_link\">",
"       \"Uveitis: Etiology, clinical manifestations, and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/10/10407?source=see_link\">",
"       \"Uveitis: Treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Skin and mucous membrane lesions &mdash; Patients with very mild skin involvement or oral ulcers may not require intervention [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/27/33210/abstract/45\">",
"       45",
"      </a>",
"      ]. Symptomatic treatment may be sufficient in patients with oral mucosal ulcers, and topical steroids are effective in some patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/27/33210/abstract/47\">",
"       47",
"      </a>",
"      ]. The treatment of oral mucosal ulcers is discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/11/25786?source=see_link&amp;anchor=H16#H16\">",
"       \"Oral lesions\", section on 'Aphthous ulcerations'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      More symptomatic involvement with mild to moderate keratoderma blennorrhagica may benefit from the use of topical steroids, and some skin lesions can be treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/23/30072?source=see_link\">",
"       topical salicylates",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/27/33210/abstract/13,46-48\">",
"       13,46-48",
"      </a>",
"      ]. In general, treatment of these manifestations is very similar to the approach in patients with palmoplantar pustulosis from other causes. The treatment of circinate balanitis is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/43/30393?source=see_link&amp;anchor=H25#H25\">",
"       \"Neutrophilic dermatoses\", section on 'Palmoplantar pustulosis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/33/14872?source=see_link\">",
"       \"Balanitis and balanoposthitis in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/33/14872?source=see_link&amp;anchor=H13#H13\">",
"       \"Balanitis and balanoposthitis in adults\", section on 'Circinate balanitis'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Patients with more severe keratoderma blennorrhagica and pustular lesions who do not respond to topical medications may require systemic disease-modifying antirheumatic drugs, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      or a tumor necrosis factor inhibitor [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/27/33210/abstract/44,48\">",
"       44,48",
"      </a>",
"      ]. Other treatments that may be of benefit in keratoderma blennorrhagica include topical vitamin D",
"      <span class=\"nowrap\">",
"       (",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?5/54/5988?source=see_link\">",
"        calcipotriol",
"       </a>",
"       /calcipotriene)",
"      </span>",
"      in mild to moderate cases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/27/33210/abstract/49\">",
"       49",
"      </a>",
"      ] and retinoids in patients with more severe involvement [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/27/33210/abstract/46,50,51\">",
"       46,50,51",
"      </a>",
"      ]. Therapy of these skin findings and of nail involvement is similar to that used in patients with psoriasis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/6/40042?source=see_link\">",
"       \"Treatment of psoriasis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30217817\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The course of reactive arthritis varies considerably, probably depending upon the triggering pathogen and the genetic background of the host [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33210/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. The typical disease duration is three to five months. Most patients either remit completely or have little active disease within six to twelve months after presentation, but 15 to 20 percent may experience more chronic persistent arthritis. After entering remission of peripheral joint arthritis, pain is occasionally still noted in the joints, at entheses, or in the spine. Representative results are illustrated by the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A European League Against Rheumatism (EULAR) study evaluated 152 patients with reactive arthritis who were enrolled within 2 months of the onset of arthritis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/27/33210/abstract/20\">",
"       20",
"      </a>",
"      ]. By the end of an additional 24 weeks of observation, almost all patients had very low disease activity as determined by clinician- and patient-global assessments.",
"     </li>",
"     <li>",
"      In other studies, reactive arthritis that lasted for more than one year occurred in 4 to 19 percent of patients in Finland whose arthritis was induced by Yersinia, Salmonella, Shigella, and Chlamydia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/27/33210/abstract/6,10\">",
"       6,10",
"      </a>",
"      ]. It is difficult to know whether this proportion of patients who develop chronic disease can be generalized to other geographic regions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some patients with chronic reactive arthritis later develop features characteristic of another of the spondyloarthritides, eg, psoriatic arthritis, ankylosing spondylitis, or the arthritis associated with inflammatory bowel disease. HLA-B27 testing has been associated with a worse prognosis in some, but not all studies, with findings suggesting that patients who are HLA-B27 positive are more likely to develop a chronic spondyloarthropathy with radiographic changes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33210/abstract/7,20,52\">",
"     7,20,52",
"    </a>",
"    ]. Patients with the triad of postinfectious arthritis, urethritis, and conjunctivitis may also have a poorer prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/27/33210/abstract/53,54\">",
"     53,54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?29/0/29698?source=see_link\">",
"       \"Patient information: Reactive arthritis (Reiter syndrome) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/0/30721?source=see_link\">",
"       \"Patient information: Reactive arthritis (formerly Reiter syndrome) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reactive arthritis is a form of arthritis that is associated with a co-existing or recent antecedent extraarticular infection. Only certain enteric and genitourinary pathogens are commonly accepted as capable of causing reactive arthritis. These include Chlamydia trachomatis, Yersinia, Salmonella, Shigella, Campylobacter, Clostridium difficile, and Chlamydia pneumoniae. Various other bacterial and viral infections have been suggested as triggers for postinfectious arthritis but they are by convention not considered as &ldquo;reactive arthritis&rdquo;. (See",
"      <a class=\"local\" href=\"#H27140925\">",
"       'Definition'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Preceding infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Musculoskeletal features of reactive arthritis typically develop one to four weeks following an acute infection with one of the triggering organisms. These include asymmetric oligoarthritis (often affecting the lower extremities), enthesitis, dactylitis, and inflammatory back pain. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Musculoskeletal signs and symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Extraarticular manifestations occur in some patients, but none are specific for reactive arthritis. These include eye involvement, most often with conjunctivitis, but infrequently with anterior uveitis; genitourinary tract symptoms; oral mucosal ulcers; constitutional symptoms, usually during the acute phase of illness; and cutaneous manifestations, such as keratoderma blennorrhagica, circinate balanitis, and psoriasis-like nail changes. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Extraarticular signs and symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Laboratory findings may include evidence of the antecedent infection, although cultures of stool and serologic studies are often negative; elevated acute phase reactants; and findings of inflammatory joint fluid in patients with arthritis. Plain radiographs are generally nondiagnostic. (See",
"      <a class=\"local\" href=\"#H19942326\">",
"       'Laboratory findings'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H86466394\">",
"       'Imaging abnormalities'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis is based upon the presence of characteristic musculoskeletal and other clinical features in a patient with a preceding or ongoing enteric or genitourinary infection, in whom other causes of arthritis have been excluded. There is no single definitive test for reactive arthritis. Laboratory testing to confirm infection includes stool cultures in patients with gastrointestinal symptoms and urine testing for Chlamydia trachomatis in patients with genitourinary symptoms and those without localizing symptoms of infection. (See",
"      <a class=\"local\" href=\"#H19942416\">",
"       'Diagnostic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis encompasses disorders that can cause acute mono- or oligoarthritis, particularly those associated with bowel diseases or genitourinary symptoms (eg, enterovirus infection, inflammatory bowel disease, and disseminated gonococcal infection), acute septic or crystal arthritis, undifferentiated spondyloarthritis, and other postinfectious arthritic disorders. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antibiotic therapy should be used for treatment of active Chlamydia trachomatis infection, if present. In general, antibiotics are not indicated for uncomplicated enteric infections. (See",
"      <a class=\"local\" href=\"#H372392485\">",
"       'Genitourinary tract infection'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H372392478\">",
"       'Enteric infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest treatment of arthritis in most patients initially with nonsteroidal anti-inflammatory drugs (NSAIDs) in antiinflammatory doses (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/43/43705?source=see_link\">",
"       naproxen",
"      </a>",
"      500 mg two to three times daily,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/29/38352?source=see_link\">",
"       diclofenac",
"      </a>",
"      50 mg three times daily, or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/50/36649?source=see_link\">",
"       indomethacin",
"      </a>",
"      50 mg three times daily), rather than starting a disease-modifying antirheumatic drugs (DMARD) upon diagnosis (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H205784\">",
"       'Initial therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients who do not respond adequately to NSAIDs, we suggest intraarticular glucocorticoids, rather than initiating therapy with daily oral glucocorticoids or a disease-modifying antirheumatic drug (DMARD). (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H205791\">",
"       'Intraarticular glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients who do not respond adequately to NSAIDs and intraarticular glucocorticoid injections, we suggest low to moderate doses of systemic glucocorticoids, rather than initiating treatment with a DMARD. (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). A typical dose would be",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      , 20 mg daily, titrated to the lowest dose required to control symptoms (See",
"      <a class=\"local\" href=\"#H27140953\">",
"       'Systemic glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients who have not responded adequately to NSAIDs over at least four weeks and who require ongoing therapy with more than 7.5 mg of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      or equivalent for more than three to six months we suggest a trial of a nonbiologic DMARD, rather than continuing moderate to high dose glucocorticoids without a DMARD (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We usually prescribe",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      (beginning with 500 mg daily and titrating the dose to a maximum of 3 g daily).",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       Methotrexate",
"      </a>",
"      (up to 25 mg one day weekly) is an alternative to SSZ. (See",
"      <a class=\"local\" href=\"#H206213\">",
"       'Nonbiologic DMARD use'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20433847\">",
"       'Sulfasalazine'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20433855\">",
"       'Methotrexate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The prognosis is good in the majority of patients, with spontaneous remission within six to twelve months of onset of arthritis. However, some patients have persistent but mild musculoskeletal symptoms, and others develop radiologic evidence of joint injury and evolve to a more chronic form of spondyloarthritis. (See",
"      <a class=\"local\" href=\"#H30217817\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33210/abstract/1\">",
"      Ahvonen P, Sievers K, Aho K. Arthritis associated with Yersinia enterocolitica infection. Acta Rheumatol Scand 1969; 15:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33210/abstract/2\">",
"      Braun J, Kingsley G, van der Heijde D, Sieper J. On the difficulties of establishing a consensus on the definition of and diagnostic investigations for reactive arthritis. Results and discussion of a questionnaire prepared for the 4th International Workshop on Reactive Arthritis, Berlin, Germany, July 3-6, 1999. J Rheumatol 2000; 27:2185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33210/abstract/3\">",
"      Townes JM. Reactive arthritis after enteric infections in the United States: the problem of definition. Clin Infect Dis 2010; 50:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33210/abstract/4\">",
"      Rohekar S, Pope J. Epidemiologic approaches to infection and immunity: the case of reactive arthritis. Curr Opin Rheumatol 2009; 21:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33210/abstract/5\">",
"      Pope JE, Krizova A, Garg AX, et al. Campylobacter reactive arthritis: a systematic review. Semin Arthritis Rheum 2007; 37:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33210/abstract/6\">",
"      Hannu T. Reactive arthritis. Best Pract Res Clin Rheumatol 2011; 25:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33210/abstract/7\">",
"      Hannu T, Inman R, Granfors K, Leirisalo-Repo M. Reactive arthritis or post-infectious arthritis? Best Pract Res Clin Rheumatol 2006; 20:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33210/abstract/8\">",
"      Panush RS, Wallace DJ, Dorff RE, Engleman EP. Retraction of the suggestion to use the term \"Reiter's syndrome\" sixty-five years later: the legacy of Reiter, a war criminal, should not be eponymic honor but rather condemnation. Arthritis Rheum 2007; 56:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33210/abstract/9\">",
"      Keynan Y, Rimar D. Reactive arthritis--the appropriate name. Isr Med Assoc J 2008; 10:256.",
"     </a>",
"    </li>",
"    <li>",
"     Leirisalo-Repo M, Sieper J. Reactive arthritis: epidemiology, clinical features, and treatment. In: Ankylosing spondylitis and the spondyloarthropathies, Weisman MH, van der Heijde D, Reveille JD (Eds), Mosby Elsevier, Philadelphia 2006. p.53.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33210/abstract/11\">",
"      Townes JM, Deodhar AA, Laine ES, et al. Reactive arthritis following culture-confirmed infections with bacterial enteric pathogens in Minnesota and Oregon: a population-based study. Ann Rheum Dis 2008; 67:1689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33210/abstract/12\">",
"      Collantes E, Zarco P, Mu&ntilde;oz E, et al. Disease pattern of spondyloarthropathies in Spain: description of the first national registry (REGISPONSER) extended report. Rheumatology (Oxford) 2007; 46:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33210/abstract/13\">",
"      Carter JD, Hudson AP. Reactive arthritis: clinical aspects and medical management. Rheum Dis Clin North Am 2009; 35:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33210/abstract/14\">",
"      Carter JD, Inman RD. Chlamydia-induced reactive arthritis: hidden in plain sight? Best Pract Res Clin Rheumatol 2011; 25:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33210/abstract/15\">",
"      Cuellar ML, Espinoza LR. Rheumatic manifestations of HIV-AIDS. Baillieres Best Pract Res Clin Rheumatol 2000; 14:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33210/abstract/16\">",
"      Clark MR, Solinger AM, Hochberg MC. Human immunodeficiency virus infection is not associated with Reiter's syndrome. Data from three large cohort studies. Rheum Dis Clin North Am 1992; 18:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33210/abstract/17\">",
"      Reveille JD, Conant MA, Duvic M. Human immunodeficiency virus-associated psoriasis, psoriatic arthritis, and Reiter's syndrome: a disease continuum? Arthritis Rheum 1990; 33:1574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33210/abstract/18\">",
"      Stein CM, Davis P. Arthritis associated with HIV infection in Zimbabwe. J Rheumatol 1996; 23:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33210/abstract/19\">",
"      Leirisalo-Repo M. Reactive arthritis. Scand J Rheumatol 2005; 34:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33210/abstract/20\">",
"      Kvien TK, Gaston JS, Bardin T, et al. Three month treatment of reactive arthritis with azithromycin: a EULAR double blind, placebo controlled study. Ann Rheum Dis 2004; 63:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33210/abstract/21\">",
"      Ehrenfeld M. Spondyloarthropathies. Best Pract Res Clin Rheumatol 2012; 26:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33210/abstract/22\">",
"      Leirisalo-Repo M, Helenius P, Hannu T, et al. Long-term prognosis of reactive salmonella arthritis. Ann Rheum Dis 1997; 56:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33210/abstract/23\">",
"      Rothschild BM, Pingitore C, Eaton M. Dactylitis: implications for clinical practice. Semin Arthritis Rheum 1998; 28:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33210/abstract/24\">",
"      Rihl M, Klos A, K&ouml;hler L, Kuipers JG. Infection and musculoskeletal conditions: Reactive arthritis. Best Pract Res Clin Rheumatol 2006; 20:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33210/abstract/25\">",
"      Fendler C, Laitko S, S&ouml;rensen H, et al. Frequency of triggering bacteria in patients with reactive arthritis and undifferentiated oligoarthritis and the relative importance of the tests used for diagnosis. Ann Rheum Dis 2001; 60:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33210/abstract/26\">",
"      Sieper J, Rudwaleit M, Braun J, van der Heijde D. Diagnosing reactive arthritis: role of clinical setting in the value of serologic and microbiologic assays. Arthritis Rheum 2002; 46:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33210/abstract/27\">",
"      Aho K, Ahvonen P, Lassus A, et al. HL-A antigen 27 and reactive arthritis. Lancet 1973; 2:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33210/abstract/28\">",
"      Leirisalo-Repo M, Hannu T, Mattila L. Microbial factors in spondyloarthropathies: insights from population studies. Curr Opin Rheumatol 2003; 15:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33210/abstract/29\">",
"      Gerster JC, Vischer TL, Bennani A, Fallet GH. The painful heel. Comparative study in rheumatoid arthritis, ankylosing spondylitis, Reiter's syndrome, and generalized osteoarthrosis. Ann Rheum Dis 1977; 36:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33210/abstract/30\">",
"      Yli-Kerttula T, Luukkainen R, Yli-Kerttula U, et al. Effect of a three month course of ciprofloxacin on the late prognosis of reactive arthritis. Ann Rheum Dis 2003; 62:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33210/abstract/31\">",
"      Lauhio A, Leirisalo-Repo M, L&auml;hdevirta J, et al. Double-blind, placebo-controlled study of three-month treatment with lymecycline in reactive arthritis, with special reference to Chlamydia arthritis. Arthritis Rheum 1991; 34:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33210/abstract/32\">",
"      Yli-Kerttula T, Luukkainen R, Yli-Kerttula U, et al. Effect of a three month course of ciprofloxacin on the outcome of reactive arthritis. Ann Rheum Dis 2000; 59:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33210/abstract/33\">",
"      Laasila K, Laasonen L, Leirisalo-Repo M. Antibiotic treatment and long term prognosis of reactive arthritis. Ann Rheum Dis 2003; 62:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33210/abstract/34\">",
"      Bardin T, Enel C, Cornelis F, et al. Antibiotic treatment of venereal disease and Reiter's syndrome in a Greenland population. Arthritis Rheum 1992; 35:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33210/abstract/35\">",
"      Carter JD, Espinoza LR, Inman RD, et al. Combination antibiotics as a treatment for chronic Chlamydia-induced reactive arthritis: a double-blind, placebo-controlled, prospective trial. Arthritis Rheum 2010; 62:1298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33210/abstract/36\">",
"      Putschky N, Pott HG, Kuipers JG, et al. Comparing 10-day and 4-month doxycycline courses for treatment of Chlamydia trachomatis-reactive arthritis: a prospective, double-blind trial. Ann Rheum Dis 2006; 65:1521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33210/abstract/37\">",
"      Rudwaleit M, Braun J, Sieper J. Treatment of reactive arthritis: a practical guide. BioDrugs 2000; 13:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33210/abstract/38\">",
"      Petersel DL, Sigal LH. Reactive arthritis. Infect Dis Clin North Am 2005; 19:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33210/abstract/39\">",
"      Flores D, Marquez J, Garza M, Espinoza LR. Reactive arthritis: newer developments. Rheum Dis Clin North Am 2003; 29:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33210/abstract/40\">",
"      Juvakoski T, Lassus A. A double-blind cross-over evaluation of ketoprofen and indomethacin in Reiter's disease. Scand J Rheumatol 1982; 11:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33210/abstract/41\">",
"      Lassus A. A comparative pilot study of azapropazone and indomethacin in the treatment of psoriatic arthritis and Reiter's disease. Curr Med Res Opin 1976; 4:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33210/abstract/42\">",
"      Clegg DO, Reda DJ, Weisman MH, et al. Comparison of sulfasalazine and placebo in the treatment of reactive arthritis (Reiter's syndrome). A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996; 39:2021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33210/abstract/43\">",
"      Flagg SD, Meador R, Hsia E, et al. Decreased pain and synovial inflammation after etanercept therapy in patients with reactive and undifferentiated arthritis: an open-label trial. Arthritis Rheum 2005; 53:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33210/abstract/44\">",
"      Meyer A, Chatelus E, Wendling D, et al. Safety and efficacy of anti-tumor necrosis factor &alpha; therapy in ten patients with recent-onset refractory reactive arthritis. Arthritis Rheum 2011; 63:1274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33210/abstract/45\">",
"      Carlin EM, Keat AC, European Branch of the International Union against Sexually Transmitted Infection and the European Office of the World Health Organization. European guideline for the management of sexually acquired reactive arthritis. Int J STD AIDS 2001; 12 Suppl 3:94.",
"     </a>",
"    </li>",
"    <li>",
"     Carter JD. Reactive Arthritis. In: Fitzpatrick's Dermatology in General Medicine, Eighth edition, Goldsmith LA, Katz SI, Gilchrest BA, et al.  (Eds), McGraw Hill Medical, New York 2012. p.243.",
"    </li>",
"    <li>",
"     Leirisalo-Repo M, Repo H. Reactive arhtirits: clinical features and treatment. In: Rheumatology, 5th edition, Hochberg MC, Silman AJ, Smolen JS et al.  (Eds), Elsevier/Mosby, Philadelphia, PA 2011. p.1113.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33210/abstract/48\">",
"      Wu IB, Schwartz RA. Reiter's syndrome: the classic triad and more. J Am Acad Dermatol 2008; 59:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33210/abstract/49\">",
"      Thiers BH. The use of topical calcipotriene/calcipotriol in conditions other than plaque-type psoriasis. J Am Acad Dermatol 1997; 37:S69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33210/abstract/50\">",
"      Louthrenoo W. Successful treatment of severe Reiter's syndrome associated with human immunodeficiency virus infection with etretinate. Report of 2 cases. J Rheumatol 1993; 20:1243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33210/abstract/51\">",
"      Benoldi D, Alinovi A, Bianchi G, Buticchi G. Reiter's disease: successful treatment of the skin manifestations with oral etretinate. Acta Derm Venereol 1984; 64:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33210/abstract/52\">",
"      Leirisalo-Repo M, Suoranta H. Ten-year follow-up study of patients with Yersinia arthritis. Arthritis Rheum 1988; 31:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33210/abstract/53\">",
"      Fox R, Calin A, Gerber RC, Gibson D. The chronicity of symptoms and disability in Reiter's syndrome. An analysis of 131 consecutive patients. Ann Intern Med 1979; 91:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/27/33210/abstract/54\">",
"      Hart HH, McGuigan LE, Gow PJ, Grigor RR. Reiter's syndrome: chronicity of symptoms and employment. Aust N Z J Med 1986; 16:452.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7794 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-813CF6A707-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_27_33210=[""].join("\n");
var outline_f32_27_33210=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H38\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27140925\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Preceding infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Musculoskeletal signs and symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Arthritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Enthesitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H915480\">",
"      - Dactylitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Extraarticular signs and symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H86465727\">",
"      LABORATORY AND IMAGING FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19942326\">",
"      Laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H86465809\">",
"      - Antecedent or concommitant infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H86466138\">",
"      - Acute inflammatory changes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H86465746\">",
"      - Genetic predisposition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H86466217\">",
"      - Inflammatory synovitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H86466394\">",
"      Imaging abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19942542\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19942416\">",
"      Diagnostic evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H372392471\">",
"      Treatment of the infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H372392478\">",
"      - Enteric infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H372392485\">",
"      - Genitourinary tract infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H372392492\">",
"      Chronic Chlamydia-related arthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H206516\">",
"      Treatment of arthritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H205667\">",
"      - Acute reactive arthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H205784\">",
"      Initial therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H173124366\">",
"      Inadequate response to NSAIDs",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H205791\">",
"      - Intraarticular glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H27140953\">",
"      - Systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H206028\">",
"      Resistant to NSAIDs and glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H205684\">",
"      - Chronic reactive arthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H206213\">",
"      Nonbiologic DMARD use",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H20433847\">",
"      - Sulfasalazine",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H20433855\">",
"      - Methotrexate",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H20433862\">",
"      - Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H206245\">",
"      Resistant to nonbiologic DMARDs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H286986590\">",
"      Treatment of other clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30217817\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/7794\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7794|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?2/57/2962\" title=\"picture 1\">",
"      Reactive arthritis of knee",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?1/31/1521\" title=\"picture 2\">",
"      Sausage digit second toe",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?40/16/41219\" title=\"picture 3\">",
"      Conjunctivitis and uveitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?9/55/10100\" title=\"picture 4\">",
"      Reactive arthritis - oral lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?23/32/24066\" title=\"picture 5\">",
"      Palatal erosion in reactive arthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?11/52/12099\" title=\"picture 6\">",
"      Keratoderma blennorrhagicum 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?8/46/8943\" title=\"picture 7\">",
"      Erythema nodosum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?13/16/13573\" title=\"picture 8\">",
"      Nail changes in reactive arthritis I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?5/50/5923\" title=\"picture 9\">",
"      Nail changes in reactive arthritis II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?5/9/5267\" title=\"picture 10\">",
"      Circinate balanitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/17/32025?source=related_link\">",
"      Approach to the adult with acute diarrhea in developed countries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/44/25289?source=related_link\">",
"      Arthritis associated with gastrointestinal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/23/35194?source=related_link\">",
"      Assessment and treatment of ankylosing spondylitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/33/14872?source=related_link\">",
"      Balanitis and balanoposthitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/30/10729?source=related_link\">",
"      Clinical manifestations and diagnosis of Chlamydia trachomatis infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/63/41974?source=related_link\">",
"      Clinical manifestations and diagnosis of Yersinia infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/20/23879?source=related_link\">",
"      Clinical manifestations and diagnosis of acute rheumatic fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/38/7785?source=related_link\">",
"      Clinical manifestations and diagnosis of calcium pyrophosphate crystal deposition disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/49/4890?source=related_link\">",
"      Clinical manifestations and diagnosis of gout",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/9/151?source=related_link\">",
"      Clinical manifestations of ankylosing spondylitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/57/9114?source=related_link\">",
"      Clinical manifestations, diagnosis, and management of undifferentiated spondyloarthritis and related spondyloarthritides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/23/31096?source=related_link\">",
"      Complications of intravesical BCG immunotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/17/20760?source=related_link\">",
"      Conjunctivitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/55/6010?source=related_link\">",
"      Diagnosis and differential diagnosis of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/35/26166?source=related_link\">",
"      Diagnosis of gonococcal infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/44/24265?source=related_link\">",
"      Differential diagnosis of microbial foodborne disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/56/3976?source=related_link\">",
"      Disseminated gonococcal infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/46/26345?source=related_link\">",
"      Epidemiology and causes of acute diarrhea in developed countries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/14/28904?source=related_link\">",
"      Evaluation of the adult with monoarticular pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/15/34039?source=related_link\">",
"      Evaluation of the adult with polyarticular pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/18/18728?source=related_link\">",
"      Genital Chlamydia trachomatis infections in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/46/42728?source=related_link\">",
"      Genital Chlamydia trachomatis infections in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/43/19126?source=related_link\">",
"      Infectious causes of dysuria in adult men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/14/30951?source=related_link\">",
"      Intraarticular and soft tissue injections: What agent(s) to inject and how frequently?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/57/28564?source=related_link\">",
"      Joint aspiration or injection in adults: Complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/52/23368?source=related_link\">",
"      Joint aspiration or injection in adults: Technique and indications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11223?source=related_link\">",
"      Major side effects of low-dose methotrexate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/14/6377?source=related_link\">",
"      Mechanisms for the induction of rheumatic symptoms by gastrointestinal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/36/5703?source=related_link\">",
"      NSAIDs: Therapeutic use and variability of response in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/43/30393?source=related_link\">",
"      Neutrophilic dermatoses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/49/17177?source=related_link\">",
"      Nonselective NSAIDs: Overview of adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/11/25786?source=related_link\">",
"      Oral lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/48/13066?source=related_link\">",
"      Overview of selective COX-2 inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/51/12090?source=related_link\">",
"      Pathogenesis of spondyloarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?29/0/29698?source=related_link\">",
"      Patient information: Reactive arthritis (Reiter syndrome) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/0/30721?source=related_link\">",
"      Patient information: Reactive arthritis (formerly Reiter syndrome) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/36/17994?source=related_link\">",
"      Prevention and treatment of glucocorticoid-induced osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/13/8408?source=related_link\">",
"      Screening for Chlamydia trachomatis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/51/23354?source=related_link\">",
"      Specific viruses that cause arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/27/2490?source=related_link\">",
"      Sulfasalazine in the treatment of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/56/20360?source=related_link\">",
"      Synovial fluid analysis and the diagnosis of septic arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/29/29145?source=related_link\">",
"      Travelers' diarrhea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/44/34505?source=related_link\">",
"      Treatment of Chlamydia trachomatis infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/6/40042?source=related_link\">",
"      Treatment of psoriasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/18/40234?source=related_link\">",
"      Treatment of psoriatic arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/6/42090?source=related_link\">",
"      Treatment of rheumatoid arthritis resistant to initial DMARD therapy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/55/40825?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: An overview of adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/6/41065?source=related_link\">",
"      Use of glucocorticoids in the treatment of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/26/32169?source=related_link\">",
"      Use of methotrexate in the treatment of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/16/23817?source=related_link\">",
"      Uveitis: Etiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/10/10407?source=related_link\">",
"      Uveitis: Treatment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_27_33211="Knee pain referred causes";
var content_f32_27_33211=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F64319&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F64319&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Extrinsic (referred) causes of knee pain in adults",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Lumbosacral disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lumbosacral radiculopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spinal stenosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spondylolisthesis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Sacroiliac disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sacroiliac strain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sacroiliitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Hip disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trochanteric bursitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gluteus medius tendinopathy or bursitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Piriformis syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Osteoarthritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Avascular necrosis of the femoral head",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Transient idiopathic osteoporosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Femoral disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stress or nonstress fracture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Paget's disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Other disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vascular claudication",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_27_33211=[""].join("\n");
var outline_f32_27_33211=null;
var title_f32_27_33212="Causes of chylothorax";
var content_f32_27_33212=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F61456&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F61456&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Etiology of chylothorax",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Etiology",
"       </td>",
"       <td class=\"subtitle1\">",
"        Number of cases",
"        <sup>",
"         [1]",
"        </sup>",
"        (percent)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Number of cases",
"        <sup>",
"         [2]",
"        </sup>",
"        (percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Nontraumatic",
"       </td>",
"       <td>",
"        138 (72)",
"       </td>",
"       <td>",
"        34 (46)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Malignant",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        87 (45)",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        13 (18)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Lymphomatous",
"       </td>",
"       <td class=\"sublist_other\">",
"        70 (37)",
"       </td>",
"       <td class=\"sublist_other\">",
"        9 (12)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Nonlymphomatous (primary pulmonary, mediastinal, metastatic extrathoracic malignancies)",
"       </td>",
"       <td class=\"sublist_other\">",
"        17 (9)",
"       </td>",
"       <td class=\"sublist_other\">",
"        4 (5)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Nonmalignant",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        51 (27)",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        21 (28)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Idiopathic",
"       </td>",
"       <td class=\"sublist_other\">",
"        26 (14)",
"       </td>",
"       <td class=\"sublist_other\">",
"        7 (9)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Miscellaneous (benign tumors, lymphangioleiomyomatosis, intestinal lymphangiectasis, protein-losing enteropathy, regional ileitis, reticular hyperplasia, pleuritis, cirrhosis, thoracic aortic aneurysm, lupus, tuberculosis, sarcoidosis, amyloidosis, venous thrombosis, mitral stenosis, nephrosis, thyroid goiter, tuberous sclerosis, filariasis, heart failure, Down syndrome, Noonan syndrome)",
"       </td>",
"       <td class=\"sublist_other\">",
"        15 (8)",
"       </td>",
"       <td class=\"sublist_other\">",
"        14 (19)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\">",
"        Traumatic",
"       </td>",
"       <td>",
"        53 (28)",
"       </td>",
"       <td>",
"        40 (54)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Surgical (cardiovascular, aortic, thoracoplasty, esophagectomy, lobectomy, pneumonectomy, Bochdalek herniorrhaphy, transabdominal vagotomy, venous catheterization, esophageal endoscopic sclerotherapy, neck surgery)",
"       </td>",
"       <td>",
"        48 (25)",
"       </td>",
"       <td>",
"        40 (54)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nonsurgical (penetrating or nonpenetrating trauma to the neck, thorax, and upper abdomen, straining, coughing, yawning, vomiting)",
"       </td>",
"       <td>",
"        5 (3)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Valentine VG, Raffin TA. The management of chylothorax. Chest 1992; 102:586.",
"       </li>",
"       <li>",
"        Doerr CH, Allen MS, Nichols FC 3rd, Ryu JH. Etiology of chylothorax in 203 patients. Mayo Clin Proc 2005; 80:867.&nbsp;",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_27_33212=[""].join("\n");
var outline_f32_27_33212=null;
var title_f32_27_33213="Asperger resources";
var content_f32_27_33213=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F70862&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F70862&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Resources on Asperger disorder for healthcare providers, educators, patients, and families",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Web sites",
"       </td>",
"       <td class=\"subtitle1_single\">",
"        Description",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Asperger's Association of New England (AANE)",
"        </p>",
"        <p>",
"         <a href=\"file://www.aane.org\" target=\"_blank\">",
"          www.aane.org",
"         </a>",
"        </p>",
"       </td>",
"       <td>",
"        To foster awareness, respect, acceptance, and support for individuals with Asperger syndrome and related conditions and their families",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Asperger Syndrome Education Network (ASPEN)",
"        </p>",
"        <p>",
"         <a href=\"file://www.aspennj.org\" target=\"_blank\">",
"          www.aspennj.org",
"         </a>",
"        </p>",
"       </td>",
"       <td>",
"        Devoted to education, support, and advocacy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Autism Society",
"        </p>",
"        <p>",
"         <a href=\"file://www.autism-society.org\" target=\"_blank\">",
"          www.autism-society.org",
"         </a>",
"        </p>",
"       </td>",
"       <td>",
"        Provides written materials, including newsletters, book lists, and research updates",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         The Gray Center for Social Learning and Understanding",
"        </p>",
"        <p>",
"         <a href=\"file://www.thegraycenter.org\" target=\"_blank\">",
"          www.thegraycenter.org",
"         </a>",
"        </p>",
"       </td>",
"       <td>",
"        Dedicated to individuals with autism spectrum disorders (ASD) and those who work alongside them to improve mutual understanding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Online Asperger Syndrome Information and Support at MAAP",
"        </p>",
"        <p>",
"         <a href=\"file://www.aspergersyndrome.org\" target=\"_blank\">",
"          www.aspergersyndrome.org",
"         </a>",
"        </p>",
"       </td>",
"       <td>",
"        Provides information and advice to families of individuals with autism, Asperger syndrome, and pervasive developmental disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         University Students with Autism and Asperger's Syndrome",
"        </p>",
"        <p>",
"         <a href=\"file://www.users.dircon.co.uk/~cns/\" target=\"_blank\">",
"          www.users.dircon.co.uk/~cns/",
"         </a>",
"        </p>",
"       </td>",
"       <td>",
"        Focuses on concerns of young adults in higher education",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Books for providers, educators, and parents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        <ul>",
"         <li>",
"          <strong>",
"           A Parent's Guide to Asperger Syndrome &amp; High-Functioning Autism: How to Meet the Challenges and Help Your Child Thrive",
"          </strong>",
"          by Sally Ozonoff, Geraldine Dawson, and James McPartland",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        <ul>",
"         <li>",
"          <strong>",
"           Asperger Syndrome: A Guide for Educators and Parents",
"          </strong>",
"          by Brenda Smith Myles and Richard Simpson",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        <ul>",
"         <li>",
"          <strong>",
"           Asperger Syndrome: A Guide for Parents and Professionals",
"          </strong>",
"          by Tony Attwood",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        <ul>",
"         <li>",
"          <strong>",
"           Asperger Syndrome: A Practical Guide for Teachers",
"          </strong>",
"          by Val Cumine, Julia Dunlop, and Gill Stevenson",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        <ul>",
"         <li>",
"          <strong>",
"           Asperger Syndrome and Difficult Moments: Practical Solutions for Tantrums, Rage, and Meltdowns",
"          </strong>",
"          by Brenda Smith Myles and Jack Southwick",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        <ul>",
"         <li>",
"          <strong>",
"           Asperger Syndrome and Sensory Issues: Practical Solutions for Making Sense of the World",
"          </strong>",
"          by Brenda Smith Myles, Katherine Tapscott Cook, Nancy E Miller, Louann Rinner, and Lisa A Robbins",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        <ul>",
"         <li>",
"          <strong>",
"           Comic Strip Conversations",
"          </strong>",
"          by Carol Gray",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        <ul>",
"         <li>",
"          <strong>",
"           The New Social Story Book",
"          </strong>",
"          by Carol Gray",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Books for children",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        <ul>",
"         <li>",
"          <strong>",
"           Asperger's huh?",
"          </strong>",
"          by John Strachan and Rosina G Schnurr",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        <ul>",
"         <li>",
"          <strong>",
"           Asperger's: What Does it Mean to Me?",
"          </strong>",
"          by Catherine Faherty and Gary B Mesibov",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        <ul>",
"         <li>",
"          <strong>",
"           Finding out About Asperger Syndrome, High Functioning Autism and PDD",
"          </strong>",
"          by Gunilla Gerland",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        <ul>",
"         <li>",
"          <strong>",
"           This Is Asperger Syndrome",
"          </strong>",
"          by Elisa Ganon and Brenda Smith Myles",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      <ol>",
"       <li>",
"        Safran JS. A practitioner's guide to resources on Asperger syndrome. Intervention in School and Clinic 2002; 37:283.",
"       </li>",
"       <li>",
"        Saulnier CA, Volkmar FR. Asperger syndrome. In: Developmental and Behavioral Pediatrics: A handbook for primary care, 2nd ed, Parker S, Zuckerman B, Augustyn M (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2005. p.110.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_27_33213=[""].join("\n");
var outline_f32_27_33213=null;
var title_f32_27_33214="Eosinophilic esophagitis barium swallow";
var content_f32_27_33214=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F73447&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F73447&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Eosinophilic esophagitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Barium swallow in a patient with eosinophilic esopahgitis showing mild segmental ring-like areas of narrowing in the proximal and mid esophagus representing \"trachealization\" of the esophagus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Norman Joffe, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_27_33214=[""].join("\n");
var outline_f32_27_33214=null;
var title_f32_27_33215="Measurement of popliteal angle";
var content_f32_27_33215=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F79116&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F79116&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 549px\">",
"   <div class=\"ttl\">",
"    Measurement of popliteal angle",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 529px; height: 383px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    With the patient in the supine position, the hip and knee are flexed 90&deg;, then the knee is extended to the point of resistance. The popliteal angle is the angle between the axis of the tibia and the axis of the femur, as depicted above.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_27_33215=[""].join("\n");
var outline_f32_27_33215=null;
